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Abstract 
The TAM receptors TYRO3, AXL, and MER are well characterized for their roles in cell 
proliferation and survival, phagocytosis, and inhibition of inflammation. The complexities of these 
TAM receptor responses imply a level of orchestration beyond binding to the two well-
characterized ligands GAS6 and Protein S.  
The here presented study was initiated to identify novel TAM receptor interacting proteins to 
gain novel insight into TAM receptor functions. Previously published studies aimed to identify 
ligands were insufficiently sensitive to capture weak and transient interactions, yet identified 
TUBBY, TULP1, and Galectin 3 as TAM activators by screening retinal cDNA libraries. The 
screen performed for this study was tailored to capture weak and transiently interacting proteins 
in a wide range of tissues. The attachment of tri-functional Diazirine cross-linker molecules to the 
n-termini of bait proteins was established via the bacterial transpeptidase Sortase A, as the 
enzymatic method provides site specificity and product homogeneity superior to chemical linking 
techniques. The cross-linker tagged bait proteins produced for this study enabled a variety of 
methods to enrich captured proteins. In total, three methods were compared for their capacity to 
enrich novel TAM ligand candidates. Applying the optimal enrichment method, several human 
and mouse tissues were screened for novel TAM receptor interacting proteins. Enriched proteins 
were identified by mass spectrometry and evaluated by bioinformatic and biochemical methods. 
A sum of 83 proteins was found to be potential TAM receptor ligands, which were not previously 
associated with TAM receptors. Beside proteins indicated to interact individually, clusters of 
proteins were enriched. AHSG (Fetuin A) links TAM receptors to mineralo-organic complexes 
and calcification of soft tissues such as atherosclerotic plaques, where AHSG inhibits 
calcification and acts cytoprotective. 19 proteins are characterized as vesicle markers. Recent 
publications link the release of vesicles by activated immune cells to immunosuppressive TAM 
receptor signals in cells recognizing these vesicles. In addition, 12 ribosomal proteins were 
enriched that may be recognized by TAM receptors as an alternative ‘eat me’ signal for 
phagocytosis, as ribosomal proteins translocate to the outer membrane in apoptotic bodies. 
The identification of additional ‘eat-me’ signals and the identified interaction of TAM receptors 
with vesicles emphasize the question of how TAM receptors differentially recognize vesicles and 
cells that either do, or do not present Phosphatidylserine. The 83 novel TAM receptor enriched 
proteins therefore may serve as starting points for the better understanding of TAM receptor 
mediated regulation of our immune system, maintenance of tissue homeostasis by clearing 
apoptotic cells and debris, and supporting healthy or causing malignant cell survival and 
proliferation. 
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1. Introduction 
 
 
The immune system 
 
At all time we are confronted with microbes, parasites, and viruses that surround and colonize 
us. Epithelial surfaces as the skin, the gastrointestinal tract and mucosa as the respiratory tract 
provide a physical barrier to prevent infection (1-3). Microorganisms and other agents passing 
these barriers and thereby causing harm are referred to as pathogens. As defense against 
pathogens mammals have developed specialized immune cells separated into the innate and 
the adaptive immune system.  
Specialized immune cells of the innate immune system are Monocytes, Dendritic cells and 
Macrophages, Mast cells, Neutrophils, Basophils and Eosinophils, all of which are derive from 
myeloid progenitor cells (4-7). These cells recognize molecular patterns characteristic for 
pathogens and dangers by several receptor families collectively called pattern recognition 
receptors (PRR) (8). Pathogen associated molecular patterns (PAMPs) are for example proteins 
of bacterial secretion systems and Flagellin, peptidoglycans, lipoglycans and polysaccharides 
common to pathogen membranes and foreign to host tissues. Further, pathogenic RNA and 
DNA is recognized due modifications or localization foreign to host tissues and cells. 
Endogenous stress signals or danger associated molecular patterns (DAMPs) are for example 
high levels of extracellular ATP as a result of tissue damage and cellular stress (9). Pattern 
recognition receptors of the Toll-like receptor family (TLRs) are best known for the recognition of 
bacterial lipopolysaccharides by TLR4. Other TLRs recognize proteins, DNA and RNA of 
bacterial origin. Upon recognition of PAMPs, TLR mediated signaling induces the secretion of 
cytokines and interferons (IFNs) orchestrating the immune response. Similarly to TLRs, C-Type 
Lectin receptors induce the secretion of cytokines upon recognition of pathogen characteristic 
glycoproteins. Further certain C-Type Lectin receptors mediate or regulate the uptake of 
pathogens (10). While TLRs and C-Type Lectin receptors recognize extracellular PAMPs and 
DAMPs, NOD-like receptors (NLRs) and RIG-I-like receptors (RLRs) recognize intracellular 
PAMPs and DAMPs. Like TLRs, the activation of RLRs lead to the secretion of cytokines and 
interferons (IFNs) orchestrating the immune response, while the activation of NLRs like NLRP1, 
NLRP3, and AIM2 lead to the inflammatory death of the cell called pyroptosis and the secretion 
of IL1 and IL18 (11, 12).  
Additional to immune cells, pathogens can be recognized by proteins complementing the cellular 
innate immune response, which are therefore summarized as the complement system. Proteins 
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of the complement system are secreted into the plasma where they either bind to pathogen 
surfaces directly, to antigen/antibody complexes or to mannose on bacteria. In a cascade of 
complement protein recruitment and cleavage, immune cells are recruited for phagocytosis and 
pores are formed in pathogen membranes for direct lysis of the pathogen (13). 
While the innate immune system recognizes conserved molecular patterns, the adaptive 
immune system is designed to recognize an infinite variety of foreign molecular patterns. To 
achieve this variety of receptors the lymphocyte derived B and T cells each have evolved 
receptors with a variable antigen recognition domain (14-16). As the antigen binding domains of 
B & T-cell receptors potentially bind host antigens, cells are negatively selected for affinities to 
host antigens (17, 18). Upon recognition of a foreign antigen, B cells begin to secrete Antibodies 
of the isotypes IgM, IgG, IgA, and IgE. Dependent on cytokines and stimuli by interacting cells, 
the secretion of the respective isotype is induced or inhibited (19). While B-cell receptors and 
antibodies potentially bind all accessible foreign antigens, the T-cell receptors recognize foreign 
peptides only when presented by major histocompatibility complex (MHC) molecules (20). 
Functionally, T cells can be separated in helper (CD4+), killer (CD8+) and regulatory T-cells 
together called effector T-cells. Further subtypes include memory T cells, natural killer T cells 
and gamma-delta T cells (21). 
 
 
TAM receptors in health and disease 
 
As described, the immune system has a vast array of receptors to identify hostile patterns and to 
induce an orchestrated inflammatory response. To balance a pro-inflammatory response, to 
repair damage inflicted during the response, and in order to return to homeostasis a respectively 
orchestrated anti-inflammatory response is needed. One family of receptors acting as a counter 
balance to inflammation is the family of the TAM receptors tyrosine kinases TYRO3, AXL, and 
MER. TAM receptors inhibit pro-inflammatory pathways during inflammation, thereby providing a 
threshold for a pro-inflammatory response and further limit its intensity (22, 23). During the 
immune response but also during homeostasis TAM receptors promote phagocytic clearance of 
apoptotic cells and debris (24-26). And finally, TAM receptors restore vascular integrity following 
an immune response (27, 28).  
The main ligands activating the TAM receptors are Protein S and GAS6. Protein S was identified 
1995 as a TYRO3 and MER ligand after observing that TYRO3 transfected cells showed an 
enhanced growth upon treatment with bovine serum. The TYRO3 ectodomain fused to an 
Immunoglobulin (Ig) Fc domain was used to enrich TYRO3 from serum by affinity 
chromatography. GAS6 sharing the domains of Protein S was identified in the same study as a 
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ligand for AXL (29). Later studies have identified GAS6 as a ligand for all three TAM receptors 
(30). Additional to the activation of TAM receptors, Protein S is known for its anti-coagulant 
function (31). Although Protein S and GAS6 have a high sequence homology and an identical 
domain structure of an n-terminal GLA domain, four epidermal growth factor-like domains and 
two c-terminal Laminin G-like domains, GAS6 affinity is highest to AXL, then TYRO3, and lowest 
to MER. Protein S binds equally to TYRO3 and MER but not to AXL (30, 32, 33). As their 
ligands, also the receptors share a common domain structure. The extracellular n-terminus 
begins with two Immunoglobulin-like domains followed by two fibronectin type III-like domains 
essential for receptor dimerization. Within their cytosolic part, TAM receptors posses a tyrosine 
kinase domain, which auto-phosphorylates and phosphorylate signaling adapter molecules upon 
activation (34-36). Active TAM receptor / ligand complexes have a stoichiometry of 2 receptors 
and 2 ligands (37).  
Beside GAS6 and Protein S additional interacting proteins were identified. Retinal pigment 
epithelial cells were shown to secrete the Mer binding protein Tubby and Tubby like protein 1 
(Tulp1), which binds to Tyro3, Axl, and Mer (38). Similarly to GAS6 and Protein S, Tubby and 
Tulp1 bridge the TAM receptors to apoptotic cells in the retina pigment epithelium and Tubby to 
microglia in the brain (39). The same group later identified Galectin-3 released by TLR activated 
microglia as a fifth MER ligand (40, 41). 
 
TAM receptor dependent immune regulation: 
TAM receptors regulate, and are regulated, by many ways during an inflammatory response. 
Pattern recognition receptors on innate immune cells drive a pro-inflammatory response by the 
secretion of pro-inflammatory cytokines and chemokines to activate and recruit other innate and 
adaptive immune cells. Together with this pro-inflammatory response, counter balancing anti-
inflammatory factors are produced and activated. IL10 is secreted suppressing T-cell, DC and 
macrophage functions (42). Regulatory and helper T-cells balance the adaptive immune 
response as well as dampen the innate immune response. In the year 1999 MER was first linked 
to the inhibition of an immune response when Camenisch and colleagues reported an increased 
production of TNFα by Mer-/- mice’s peritoneal exudates upon LPS challenge (23). Dendritic cells 
up-regulate the expression of TAM receptors after TLR and type I interferon stimulation (22, 43). 
Additionally AXL up regulation was shown to be due to type-I IFN stimulation in macrophages. 
The same study demonstrated that TAM receptors stimulated with apoptotic cells, GAS6, or 
Protein S induced the expression of TWIST1 and TWIST2, which repress NF-κB induced gene 
transcription and promotes GAS6 expression.(44, 45) A second way TAM receptors inhibit pro-
inflammatory responses was observed when dendritic cells were co-stimulated with AXL and 
IFNα. AXL binds to IFNAR1 and usurps its signaling cascade and leads to STAT1 homo-
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dimerization in turn inducing the expression of suppressor of cytokine signaling 1 and 3 (SOCS1 
& SOCS3). As the name implies, SOCS1 and SOCS3 inhibit cytokine inducing signaling 
cascades by the inhibition of adaptor proteins TRAF3, TRAF6 and MAL as well as the NF-κB 
protein p65, and by the inhibition of the cytokine receptor induced JAK/STAT pathway (22, 46-
50). Additional to the stimulation of TAM receptors by free ligands it was shown, that Protein S is 
transiently exposed on the surface of activated CD4+ and CD8+ T cells (51, 52) and that T cell 
derived Protein S limits the activation of antigen presenting cells (APC) and the expression of 
cytokines (53). As Phosphatidylserine (PtdSer) was found to be presented on T cells and B cells 
when activated (54), it was proposed that these cells utilize Protein S bound to surface 
presented PtdSer for the inhibition of TAM receptor presenting innate immune cells (55). During 
an acute phase immune response, Protein S serum levels are increased together with the levels 
of C4BP blocking Protein S function by binding, and leading to a constant concentration of 
approximately 126 nM free Protein S (56). GAS6 is present in plasma complexed to soluble AXL 
(57). The soluble forms of AXL and MER are generated by shedding the ectodomain of the 
receptors by the metalloprotease ADAM17, who’s expression is up-regulated by TLR stimulation 
(58, 59). Protein S in serum might therefore serve as a threshold for an inflammatory immune 
response, as well as to enable a quick removal of apoptotic cells and debris within the vascular 
system. 
 
TYRO3, AXL and MER as receptors of apoptosis: 
Apoptosis of cells is part of the regular cellular turnover during the development of tissues and 
during homeostasis. During inflammation and cellular stress non-homeostatic factors lead to an 
increased cell death (60). The clearance of apoptotic cells and debris is elemental to maintain 
homeostasis as deficiencies lead to chronic inflammation and autoimmune disease (61). TAM 
receptors were demonstrated to be major receptors for the sensing of apoptosis and for the 
subsequent efferocytosis of apoptotic cells and debris. The ability of macrophages to 
phagocytize apoptotic thymocytes was reduced approximately by half in Tyro3-/-, Axl-/- as well as 
in Axl-/-, Mer-/- macrophages, while in other cells types as in bone-marrow derived dendritic cells 
knock out of Mer-/- did not lead to a significant reduction of efferocytosis efficiency (24, 62). 
Despite this plasticity of impact TAM receptors have on the efficiency of efferocytosis in 
individual cell types, the general importance of TAM receptors is demonstrated by the 
development of a lupus-like disease in Mer-/- mice (63). Interestingly it was found that 
macrophage efferocytosis of apoptotic cells was increased when serum was present, while the 
efferocytosis of necrotic cells remained unchanged in vitro. Apoptosis is characterized by the 
exposure of PtdSer on the outer leaflet of the plasma membrane (64). The TAM receptor ligands 
GAS6 and Protein S bind to PtdSer via their -carboxylated GLA domain in dependence of 
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Vitamin K and Ca2+, serving as bridging molecules to the TAM receptors (65-68). Further TAM 
receptor co-expressed PtdSer binding and phagocytosis associated receptors are TIM-4 binding 
PtdSer directly, and the αvβ5 integrin binding the PtdSer binding MFG-E8 (69, 70). TAM 
receptors were shown to SRC-dependently phosphorylate the cytosolic protein FAK that in turn 
phosphorylates and recruits αvβ5 integrin (71).  
 
 
Figure 1. TAM receptors and the regulation of inflammation, phagocytosis and survival. 
TAM receptors bind a variety of ligands (A), are regulated on a transcriptional level, by cleavage and ubiquitylation, 
and are stabilized by heat-shock proteins. TAM receptors sense apoptotic cells by their PtdSer binding ligands and 
co-operate with certain apoptosis sensing receptors, while no connection of TAM receptors with PtdSer receptors as 
SCARB1, BAI1, TIM-4, and Stabilin 2 is reported (B). TAM receptors induce proliferation and survival of cells (C). In 
inflammatory environments, TAM receptors inhibit immune responses by usurping IFNAR signaling and thereby 
inducing the expression of SOCS1/3 (D).  
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Additional to the clearance of apoptotic cells by immune cells, TAM receptors are essential for 
phagocytic processes in other cell types. TAM receptor deficient mice (Tyro3-/-, Axl-/-, Mer-/- or so-
called triple knock out mice (TAM TKO) turn blind after birth due to the retina pigment 
epithelium’s inability to phagocytize and degrade the shed outer segments of photoreceptors 
(26, 33). Further male TAM TKO mice become infertile due to inefficient clearance of apoptotic 
spermatogenic cells during spermatogenesis by phagocytosis specialized Sertoli cells (25, 26). 
 
TAM receptors role in vascular integrity: 
While drawing blood from TAM TKO mice by tail clipping an increased blood loss was noticed 
and linked to impaired GAS6 dependent thrombus formation. An inflicted wound in the 
vasculature activates platelets and increases their αIIBβ3 integrin’s affinity to fibrinogen. Co-
stimulation of TAM receptors with GAS6 was shown to be essential for αIIBβ3 integrin 
phosphorylation and PI3K and AKT signaling at low levels of platelet activation (72, 73). Further, 
the TAM receptor AXL is required by VEGF-A to induced neovascularization and migration of 
epithelial cells. Endothelial cells in the retina showed GAS6 stimulated proliferation, tube 
formation and migration (74). Tyro3 dependent Protein S stimulation prevents the disruption of 
brain endothelial cell formed barriers, challenged with hypoxia. Protein S stimulates mitosis of 
vascular smooth muscle cells (67, 75). All together, effects of TAM receptor signaling on the 
vascular integrity are evident, but complicated to dissect from other effects, as for Protein S a 
complete knock out is embryonic lethal. Further Protein S is secreted by cells as various as 
hepatocytes, endothelial cells, and hematopoietic cells where a conditional knock out would only 
limit one source of Protein S (27). 
 
TAM receptors in disease: 
TAM receptors are reported to cause or effect diseases like systemic lupus erythematosus 
(SLE), rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis, which have a 
chronic or autoimmune inflammatory character in common. TAM receptors impact 
cancerogenesis and the infectiousness of several viruses.   
TAM receptor triple knock out mice show characteristics of chronic inflammation and SLE 
beginning 4 weeks after birth and intensifying with age. High levels of antibodies to dsDNA, 
collagen, and phospholipids as PtdSer, phosphatidylethanolamine, phosphatidylinositol, and 
cardiolipin were detected. Mice had swollen footpads and joints, lesions in the skin, and 
especially female mice showed hemorrhages and thrombosis (76). Apoptotic cells accumulated 
in the germinal centers of Mer-/- mice’s lymph nodes, which is characteristic for human SLE 
patients as well (77, 78).  Another characteristic found in SLE patients but also in patients 
suffering from Crohn’s disease and ulcerative colitis is a deficiency in Protein S (79-81).  
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TAM receptors were linked to multiple sclerosis investigating the impact of GAS6/AXL signaling 
on proliferation and survival during toxic demyelination induced by feeding Cuprizone to young 
mice. Axl-/- mice accumulated more apoptotic oligodendrocytes and myelin debris upon 
Cuprizone treatment compared to wild type mice and axonal damage and recovery was 
prolonged (82). An effect similarly observed in GAS6-/- mice while exogenous administration of 
GAS6 into the brain had an opposite effect (83, 84). In humans suffering from multiple sclerosis, 
polymorphisms in the MER gene were associated with a higher susceptibility to the disease (85). 
The implications of TAM receptors in cancer are ambiguous. TAM receptors are transforming 
oncogenes (34, 86-88) leading to several types of cancer further described by Wu and 
colleagues (89). Most prominently acute myeloid leukemia is GAS6/TAM dependent where 
GAS6 expression levels implicate disease severity (90, 91). TAM receptors were also described 
to dampen anti-tumor responses (92). Contrasting the pro-oncogenic functions described, TAM 
receptor deficiencies in inflammation induced colon cancers mouse models lead to increased 
disease susceptibility and reduced survival (93, 94). Another way AXL is involved in the 
development of cancer is the intramembrane proteolysis by γ-secretase resulting in a 
cytoplasmic domain with a nuclear localization domain. Translocation of AXL’s intracellular 
domain into the nucleus was reported for various cancer cell lines. NF-κB signaling was partially 
inhibited by AXL ICD translocation. First experiments indicate an increased chemo-resistance 
induced by over-expression of an AXL mutant unable to be cleaved by γ-secretase (95). 
In 2006 Shimojima and colleagues revealed the use of TAM receptors by the filoviridae family 
member Ebola virus to enhance virus entry into TAM receptor expressing cells. Ebola 
pseudotype virus infection of AXL and MER overexpressing Jurcat cells was highly increased 
while TYRO3 overexpression only led to a lesser yet significant increase (96). The deletion of 
AXL’s Ig-like C2-type 1 domain, the intracellular domains, or preventing ATP binding by 
introducing a K567M mutation reduced the infection efficiency to levels observed with control 
cells (97). In the following years TAM receptors were found to increase infections with viruses as 
Vaccinia (98), Lassa (99), and the flaviviridae Dengue (100), West-Nile (101), and Zika (102). 
Since the causal association between microcephaly and the Zika outbreak in mid 2015 (103), 
many publications focus on investigating this connection. As all of these viruses are enveloped, 
TAM receptors might not interact with enveloped proteins but indirectly with PtdSer exposed by 
many viruses for apoptotic mimicry. Indeed many studies revealed a dependency for GAS6 and 
Protein S to mediate TAM receptor dependent infections (98, 100, 101). However the major 
capsid protein of Simian virus SV40 binds directly to TAM receptors and shows structural 
similarity to the TAM receptor ligands (104). Beside the apoptotic mimicry to avoid an 
extracellular immune reaction, virus infection by TAM receptors caused expression of SOCS1 
and SOCS3 and their suppression of PRR signaling and thereby IFN secretion (101).  
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Sortase A mediated transpeptidation 
 
 
Figure 2. Transpeptidation reaction by sortase A 
Schematic description of n-terminal (A) and c-terminal (B) sortase A mediated transpeptidation reactions. The 
recognition motif LPXTG recognized by S. aureus srtA is shown representatively. The enzymes Cysteine marked as C 
and it’s side chains sulfhydryl group marked as HS are shown. 
 
Mazmanian et al., 1999, first characterized the product of the Staphylococcus aureus gene srtA 
and named it surface protein sorting A or Sortase A. Sortase A is a membrane-anchored 
transpeptidase expressed by S. aureus and other pathogenic gram-positive bacteria like 
Streptococcus pyogenes. The transpeptidase of S. aureus recognizes the peptide motif LPXTG, 
while S. pyogenes srtA recognizes LPXTA/G. After recognition of the motif in proteins secreted, 
srtA covalently attaches them to the bacterial cell wall by hydrolyzing the peptide bond between 
Thr and Gly/Ala followed by the ligation to any available n-terminal Gly/Ala (105, 106). Those 
proteins promote the infection of a host by binding fibrinogen in vascular and endocardial lesions 
by ClfA and ClfB (107), by promoting the interaction with host tissues and invasion of cells via 
fibronectin binding proteins FnbA and FnbB (108, 109), or by evading the host immune response 
preventing opsono-phagocytosis binding host antibodies (110) and inducing TNFAR1 shedding 
with Immunoglobulin G-binding protein A (Protein A / spa) (111). As expected S. aureus srtA-/- 
was shown to be less virulent compared to wild type S. aureus and was therefore suggested as 
possible antimicrobial drug target (112, 113).   
To transform the bacterial enzyme in a biochemical tool, the n-terminal transmembrane domain 
was removed and replaced by a hexa-His tag for purification (114). Since the recognition of 
sortase as a powerful tool to ligate peptides, mutations in S. aureus srtA were characterized 
improving the enzymatic activity (115-117), removing srtA dependency for Ca2+ (118), and 
reprogramming the specificities of srtA (119). Many studies have shown the use of sortase to 
link dyes or small molecules to proteins like antibodies (120), to label cell surface proteins (121), 
or to link proteins with proteins. One example where sortase ligation of protein to protein is the 
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development of a papaya mosaic virus (PapMV) coat protein based vaccination platform. As 
PapMV coat protein stimulates TLR7 (122), it serves as an ad uvant expressed with LPETGG as 
srtA recognition motif. Th rien and colleagues used sortase to tag viral peptides to the PapM  
coat proteins and could show that the combinations elicited specific immune responses (123). 
This is just one of many examples where sortase enzymes have been used as a versatile tool of 
protein engineering. 
 
 
 
Rationale and aims of the study 
 
Four years after the discovery of TYRO3, AXL, and MER as an independent family of receptor 
tyrosine kinases, the major ligands GAS6 and Protein S were identified, followed five years later 
by TUBBY, TULP1, and Galectin 3. By the extensive research in the past years TAM receptors 
were uncovered as essential receptors for phagocytosis, the regulation of inflammatory 
responses and cell proliferation and survival. However, with the ongoing characterization of the 
known ligands stimulating TAM receptors, more and more situations were discovered where 
these identified TAM receptor ligands alone could not explain the observed effects. All TAM 
receptor ligands described induce phagocytosis by recognizing PtdSer, an ‘eat me’ signal 
recognized by many redundant receptors. Why are TAM receptors so important for efficient 
phagocytosis that mice lacking them fail to clear apoptotic cells although PtdSer is redundantly 
recognized? Why are B cells and T cells hyper-activated in mice lacking TAM receptors and why 
are they spared by TAM expressing antigen-presenting cells when activated and presenting 
PtdSer? The question how TAM receptors regulate inflammatory responses was partly 
answered in 2007 by Carla Rothlin and colleagues, where they showed that TAM receptors 
usurp Interferon-alpha receptor signaling upon co-stimulation and thereby induce the expression 
of inflammatory signaling inhibitors. But, as all TAM receptor functions described by now are 
stimulated either by free or Phosphatidylserine bound ligands, the question remains on how 
TAM receptors discriminate between Phosphatidylserine presenting living and apoptotic cells. 
Therefore by investigating whether TAM receptors engage additional unidentified proteins or 
molecules, light can be shed on TAM receptor regulated phagocytic events, immune responses, 
and homeostatic and malignant cell proliferation and survival.  
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The specific aims of this project were: 
 
1. To establish a method for the attachment of cross-linker molecules to bait proteins in 
order to capture weak and transient interacting proteins by: 
a. Optimizing the Sortase A reaction towards the 5M srtA enzyme variant’s 
transpeptidation of small molecules. 
b. Determining at which level of UV irradiation efficient activation of the cross-linker 
Diazirine is reached comparing two UV light sources, under consideration of time 
and adverse effects caused by UV irradiation.  
c. Establishing the concept of specific ligand capture and labeling by the bait 
proteins designed for this study. 
2. To select an optimal enrichment method capturing weak and transient interacting 
proteins by comparing potential enrichment methods possible to be used with regard to 
the enrichment of weak and transient interacting proteins. 
3. To identify novel TAM receptor interacting proteins by screening of multiple TAM receptor 
expressing tissues, and to characterize the identified interacting proteins by biochemical 
and bioinformatic methods towards their potential role in regulating TAM receptor 
functions. 
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2. Materials and Methods 
 
Instruments 
Name Description REF number Supplier 
DynaMag™-2 Magnet For 1.5 ml to 2 ml microcentrifuge tubes 12321D Thermo Fisher 
Scientific 
gentleMACS Octo 
Dissociator 
Bench-top instrument for the semi-
automated and standardized tissue 
dissociation or homogenization of up to 
eight samples 
130-095-937 Miltenyi Biotec 
HOKImag Free-flow magnetic separation system with 
a high-gradient 2-Tesla permanent 
magnetic field. The disposable flow columns 
do not contain ferromagnetic materials 
inside, the focusing gradient of the magnetic 
field is provided from outside the columns 
by a patented device. 
HOKImag Hoock GmbH Kiel 
MACSmix Tube Rotator Small rack for tubes from 0.5 mL to 2 mL in 
size, 
Large rack for tubes from 5 mL to 50 mL in 
size 
130-090-753 Miltenyi Biotec 
MINIPULS® 3 Adjustable speed from 0 to 48 rpm by 
increments of 0.01 rpm up to 9.99 rpm and 
by 0.1 rpm at above 10 rpm 
n.a. Gilson 
Sonopuls HD 2070 Generator GM 2070, ultrasonic transducer 
UW 2070, diameter probe SH70, micro tip 
MS 73 with a diameter of 3 mm, the system 
is set up for volumes of 2 to 50 ml.  
n.a. Bandelin  
T Professional TRIO 
Thermocycler 
Multiblock thermocycler with heated lid for 
DNA amplification. 
n.a. Biometra 
T3000 Thermocycler 3 independent 0.2ml blocks with 6x8 wells 
each 
n.a. Biometra 
Neubauer chamber 4 cell counting areas with 1x1x0.1 mm (0.1 
mm
3
, or 0.1 µl), number of cells in 4 
counting areas / 4 * 10,000 = number of 
cells / ml  
n.a. n.a. 
Microplate Washer 405 T5 Automatic removal and washing of 96 well 
plates 
n.a. BioTek 
EPOCH Microplate spectrophotometer, 200 nm to 
999 nm for UV-Vis applications, micro-
volume detection with Take3 plate 
n.a. BioTek 
SpectraMax i3 Operated with SoftMax Pro software, for 96 
or 384 well plates, additional cartridges: 
Alpha Screen - Alpha 384 STD (0200-
7017POS), FP-FLUO (0200-7009POS), 
HTRF (0200-7011POS), additional 
equipment: SpectraDrop
TM
 Micro-Volume 
Microplate,  
n.a. Molecular Devices 
OPS-A500 200-500 W DC Arc Lamp Power Supply, 
Power, Current, and Intensity Control 
Modes, RS-232/USB control, CE and RoHS 
compliant, from Oriel Instruments 
OPS-A500 Newport Corporation 
500W Xe/Hg Arc Lamp 500 Watt Mercury-Xenon Arc Lamp 66142 Newport Corporation 
LIK-LMP Light Intensity 
Controller Kit 
A TE cooled Si detector provides light 
intensity feedback. 
71582 Newport Corporation 
Liquid Filter 280 to 950 nm light transmission, filters 
unwanted IR light and resultant heat, hose 
fittings provided for use with external 
cooling chamber 
6214 Newport Corporation 
Beam Turning Mirror 
Housing 
1.5 Inch Series Flange 66245 Newport Corporation 
280-400nm dichroic mirror 3 inch series model 66236 Newport Corporation 
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Lamp Socket Adapter for 500 W Hg(Xe) Lamp 66159 Newport Corporation 
Arc Lamp Housing For 50-500W, F/0.7, 4 Element FS 
Aspherab, Collimated, 3 In 
66905 Newport Corporation 
Electronic Safety Shutter For 1.5 Inch Series Flange 71445 Newport Corporation 
Bio-Link BLX-365 5 x 8 Watt UV lamps, 365 nm, sensor 
controlled irradiation 
n.a. AG Hornung 
X Cell system XCell SureLock™ Mini-Cell Electrophoresis 
System 
EI0001 Thermo Fisher 
Scientific 
VersaDoc VersaDoc 4000MP n.a. Bio-Rad 
28-80mm objective 28-80mm f1/3.5-5.6 AF aspherical n.a. Tamron 
EPOCH Reader Microplate Spectrophotometer, 
monochromator-based optics 
n.a. BioTek Instruments 
Take3 Micro-volume plate 2 µL sample volumes for direct DNA, RNA 
and protein quantification 
n.a. BioTek Instruments 
Table 1. List of instruments. 
 
Software 
Software Supplier 
Gel Scan Quantity One (version 4.6.9) Bio-Rad 
SoftMax Pro (version 6.3) Molecular Devices 
Excel for Mac 2011 Microsoft 
Word for Mac 2011 Microsoft 
Prism 6 GraphPad Software, Inc. 
Prism 7 GraphPad Software, Inc. 
Image Studio Lite LI-COR Biosciences 
Image Studio Ver 4.0 LI-COR Biosciences 
Geneious Biomatters Ltd. 
Papers 3 Digital Science & Research Solutions Inc. 
Gen 5 (version 1.11) BioTek Instruments 
Perseus v1.5.2.11 Prof. Jürgen Cox, PhD, http://www.coxdocs.org 
Cytoscape 3.6.0 Open source 
ClueGO 2.5.0 & CluePedia 1.5.0, Cytoscape PlugIn Open source 
Table 2. List of software. 
 
General chemicals and reagents 
Name Formulation REF number Supplier 
Acetic acid C2H4O2, 100% 3738.5 Carl Roth 
BSA Bovine Serum Albumin, heat shock fraction, pH 7, 
≥98% purity, CAS # 9048-46-8 
A9647 Sigma Aldrich 
Calcium chloride CaCl2 1.06404.5000 VWR 
cOmplete™ EDTA-free Protease Inhibitor Cocktail, inhibit a 
broad spectrum of serine and cysteine proteases 
11873580001  Roche 
Disodium 
hydrogen 
phosphate 
Na2HPO4, heptahydrated X987.1 Carl Roth 
EDTA, 500 mM UltraPure™ 0.5M EDTA, pH 8.0 15575020 Thermo Fisher 
Scientific 
EDTA, 500 mM Ethylenediaminetetraacetic acid solution, pH 8.0, 
~0.5 M in H2O, CAS#: 60-00-4 
03690-100ml Sigma Aldrich 
EDTA Ethylenediaminetetraacetic acid CAS#: 10378-23-1 A1105 PanReac AppliChem 
Glycerol Glycerol BioXtra, ≥99% (GC), CAS#: 56-81-5 G6279 Sigma Aldrich 
HCl, 32% hydrochloric acid, 32% (v/v) 
CAS#: 7647-01-0 
 
P074 Carl Roth 
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HEPES HEPES solution, 1 M, pH 7.0-7.6, sterile-filtered, 
BioReagent, suitable for cell culture 
H0887 Sigma 
IPTG Isopropyl-β-D-thiogalactopyranosid, C9H18O5S, CAS 
# 367-93-1 
CN08.2 Carl Roth 
Isopropanol, 
analytical 
CH3CHOHCH3, CAS # 67-63-0 131090 PanReac AppliChem  
Isopropanol, 
technical 
CH3CHOHCH3, CAS # 67-63-0 211090 PanReac AppliChem 
Methanol  analytical A0688 PanReac AppliChem 
Milk powder blotting grade, powdered, low fat 
Milk contains biotin. Not suitable for 
biotin/streptavidin mediated detection systems. 
T145.1 Carl Roth 
Sodium hydroxide 
solution, 1N 
NaOH, 1.0N 
CAS#: 1310-73-2 
S2770 Sigma Aldrich 
Nonidet P-40 Nonidet® P40 (Substitute) BioChemica A1694 PanReac AppliChem 
Phosphate 
buffered saline, 
10x 
1.37M NaCl, 27mM KCl, 100mM Na2HPO4, 20 mM 
KH2PO4 
P04-53500 PAN Biotech 
 
PhosSTOP PhosSTOP™, inhibitor tablets for phosphatase 4906845001 Sigma Aldrich 
Potassium chloride KCl 1.04936.1000 Merck 
Potassium 
dihydrogen-
phosphate 
KH2PO4 P018.2 Carl Roth 
SDS Sodium dodecyl sulfate, CH3(CH2)11OSO3Na,  
CAS#: 151-21-3 
L5750 Sigma Aldrich 
Sodium chloride NaCl, CAS#: 7647-14-5 1.06404.5000 VWR 
Sodium 
deoxycholate 
3, 12-α-Dihydroxy-5β-cholan-24-oic acid, 
monosodium salt 
89905 Thermo Fisher 
Scientific 
Sulfuric acid Sulfuric acid, 2N X873.1 Carl Roth 
TBS Tris Buffered Saline sc-362305 ChemCruz 
TRIS, 1M, pH8.0 121.14 g/L (1 M) Tris A4577 PanReac AppliChem 
TRIS base 2-Amino-2-(hydroxymethyl)-propan-1,3-diol 
CAS#: 77-86-1 
A2264 PanReac AppliChem 
Triton X-100 Triton® X 100, Alkylphenylpolyethylenglykol, CAS#: 
9036-19-5 
3051 Carl Roth 
Tween-20 TWEEN® 20, Polyethylene glycol sorbitan 
monolaurate, viscous liquid, CAS # 9005-64-5 
P1379 Sigma Aldrich 
Table 3. List of general chemicals and reagents. 
  
 
Tissue Culture  
Tissue cultures were grown in a humidified incubator at 37°C with an atmosphere of 95% air and 
5% CO2. Cell lines were passaged using a 0.05% Trypsin-EDTA solution or a solution of 5-25 
mM EDTA in PBS to detach the cells from the culture vessel. After detachment of the cells, FBS 
containing medium was added and the cells were transferred to a falcon. 10 µl of the culture 
were mixed with 90 µl of trypan blue dilutes 1/10 in PBS. 10 µl of the mixture were pipetted to a 
Neubauer chamber where the healthy and therefore unstained cells were counted. Based on the 
healthy cells per milliliter determined, cells were seeded into a culture vessel.  
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Name Formulation REF number Supplier 
293T  (Homo sapiens adherent embryonic kidney epithelial 
cells) Cultured in DMEM, 10% (v/v) FBS, Penicillin 
100U/ml, Streptomycin 100µg/ml, Seeded with >10000 
cells/cm
2
, Grown to <90 confluence 
ATCC CRL-3216 
ARPE-19 Cultured in DMEM/F12, 10% (v/v) FBS, L-Glutamine,  
Seeded to >5000 cells/cm
2
, Grown to <90% 
confluence 
Provided by  
Wen Allen 
Tseng 
n.a. 
DMEM Dulbecco's Modified Eagle Medium, high glucose 41965-039 Gibco 
DMEM, 
supplemented 
DMEM supplemented with 10% (v/v) FBS and 100 
U/ml PenStrep 
n.a. n.a. 
DMEM/F12 Dulbecco's Modified Eagle Medium, with L-glutamine 
and phenol red, without HEPES 
11320074 Thermo Fisher  
DMEM/F12, 
supplemented 
DMEM/F12 supplemented with 10% (v/v) FBS and 100 
U/ml PenStrep 
n.a. n.a. 
FBS Fetal Bovine Serum, heat inactivated 10270106 Invitrogen/Gibco 
PenStrep Penicillin-Streptomycin (10,000 U/mL) 15140122 Gibco 
Phosphate buffered 
saline 
Dulbecco`s Phosphate Buffered Saline, without Ca 
and Mg, 1x solution, sterile 
Gibco  14190-094 
Trypsin Trypsin-EDTA (0.05%), phenol red Thermo Fisher  25300054 
Table 4. List of buffers, solutions, media, and cell lines for tissue culture. 
 
 
Lysis of organs, tissue samples, and tissue culture cells 
 
Preparation of lysates from mouse organs: 
Lungs, hearts, livers, testis, spleens and kidneys were isolated from male and female C57BL/6J 
mice. The organs were prepared from already sacrificed mice. Before the lysis the organs were 
washed with PBS to remove remaining blood and then transferred to a M Tube and weighed. 5 
ml of N-P40 tissue lysis buffer were added per gram of tissue. The tissues were homogenized 
using gentleMACS Octo Dissociator with the preset program ‘protein_01_01’. The homogenates 
were transferred from the M tubes into microcentrifuge tubes and centrifuged with 13200 g at 
4°C for 10 minutes. The supernatants were transferred to new microcentrifuge tubes. The 
protein concentrations were determined for each lysate with the BCA Protein Assay Kit from 
PierceTM according to the manufacturers manual before storing the lysates at -80°C. 
 
Preparation of lysates from human tissue samples:  
Human brain cortex samples from healthy patients, or patients either diagnosed with Alzheimer 
or Mild Cognitive Impairment (MCI) were provided as homogenates prepared with a cryogenic 
grinding method. Two-times concentrated N-P40 tissue lysis buffer was added to a volume ratio 
of 1/1 to the homogenates and sonicated in 3 cycles of 30 seconds sonication and 30 seconds 
resting on ice.  The lysates were then centrifuged for 10 minutes at 4°C with 13200 g before 
transferring the supernatants to new microcentrifuge tubes. The protein concentrations were 
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determined for each lysate with the BCA Protein Assay Kit from PierceTM according to the 
manufacturers manual before storing the lysates at -80°C. 
 
Preparation of lysates from tissue culture cells: 
To lyse cells grown in tissue culture dishes, the cultures were washed with ice cold PBS. As lysis 
buffers N-P40, RIPA, or Lysis Buffer 1 from Cisbio were used. Protease or phosphatase 
inhibitors as cOmplete, PhosStop, and PMSF were added as required. In case of nucleotides 
forming clots 1/20000 diluted Benzonase was added to the respective lysis buffer. The lysis 
buffer was incubated on the cells for 10 minutes at 4°C or on ice. Remaining cells were scraped 
off and the lysates were transferred to microcentrifuge tubes and centrifuged for 10 minutes at 
4°C with 13200 g before transferring the supernatants to new microcentrifuge tubes. The protein 
concentrations were determined for each lysate with the BCA Protein Assay Kit from PierceTM 
according to the manufacturers manual before either using the lysates directly or storing the 
lysates at -80°C. 
 
Name Formulation REF number Supplier 
Benzonase® 
Nuclease 
≥250 units/μl, ≥90% (SDS-PAGE), recombinant, expressed in 
E. coli, buffered aqueous glycerol solution, CAS Number 9025-
65-4, Enzyme Commission (EC) Number 3.1.30.2, MDL 
number MFCD00131010 
Sigma Aldrich E1014-25KU 
C57BL/6J mice Wild type mice n.a. Charles River / 
Janvier Labs 
Lysis buffer 1 Part of the cAMP/cGMP kits, contains potassium fluoride and 
Triton X100 
Cisbio 62CL1FDD 
M Tubes gentleMACS™ M Tubes are used in combination with the 
gentleMACS Dissociator for the fast and convenient automated 
tissue homogenization, in order to isolate biomolecules like 
mRNA or total RNA, or to extract proteins. 
130-096-335 Miltenyi Biotec 
N-P40 lysis 
buffer 
20 mM TRIS base, 150 mM NaCl, 1 mM EDTA, 1% (v/v) 
Nonidet P-40, 10% (v/v) glycerol, in H2O, pH7.4 
n.a. n.a. 
N-P40 tissue 
lysis buffer 
140 mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 2 mM KH2PO4, 
1% (v/v) Nonidet P-40, 1x cOmplete™, in H2O, pH7.4 
n.a. n.a. 
PMSF Used with 1 mM final concentration, stock dissolved in 
isopropanol and stored at 4°C 
n.a. n.a. 
RIPA lysis 
buffer 
1% (v/v) Triton X-100, 0.1% (v/v) SDS, 10% (v/v) glycerol, 20 
mM TRIS, 150 mM NaCl, 12 mM sodium deoxycholate, 1 mM 
EDTA, pH7.4 
n.a.  n.a. 
Table 5. List of buffers, tissues and mice for preparation of lysis samples. 
 
 
Cloning plasmids 
 
DNA was quantified using the EPOCH Reader with the Take 3 Micro-volume plate controlled by 
the Gen 5 software. For DNA quantification a Take 3 Session started selecting ‘Nucleic Acid 
 
  
 
16 
 
Quantification’, and dsDNA within Gen 5. The service of GATC Biotech was used to sequence 
plasmids.   
 
PCR amplification of nucleotide sequences: 
Nucleotide sequences were amplified by polymerase chain reaction (PCR). To 12.5 µl of the 
PFU Ultra II HS 2X Master Mix from Agilent Technologies 5 µg of a template DNA was added 
together with 0.4 µM per primer and adjusted to 25 µl total volume with water. The program for 
PCR was as follows:   
94°C for 60 s, then 35 cycles of 94°C for 30 s, 50-65°C for 30 s (5°C below Tm of primers), and 
72°C for 60 s / 1000 nucleotides before a final 72°C for 10 min.  
The products from the PCR were then separated in a 1% (w/v) agarose gel, purified from the gel 
and ligated into the plasmid pJet1.2 linearized with EcoRV from the CloneJET PCR Cloning Kit 
from Thermo Fisher Scientific.  
 
Annealing of complementary oligonucleotides to obtain linker sequences:  
Short linker sequences were prepared by annealing two complementary oligonucleotides. The 
oligonucleotides were designed to leave short overhangs that correspond to the restriction sites 
used to insert the linker into a plasmid. 250 pmol of each oligonucleotide was added to 50 µM 
NaCl in a total volume of 105 µl. The primer mix was heated to 95°C for 10 minutes and left in 
the thermo cycler until it reached room temperature to anneal the primers.  
 
Restriction digest of plasmids and DNA fragments:  
Restriction digests were performed with <5 µg of DNA in FastDigest Green buffer adding 2 µl 
per respective FastDigest enzyme adjusting the total volume to 50 µl with water. The digest was 
performed for 1h at 37°C. The digested fragments were separated in a 1% (w/v) agarose gel 
and excised and eluted for ligation.  
 
Agarose gel electrophoresis: 
1% (w/v) agarose was prepared in TAE buffer and heated until boiling before 0.01% (v/v) of 
SYBR Green was added and the gel was casted. DNA was loaded in FastDigest Green Buffer 
and the electrophoresis was performed with 120V.  
 
Purification of DNA from Agarose gels: 
DNA fragments needed for further cloning steps were excised from the agarose gel and 
transferred into a microcentrifuge tube. The extraction of the DNA from excised agarose pieces 
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was performed with the PureLink Quick Gel Extraction Kit according to the manufactures 
manual.  
 
Ligation of DNA fragments into a vector:  
DNA fragments with matching ends were ligated using the T4 ligase and the 5x ligation buffer 
from the Rapid DNA Ligation Kit by Thermo Fisher Scientific. Ligations were performed for 20 
minutes at 22°C. For ligations of PCR products into linearized pJet1.2, the ligation mix was 
prepared as follows: 1 µl of T4 ligase, 4 µl of 5x ligation buffer, 1 µl of pJet1.2, 8 µl of gel 
separated and purified PCR product, and 6 µl water. For ligations of DNA fragments into other 
plasmids the ligation mix was prepared as follows: 4 µl 5x ligation buffer, 1 µl T4 ligase, and 15 
µl of combined DNA fragment to be ligated and the recipient plasmid in a 3 to 1 molar ratio.  
 
Transformation of bacteria with plasmids: 
For chemo-competent transformation of DNA into bacteria the following bacterial strains were 
used: E. coli BL21, DH5α, and DH5α-T1R from Thermo Fischer Scientific, and ClearColi® 
BL21(DE3) from Lucigen.  
The chemo-competent bacterial stocks were thawed on ice and 3 µl DNA were added to 10-50 
µl bacteria and incubated for 30 minutes on ice. The bacteria were then heat shocked at 42°C 
for 60 seconds before being incubated for 2 minutes on ice. 200 µl of LB medium were added to 
the bacteria that were then shaken with 750 rpm at 37°C for 1h before 150 µl were spread on a 
LB agar plate supplemented with the antibiotic corresponding to the resistance provided by the 
transformed plasmid. The LB agar dishes were incubated over night at 37°C before colonies 
were harvested.  
 
Preparation of plasmid DNA from bacteria:  
To multiply single copies of plasmids, these plasmids were transformed into bacteria, plated on 
LB agar dishes and single colonies were used to inoculate 5 ml LB medium per colony. The 
cultures were shaken over night at 37°C before it was either used for the direct preparation of 
plasmid DNA or for storage, where 600 µl of the bacterial culture were mixed with 400 µl of 50% 
(v/v) glycerol in water and stored at -80°C. To inoculate a culture from a glycerol stock, a pipette 
tip was used to scrape off bacteria and transfer them into 5 ml LB medium for miniprep, or into 
120 ml LB medium for a maxiprep. Either way the cultures were then incubated over night at 
37°C with constant rotation. The plasmid DNA was isolated from the bacterial cultures using the 
PureLink Quick Gel Extraction Kit or the PureLink HiPure Plasmid Filter Maxiprep Kit 
respectively according to the manufacturers manual.  
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Name Description REF number Supplier 
Agarose LE agarose 840004 Biozym 
CloneJET PCR 
Cloning Kit 
Blunt-ended PCR products generated with a 
proofreading enzyme are ligated directly into the cloning 
vector. 
K1232 Thermo Fisher 
Scientific 
TAE buffer, 50x 2 M Tris, 1 M acetic acid, 50 mM EDTA in H2O, pH8.5 CL86.2 Carl Roth 
SYBR Green iQ SYBR Green Supermix 170-8884 BioRad 
PureLink Quick Gel 
Extraction Kit 
Silica spin column, binding <15 µg DNA, purification of 
DNA from TAE or TBE based agarose gels 
K210012 Thermo Fisher 
Scientific 
PureLink Quick 
Plasmid Miniprep 
Kit 
Silica Spin Column, plasmid prepared from 2-4 ml 
bacterial culture 
K210011 Thermo Fisher 
Scientific 
Rapid DNA Ligation 
Kit 
The kit contains T4 DNA ligase and a specially-
formulated 5X rapid ligation buffer optimized for fast and 
efficient DNA ligation. 
K1422 Thermo Fisher 
Scientific 
DH5α-T1R E. coli MAX Efficiency® DH5α™-T1R Competent Cells 12297016 Thermo Fisher 
Scientific 
DH5α E. coli Subcloning Efficiency™ DH5α™ Competent Cells 18265017 Thermo Fisher 
Scientific 
ClearColi® 
BL21(DE3) 
Genotype: F– ompT hsdSB (rB- mB-) gal dcm lon 
λ(DE3 [lacI lacU 5-T7 gene 1 ind1 sam7 nin5]) 
msbA148 ΔgutQΔkdsD ΔlpxLΔlpxMΔpagPΔlpxPΔeptA 
60810-1 Lucigen 
E. coli BL21 Genotype: E. coli B F– ompT gal dcm lon hsdSB(rB–
mB–) [malB+]K-12(λS) 
n.a. n.a. 
LB medium For 1L medium use 25 g X968.4 Carl Roth 
LB agar For 1L: 10 g SELECT Peptone 140, 5 g SELECT yeast 
extract, 5 g sodium chloride, 12 g SELECT Agar 
22700025 Thermo Fisher 
Scientific 
Glycerol  >99% purity, CAS # 56-81-5 G6279-500ml Sigma Aldrich 
PureLink HiPure 
Plasmid Filter 
Maxiprep Kit 
For bacterial plasmids <40kb prepared from 100 ml 
bacterial culture 
K210017 Thermo Fisher 
Scientific 
Table 6. List of buffers, reagents, and bacterial strains for plasmid cloning. 
 
Plasmid 
number 
Plasmid description Protein 
name 
Source 
#00506 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, aa: GAP, 
LPETG5 tag, Linker: AAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-
2a Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney 
murine sarcoma virus M28247.1)  
6His-
LPETG-
L2-CTRL-
Fc 
Simon 
Görgen 
#00834 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPFGSLAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-2a 
Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney 
murine sarcoma virus M28247.1)  
 
6His-
LPETG-
L9-CTRL-
Fc 
Simon 
Görgen 
#00835 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
6His-
LPETG-
L19-
CTRL-Fc 
Simon 
Görgen 
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intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPRPPDPPRPPPFGSLAA, XA cleavage site (IDGR), aa: AAASG, 
mouse gamma-2a Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 
3’LTR (Moloney murine sarcoma virus M28247.1)  
#00469 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: AP, hTYRO3 aa 42-429 (Ref. seq. NM_006293.3), aa: AAA, XA cleavage 
site (IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain Fc (Ref. Seq. 
NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma virus M28247.1)  
6His-
LPETG-
L2-
hTYRO3-
Fc 
Simon 
Görgen 
#00792 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPFGSAP, hTYRO3 aa 42-429 (Ref. seq. NM_006293.3), aa: AAA, XA 
cleavage site (IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain Fc (Ref. Seq. 
NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma virus M28247.1)  
6His-
LPETG-
L9-
hTYRO3-
Fc 
Simon 
Görgen 
#00793 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPRPPDPPRPP PFGSAP, hTYRO3 aa 42-429 (Ref. seq. 
NM_006293.3), aa: AAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-
2a Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney 
murine sarcoma virus M28247.1)  
6His-
LPETG-
L19-
hTYRO3-
Fc 
Simon 
Görgen 
#00470 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: AP, hAXL aa 33-451 (Ref. seq. NM_021913), aa: AAA, XA cleavage site 
(IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain Fc (Ref. Seq. NT96355 
Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma virus M28247.1)  
6His-
LPETG-
L2-hAXL-
Fc 
Simon 
Görgen 
#00794 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPFGSAP, hAXL aa 33-451 (Ref. seq. NM_021913), aa: AAA, XA 
cleavage site (IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain Fc (Ref. Seq. 
NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma virus M28247.1)  
6His-
LPETG-
L9-hAXL-
Fc 
Simon 
Görgen 
#00795 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPRPPDPPRPP PFGSAP, hAXL aa 33-451 (Ref. seq. NM_021913), 
aa: AAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain 
Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma 
6His-
LPETG-
L19-hAXL-
Fc 
Simon 
Görgen 
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virus M28247.1)  
#00471 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: AP, hMER aa 22-505 (Ref. seq. NM_006343 with R466K, I518V, S627S), 
aa: AAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-2a Ig heavy chain 
Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney murine sarcoma 
virus M28247.1)  
6His-
LPETG-
L2-MER-
Fc 
Simon 
Görgen 
#00832 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPFGSAP, hMER aa 22-505 (Ref. seq. NM_006343 with R466K, 
I518V, S627S), aa: AAA, XA cleavage site (IDGR), aa: AAASG, mouse gamma-2a 
Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 3’LTR (Moloney 
murine sarcoma virus M28247.1)  
6His-
LPETG-
L9-hMER-
Fc 
Simon 
Görgen 
#00833 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), SV40 early promoter, 
SV40 origin of replication, partial SV40 small t-antigen, hEF1 promoter including 
intron, signal peptide (Ref. seq. EU697460.1 nt: 1-45), hexa-His tag, LPETG5 tag, 
Linker: APPPRPPDPPRPP PFGSAP, hMER aa 22-505 (Ref. seq. NM_006343 
with R466K, I518V, S627S), aa: AAA, XA cleavage site (IDGR), aa: AAASG, 
mouse gamma-2a Ig heavy chain Fc (Ref. Seq. NT96355 Ighg2c, aa 109-340), 
3’LTR (Moloney murine sarcoma virus M28247.1)  
6His-
LPETG-
L19-
hMER-Fc 
Simon 
Görgen 
#00039 pEQ30 vector for the bacterial expression of recombinant proteins. pRB322 origin 
of replication, bla gene for Ampicillin resistance, CmR, rrnBT1 terminator. 
Bacterial transcription cassette: T5 promoter / lac operator element, MRGS amino 
acids, hexa-His tag, GS amino acids (BamHI), srtA Δ25 amino acids from n-
terminus (Ref. Seq. AP014921.1, 2599644 to 2600264), lambda t0 terminator.  
srtAΔ25  
(S. 
aureus) 
Hidde 
Ploegh 
 
#00040 pET28a vector for the bacterial expression of recombinant proteins. pRB322 origin 
of replication, f1 origin of replication, kanR gene for Kanamycin resistance, LacI 
promoter, LacI cds. Bacterial transcription cassette: T7 promoter, lac operator, 
MRSS amino acids, hexa-His tag, SSGLVPRG amino acids including BamHI site, 
srtA Δ80 amino acids from n-terminus (Ref. Seq. AP017629.1, 881384 to 
882133), T7 terminator. 
srtAΔ80  
(S. 
pyogenes) 
Hidde 
Ploegh 
 
#00595 pET30b vector for the bacterial expression of recombinant proteins. pRB322 origin 
of replication, f1 origin of replication, kanR gene for Kanamycin resistance, LacI 
promoter, LacI cds, rop cds. Bacterial transcription cassette: T7 promoter, lac 
operator, ATG start codon, srtA Δ59 amino acids from n-terminus (Ref. Seq. 
AP014921.1, 2599644 to 2600264 including the following mutations: P94R, 
D160N, D165A, G167E, K190E, K196T), LE amino acids (XhoI site), hexa-His tag, 
TGA stop codon, T7 terminator 
5M srtA 
(S. 
aureus) 
Hidde 
Ploegh 
 
 
#00636 pET30b vector for the bacterial expression of recombinant proteins. pRB322 origin 
of replication, f1 origin of replication, kanR gene for Kanamycin resistance, LacI 
promoter, LacI cds, rop cds. Bacterial transcription cassette: T7 promoter, lac 
operator, ATG start codon, srtA Δ59 amino acids from n-terminus (Ref. Seq. 
AP014921.1, 2599644 to 2600264 including the following mutations: P94R, 
E105K, E108Q, D160N, D165A, G167E, K190E, K196T), LE amino acids (XhoI 
site), hexa-His tag, TGA stop codon, T7 terminator 
7M srtA 
(S. 
aureus) 
Hidde 
Ploegh 
 
#00681 pRP vector for the integration into a mammalian genome and expression of a 
recombinant protein. pBR322 origin of replication, bla gene for Ampicillin 
resistance. Mammalian transcription cassette: CMV promoter, 5’LTR (Moloney 
murine sarcoma virus AHAH002383S1), packaging signal (FJ756409), pac gene 
for Puromycin resistance protein (Ref. Seq. M25346.1), CMV promoter, signal 
peptide (Ref. seq. EU697460.1 nt: 1-45), aa: GS, hIGHG1 (Ref. seq. P01857 (Δ1-
hIGHG1 
Fc domain 
Rainer 
Stahl 
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98,E236D, M241L, stuffer sequence, 3’LTR (Moloney murine sarcoma virus 
M28247.1) 
Note that connecting segments of amino acids are marked as ‘aa:’ followed by the respective amino acid sequence as 
one letter code. 
Table 7. List and description of plasmids. 
 
 
Design, nomenclature and production of bait and control proteins 
 
The following experiments were perfomed with bait and control proteins that were designed as 
follows: Starting from the c-terminus, a mouse IgG2a Fc domain is used for purification and 
detection. A XA cleavage site was included to separate and potentially cleave the Fc domain 
from a respective TAM receptor’s ectodomain for the bait proteins, and from the n-terminal tags 
for the control protein. The ectodomain of the TAM receptors without the endogenous signal 
peptide was fused to the recognition motif of S. aureus sortase A separated by one of three 
linkers. The linkers have a length of 2, 9, or 19 amino acids and are named L2, L9, and L19 
respectively. For detection and purification puropses I included a hexa-His tag in front of the srtA 
motif. At the n-terminus of the bait and control proteins the signal peptide of trypsin leads to the 
secretion of the proteins. The control proteins contain the same tags as the bait proteins, but do 
not contain an ectodomain.  
The bait and control proteins used in the following experiments were expressed in 293T cells 
either grown in serum freen DMEM or in 10% FBS containing DMEM and were purified via 
Protein A alone, or via Protein A followed by a HisTrap purification respectively. The molecular 
weight, the concentration, and purity of the prepared proteins were determined by comparing a 
known volume of the preparations to a titration a BSA standard in Coomassie stained SDS-
PAGE gels (data not shown).  
To distinguish the different versions of the bait and control proteins in the thesis, the proteins 
only purified and still posessing the unalterd n-terminus with the hexa-His tag will be named 
hexa-His-L2, -L9, or -L19 bait and control proteins. After the hexa-His-LPET is removed from the 
n-terminus by a srtA reaction, the proteins will be named L2, L9, or L19 bait and control proteins. 
The proteins with the diazirine cross-linker sortase tagged to the n-terminus will be named 
Diazirine-L2, L9, or L19 bait and control proteins.  
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Expression and purification of recombinant proteins  
 
Expression of recombinant proteins in bacteria: 
Transient expression of recombinant protein in bacteria was performed using the strain E. coli 
BL21. For expression of recombinant protein preventing TLR stimulation by LPS the E. coli 
strain ClearColi® BL21(DE3) by Lucigen was used. 50 ng of the expression plasmid were 
transformed into a 50 µl aliquot of chemo competent bacteria and incubated for 30 minutes on 
ice before being heat shocked at 42°C for 60 seconds and rested on ice for 2 minutes. 200 µl of 
LB medium were added to the culture, was incubated for 1 hour at 37°C with constant rotation of 
700 rpm, before 150 µl of the culture were spread on a LB dish supplemented with an antibiotic 
corresponding to the resistance provided by the transformed plasmid. The dish was incubated 
over night at 37°C. Several colonies were inoculated into 6 ml LB medium supplemented with 
the antibiotic and incubated at 37°C with constant rotation over night. The cultures were stored 
as glycerol stocks at -80°C by mixing 600 µl of the bacterial culture with 400 µl of 50% (v/v) 
glycerol in water. The cultures were then tested for expression levels. From the glycerol stock of 
the best expressing clone a pre-culture of 24 ml was inoculated and grown at 37°C and constant 
rotation over night. The optical density at 600 nm was determined and a volume resulting in an 
OD600 of 0.015 diluted in 1 liter was added to 1 liter LB medium supplemented with the 
antibiotic to select for the respective expression plasmid. The 1 liter culture was incubated at 
37°C and constant rotation until an OD600 of 0.4 was reached. The expression of the protein 
was induced by the addition IPTG to a concentration of 1 mM in the culture then further 
incubated for 4 hours. The bacteria were then harvested by centrifugation with 3200 g at 4°C for 
15 minutes, washed with 20 ml of PBS and centrifuged again with 3200 g at 4°C for 10 minutes. 
The bacterial pellet was lysed in 20 ml of bacterial lysis buffer supplemented with 1 mM PMSF, 
cOmpleteTM, and 500 units of Benzonase® Nuclease. The lysate was sonicated with 4 cycles of 
one-minute sonication with 50% cycles at 100% power and one-minute rest on ice. The lysate 
was cleared of cellular debris by centrifugation with 12000 g at 4°C for 10 minutes. The 
supernatant was filtered through a 150ml Vacuum Filter with a pre size of 0.22 µm. The 
recombinant protein was then purified from the filtrate as described under ‘Protein purification via 
FPLC’.  
 
Expression of recombinant proteins in mammalian cells: 
Transient expression of recombinant protein in mammalian cells was performed using 293T 
cells. The cells were seeded over night to 40,000 cells per cm2 a day before the transfection. On 
the day of transfection DNA and PEI are mixed in OptiMEM using 3 µg PEI per µg DNA. The 
transfection mix is incubated 20 minutes at room temperature, and then applied to the cells. 30 
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µg of plasmid was used per 15 cm dish. 4h after the transection the medium is exchanged either 
to 10% (v/v) DMEM or serum free DMEM.  
 
Protein purification via FPLC: 
For purification of proteins by affinity chromatography the ÄKTApurifier TM 100 from GE was 
used. TAMecto-Fc and Control-Fc proteins expressed in serum free medium were purified using 
Protein A columns. TAMecto-Fc and Control-Fc proteins expressed in serum containing medium 
were purified first using Protein A columns, and then NiSO4 charged HisTrap columns. For all 
proteins purified, the buffer was exchanged to srtA reaction buffer, and the sample was 
concentrated using 10k centrifugal filter units according to manufacturers recommendations. 
Purified proteins were stored at -80°C in LoBind tubes.  
 
Purifying Fc tagged proteins: 
Proteins possessing mouse immunoglobulin Fc domains were affinity purified with Protein A 
columns. For proteins tagged with a photo-activatable cross-linker the procedure was performed 
in the dark. The pre-packed Protein A columns were used according to manufacturers 
recommendations. To prevent protein cross over in between preparations, individual columns 
were used for each type of protein to be purified. The preparations were performed at 
temperatures between 4 and 10 degree Celsius.  
Before loading, the column was washed with 5 times the column volume of water and 
equilibrated with 5 times the column volume of PBS or TBS. Fc tagged protein-containing 
medium or lysate was loaded on the column and washed with 5 times the column volume of 
PBS or TBS. The Fc tagged protein was then eluted during fractionation using the Pierce IgG 
elution buffer. The protein containing fractions were either used for further purification or to 
exchange the buffer.  
 
Purifying His tagged proteins: 
Proteins possessing multi His tags were affinity purified with HisTrap columns. The columns 
were charged with NiSO4 and further used according to manufacturers recommendations at 
temperatures between 4 and 10 degree Celsius.  
Before loading, the pre-charged column was washed with 5 times the column volume of water 
and equilibrated with 5 times the column volume of His binding buffer. His-tagged protein 
containing solutions were loaded on the column and washed with 5 times the column volume of 
His wash buffer containing 5 to 20 mM Imidazole. After washing, the protein was eluted with His 
elution buffer containing 500 mM Imidazole during fractionation. The protein containing fractions 
were collected and the buffer was exchanged to srtA reaction buffer.  
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Exchanging buffers using desalting columns: 
One 5 ml column or two 5 ml columns aligned consecutively were used according to the 
manufacturers recommendations. Before loading the sample, the columns were washed with 
water and equilibrated in the desired buffer. The TAMecto-Fc proteins purified by Protein A or 
Protein A and His purification were buffered in srtA reaction buffer. The protein sample was 
loaded with the beginning of sample fractionation. Fractions were pooled from the beginning of 
protein elution until the original buffer began eluting. The combined fractions were then 
concentrated using 10k centrifugal filter units according to the manufacturers recommendations.  
 
Name Formulation REF number Supplier 
10k centrifugal 
filter units 
Amicon Ultra-2 Centrifugal Filter Unit with Ultracel-10 
membrane 
UFC201024 Millipore 
150mL Vacuum 
Filter 
13.6 cm
2
 polyethersulfone membrane with 0.22 µm pore 
size, 150 ml funnel capacity, 150 ml bottle capacity 
431153 Corning 
Ampicillin Ampicillin, ready made solution, 100 mg/mL, 0.2 μm filtered, 
CAS RN 69-52-3, used at 100 µg/ml 
A5354 Sigma Aldrich 
Bacterial lysis 
buffer 
50 mM Tris pH8.0, 10% (v/v)  glycerol, 0.1% (v/v)  Triton X-
100, 1 mM PMSF, cOmplete
TM
 
n.a. n.a. 
ClearColi® 
BL21(DE3) 
Genotype: F– ompT hsdSB (rB- mB-) gal dcm lon λ(DE3 [lacI 
lacUV5-T7 gene 1 ind1 sam7 nin5]) msbA148 ΔgutQΔkdsD 
ΔlpxLΔlpxMΔpagPΔlpxPΔeptA 
60810-1 Lucigen 
E. coli BL21 Genotype: E. coli B F– ompT gal dcm lon hsdSB(rB–mB–) 
[malB+]K-12(λS) 
n.a. n.a. 
His binding buffer 20 mM sodium phosphate, 500 mM NaCl, pH 7.4 n.a. n.a. 
His elution buffer 20 mM sodium phosphate, 500 mM NaCl, 500 mM 
Imidazole, pH 7.4 
n.a. n.a. 
His wash buffer 20 mM sodium phosphate, 500 mM NaCl, 5-20 mM 
Imidazole, pH 7.4 
n.a. n.a. 
IPTG Isopropyl-β-D-thiogalactopyranosid, CAS-Nr. [367-93-1] CN08.3 Carl Roth 
Kanamycin Kanamycin sulfate, used at 100 µg/ml 11815024 Thermo Fisher 
Scientific 
LB medium  25 g/L LB medium (Luria/Miller) in water X968.4 Carl Roth 
LB agar 32 g/L LB Agar, powder (Lennox L agar) in water 22700025 Thermo Fisher 
Scientific 
Pierce™ IgG 
Elution Buffer 
IgG elution buffer, pH2.8 21004 Thermo Fisher 
Scientific 
HiTrap Desalting Pre-packed with Sephadex G-25 Superfine 17140801 GE 
HisTrap FF Crude Pre-packed with pre-charged Ni Sepharose 6 Fast Flow 11-0004-58 GE 
HisTrap HP Pre-packed with Ni Sepharose High Performance 17-5247-01 GE 
HiTrap Protein A 
HP 
Pre-packed Protein A Sepharose High Performance column 
(1 ml) for preparative purification of antibodies 
17-0402-01 GE 
HiTrap rProtein A 
FF 
Pre-packed with rProtein A Sepharose Fast Flow for 
purification and fractionation of IgG subclasses  
17-5079-01 GE 
1.5 ml LoBind 
tubes 
Protein LoBind Tubes, Protein LoBind, 1.5 mL, PCR clean 0030108116 Eppendorf 
2 ml LoBind tubes Protein LoBind Tubes, Protein LoBind, 2.0 mL, PCR clean 0030108132 Eppendorf 
Pierce IgG elution 
buffer 
pH 2.8, amine based 21004 Thermo Fisher 
Scientific 
Table 8. List of buffers, reagents, bacterial strains, and equipment for protein expression and 
purification. 
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Immunoprecipitation of proteins 
 
Dynabeads:  
Superparamagnetic beads were used to capture, precipitate and wash proteins containing an 
affinity tag. In case the concentration of protein to be captured in the solution to be purified from 
was known, beads were used in a volume corresponding to 1.5 times the binding capacity 
compared to the actual protein concentration. In case the concentration of protein to be 
precipitated was not known, the effective volume of beads per volume of protein solution was 
determined empirically.  
The general washing procedure for Dynabeads includes 3 steps. First the beads in the sample 
or in buffer are placed on a DynaMagTM-2 magnet in microcentrifuge tubes for 1 minute. Then 
the buffer was replaced with 5 times the original bead volume or 1 ml of washing buffer. The 
microcentrifuge tube was then rotated for 2 minutes on the MACSmix Tube Rotator fitted with 
the small tube rack. After repeating these steps according to the number of washes, the wash 
buffer was removed and the beads were resolved according to the follow up procedure.  
 
Washing of Bait-Fc proteins with Protein A Dynabeads: 
To wash Bait-Fc proteins in defined solutions, beads with a binding capacity of 1.5 times the 
concentration of protein to be washed were transferred from the bead stock to a microcentrifuge 
tube. The beads were once washed with assay buffer before being added to the protein solution. 
The solution was then incubated with the beads for 30 minutes at room temperature before 
being washed 3 times with 5 times the volume of the protein solution or maximally 1 ml.  
 
Pre-clearing of lysates from biotinylated proteins via Dynabeads: 
An excess amount of twice the volume of Dynabeads M-280 Streptavidin compared to the lysate 
solution to be cleared was washed. As wash buffer the lysis buffer used during the preparation 
of the sample to be cleared was used. After washing the beads, the wash buffer was removed 
and the sample was added to the beads and incubated for 30 minutes at RT. The bead 
containing lysate was then put on the DynaMagTM-2 magnet for 1 minute, before the cleared 
lysate was transferred to a new microcentrifuge tube.  
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Magnetic separation of Microbeads with the HOKImag:  
 
Figure 3. Schematic setup for magnetic separation of microbeads. 
 
To magnetically separate microbeads from the liquid phase a HOKImag with 2-tesla field 
strength was used. For each separation a column was prepared with a drinking straw as basis. 
The tips of two 1 ml serological pipettes were cut and one was inserted into each end of the 
straw. The connections were sealed with 1 cm of a 4 mm silicone tube pushed over the straw 
and pipette overlapping area. On the long side of the column, a 1.5mm silicone tube was 
attached to the end of the pipette in order to reach into vessels containing microbead 
suspensions or buffers. On the short side of the column, a 1.5mm silicone tube was attached to 
the end of the pipette to connect the column with the pump tubing. The pump tubing was 
inserted into the MINIPLUS®3 peristaltic pump from Gilson and in turn connected to a 1.5 mm 
tube reaching into a collection tube. 
For the magnetic separation, the HOKImag containing the column was put to a flat angle of 10° 
to 30° for the liquid to move upwards but to prevent gravitational forces to overcome the suction 
and the capillary force to cause the liquid column to drip. The liquid containing the microbeads 
was slowly moved into the column until all the liquid was in the magnetic field. For an efficient 
magnetic separation the microbeads were kept for 45 minutes in the magnetic field. After the 
separation the beads were washed slowly with wash buffers.  
To remove the magnetic beads from the column, first a plunger from a 1 ml syringe was 
modified. Therefore a 1000 µl pipette tip was cut where it has about 2 mm of diameter and again 
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where it has about 5 mm diameter. The 2 to 5 mm diameter part was then used to replace the 
rubber part of a 1 ml syringe’s plunger. Then the part of the column placed in the magnet was 
emptied from all liquid before being cut above and below the magnet and transferred into a 
microcentrifuge tube. With the modified plunger the beads were pushed into the tube. With the 
plunger still stuck though the column the remaining beads were washed from the column wall 
with the respective suspension buffer. The microcentrifuge tube containing the microbeads in 
the suspension buffer, the column and the plunger was placed into a 50 ml flacon and 
centrifuged for 1 minute and 3000 g at RT. Then the column and the plunger were removed from 
the microcentrifuge tube.  
 
Washing of Bait-Fc proteins with Protein A microbeads: 
To wash Bait-Fc proteins in defined solutions, microbeads with a binding capacity of 1.5 times 
the concentration of protein to be washed were transferred from the bead stock to the protein 
solution. The solution was then incubated with the microbeads for 30 minutes at room 
temperature before being loaded into a column inserted into the HOKImag. The microbeads 
containing protein solution was incubated for 45 minutes in the magnetic field before being 
washed with 5 ml of wash buffer. The column was then removed and the microbeads were 
resolved in a desired buffer and eluted into a microcentrifuge tube.  
 
Name Description REF number Supplier 
1.5 mm tube Tubing, silicone, extended life, by Spectrum SPECACTU-E14-
25N 
VWR 
4 mm tube Sterilin™ silicone tubing, 4mm inner and 6 
mm outer diameter,  
TSR0400100P Thermo Fisher 
Scientific 
Drinking straw 5 mm x 24 cm, transparent, flexible n.a. n.a. 
Pump tubing PVC standard – pump tubing with flared end, 
2 bridges, 2.565 mm outer, and 0.889 mm 
inner diameter, color code orange/orange 
38-0035F Spetec 
Serological pipette, 1 ml with cotton plug, polystyrene, sterile, non-
pyrogenic/endotoxin-free, non-cytotoxic 
86.1251.001 Sarstedt 
Dynabeads™ M-280 
Streptavidin 
Superparamagnetic beads with a uniform 
size of 2.8 µm, covered with a monolayer of 
recombinant Streptavidin, blocked with BSA  
11205D Thermo Fisher 
Scientific 
Dynabeads™ Protein A 
for Immunoprecipitation 
Dynabeads™ Protein A are uniform, 2.8 µm 
superparamagnetic beads with recombinant 
Protein A covalently coupled to the surface. 
10008D Thermo Fisher 
Scientific 
MicroBeads Protein A µMACS Protein A MicroBeads 130-071-001 Miltenyi Biotech 
Dynabeads™ Anti-
Mouse IgG 
Dynabeads™ M-280 Sheep Anti-Mouse IgG, 
2.8 μm bead size 
11201D Thermo Fisher 
Scientific 
Table 9. List of reagents and material for immunoprecipitation of proteins. 
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Detection of protein-protein interaction 
 
Detection of protein-protein interaction with recombinant proteins: 
To detect binding between a protein of interest and TAM-Fc fusion proteins, a titration of the 
recombinant protein of interest was prepared and 25 µl from each titration step were added to a 
half-area 96-well ELISA plate in duplicates and incubated over night at 4°C. After washing to 
remove unbound protein, the plate was incubated 2h at RT with 50 µl blocking buffer per well. 
The blocking buffer was removed and 25 µl of TYRO3-Fc, AXL-Fc, MER-Fc, Control-Fc, with the 
2L linker version were used with the hexa-His tag removed via srtA tagging with triglycine if not 
stated elsewise. Proteins were concentrated to 25 µM in blocking buffer was added for 2h at RT 
if not stated otherwise. Alternatively Antibodies were used in the same volume and 
concentration. The plate was washed and the remaining Fc tagged proteins were marked with 
25 µl per well of HRP labeled rat anti-mouse IgG from Cell Signaling (REF #7076) diluted 1/2000 
for 30 minutes in the dark. After washing, 50 µl of ELISA substrate was added until a mid 
intensive blue color has appeared. The reaction was stopped using 25 µl of 1M sulfuric acid. The 
absorbance at 450 nm (Lm1) and 570 nm (Lm2) per well were measured with the SpectraMax i3 
from Molecular Devices using the SoftMax Pro 6.3 software calculating the combined 
absorbance of Lm1 – Lm2. 50 µl of 1M TRIS was used to neutralize the solution before 
discarding it.   
Washing of ELISA plates was performed using the BioTek Microplate Washer 405 T5 with 3 
cycles of 100 µl ELISA wash buffer or using a multichannel pipette. 
 
Name Formulation REF number Supplier 
α-Biotin-Rabbit-Ig Anti-biotin (D5A7) Rabbit mAb  5597 Cell Signaling 
Blocking buffer 5% (w/v) milk powder in PBS n.a. n.a. 
ELISA plate High binding, half area, flat bottom, 96-well plate 675061 Greiner Bio-
One 
ELISA substrate OptEIA™ TMB Substrate Reagent Set 555214 BD 
ELISA wash buffer 0.05% (v/v) Tween-20 in PBS n.a. n.a. 
OptEIA Substrate 
A 
ELISA substrate for HRP 51-2606KC BD 
OptEIA Substrate 
B 
ELISA substrate for HRP 51-2607KC BD 
Wash buffer 0.1% (v/v) Tween-20 in TBS n.a. n.a. 
hAHSG / hFETUA Human fetuin-A (His tag), Met1-Val367 with a C-terminal poly-
His tag, Ref seq. NP_001613.2, Expression host: human cells 
10318-H08H Sino 
Biological 
bAlb Pierce Bovine Serum Albumin Protein Assay Standard, 
buffered in 0.9% saline solution with 0.05% sodium azide, 
formulated at 2.00 +/-0.03 mg/mL 
23209 Thermo 
Scientific 
hC6 Human recombinant C6 protein, His tagged, expressed in 
HEK293 Cells, Purity > 90% as determined by SDS-PAGE 
12426-H08H-
100 
Sino 
Biological 
hCNDP2 / hCPGL Recombinant human cytosol nonspecific dipeptidase, 
Spodoptera frugiperda (Sf 21, baculovirus) derived, Met1-
Asp475, with a C-terminal 10-His tag 
3560-ZN R&D 
hENO1 Human ENO1 / Enolase 1 / alpha-enolase protein (His tag), 
Ref Seq P06733-1, Met1-Lys434 with poly His tag at N-
11554-H07E Sino 
Biological 
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terminus, expression host: E. coli 
hFINC / hFN1 Human plasma-derived Fibronectin protein, Purity > 90% 
confirmed by SDS-PAGE 
1918-FN-02M Sino 
Biological 
hGAS6 Recombinant human Gas6 protein 
Ala49-Ala678, with a c-terminal 6-His tag, reconstituted in 
water, expressed in Mouse myeloma cell line NS0, Purity 
>90% confirmed by SDS-PAGE 
885-GS-050 R&D 
hGNB2L1 / 
hRACK1 
Human GNB2L1 (P63244), Met1-Arg317, with an N-terminal 
poly-His and MBP tag, expression host: E. coli 
12498-H10E Sino 
Biological 
hMPO Recombinant human Myeloperoxidase/MPO protein 
Ala49-Ser745, with a C-terminal 10-His tag, expressed in 
Mouse myeloma cell line NS0, Purity >90% confirmed by 
SDS-PAGE 
3174-MP R&D 
mMPO Recombinant mouse Myeloperoxidase/MPO protein 
Met16-Thr718, with a C-terminal 10-His tag, expressed in 
Mouse myeloma cell line NS0, Purity >90% confirmed by 
SDS-PAGE 
3667-MP-250 R&D 
hNPEPPS Recombinant human Puromycin-sensitive aminopeptidase / 
NPEPPS, Spodoptera frugiperda (Sf 21, baculovirus) derived, 
Pro46-Val919, with an N-terminal Met and a C-terminal 10-His 
tag, Accession # P55786 
6410-ZN-010 R&D 
hPKM2 Recombinant human PKM2, E. coli derived, Ser2-Pro531, 
with N-terminal Met and 6His tag 
7244-PK-020 R&D 
hPRDX5 Human peroxiredoxin 5 (His tag), Met53-Leu214, with a poly-
His tag at N-terminus, Ref seq. P30044-2, expression host: E. 
coli 
11263-H07E Sino 
Biological 
hRAB14 Buffered in 50mM Tris HCl, 2mM beta-mercaptoethanol, 
100mM Sodium chloride, 10mM Magnesium chloride, 0.01mM 
GDP, pH 8.0 
ab90105 Abcam 
hRAN 
 
 
Recombinant protein with a His-tag corresponding to amino 
acids 1 to 216 of human RAN, Source is E. coli, Buffered in 
20 mM Tris-HCl (pH8.0) containing 1 mM DTT, 10% (v/v) 
glycerol, >90% purity confirmed by SDS-PAGE  
NBP1-45255-
0.05mg 
Novus 
Biologicals 
hRPS3 Recombinant protein with a His-tag corresponding to amino 
acids 1 to 243 of human RPS3, Source is E. coli, Buffered in 
20 mM Tris-HCl (pH8.0) containing 1 mM DTT, 10% (v/v) 
glycerol, 0.1 M NaCl, >90% purity confirmed by SDS-PAGE 
NBP1-72495-
50ug 
Novus 
Biologicals 
hS100A6 Recombinant human S100A6 with 6His tag, Source is 
Baculovirus-Insect Cells, lyophilized from 50mM Tris, 100mM 
NaCl, 0.5mM PMSF, 1mM TCEP, pH 8.0, additionally 5% - 
8% trehalose, mannitol and 0.01% Tween80, Purity > 96% 
determined by SDS-PAGE 
10939-H08B-
20 
Sino 
Biologicals 
hS100A8/A9 
chimera 
E. coli-derived human S100A8/ S100A9 non-covalently-linked 
heterodimer protein 
Met1-Glu93 (S100A8) & Thr2-Pro114 (S100A9), reconstituted 
in PBS, Purity >95% confirmed by SDS-PAGE 
8226-S8-050 R&D 
hSPR Recombinant protein with a His-tag corresponding to SPR, 
Source is E. coli, Buffered in 20 mM Tris-HCl (pH8.0), 10% 
(v/v) glycerol, >95% purity confirmed by SDS-PAGE 
NBC1-21657 Novus 
Biologicals 
hSR-B1-Fc Recombinant human SR-BI Fc protein chimera, Pro33-Tyr443 
(hSR-BI) + IEGRMD + Pro100-Lys330 (hIgG1), expressed in 
HEK293 cells, Purity >90% confirmed by SDS-PAGE 
8114-SR-050 R&D 
mThy1-Fc Recombinant Mouse CD90/Thy1 Fc Chimera Protein, Mouse 
Thy (Gln20-Lys130) + IEGRMDP + mouse IgG2A (Glu98-
Lys330), Source is mouse myeloma cell line NS0, 
reconstituted in PBS, purity confirmed >95% by SDS-PAGE 
with silver staining 
7335-CD-050 R&D 
Table 10. List of buffers and reagents for the detection of protein-protein interaction. 
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Sortase A mediated transpeptidation 
 
The enzymes used for Sortase A mediated transpeptidation was the 5M srtA (Plasmid #00595) from 
S. aureus. The enzyme was expressed and purified as described under ‘Expression of recombinant 
proteins in bacteria’ and stored as aliquots at -80°C. Bait-Fc proteins used for transpeptidation 
contained an n-terminal LPETG5 tag recognized by the enzyme. Small molecules used for 
transpeptidation by sortase A contained a c-terminal LPETGG peptide. N-terminal Sortase 
transpeptidation was performed in two steps.  
For the first step the protein to be sortase tagged was added together with 5M srtA and triglycine into 
the reaction buffer. The reaction was performed at 37°C with 6 µM 5M srtA and 1-2 mM triglycine if 
not stated elsewise. The protein was then washed utilizing affinity based magnetic separation 
methods like Dynabeads described under ‘Washing of Bait-Fc proteins with Protein A Dynabeads’, 
Microbeads described under ‘Washing of Bait-Fc proteins with Protein A microbeads’ or affinity 
matrices in FPLC columns described under ‘Purifying Fc tagged proteins’ binding the Fc tag of the 
Bait-Fc proteins. As wash buffers PBS, TBS, or the reaction buffer without any additives were used.  
For the second step the Bait-Fc proteins from the first Sortase tagging step were added to the 
reaction buffer together with a small molecule linked to a LPETGG peptide and the respective 
sortase. If not stated elsewise the reaction was performed using 6 µM 5M srtA and the small 
molecule with 40 times the concentration of Bait-Fc protein for 30 minutes at 37°C. The reaction was 
stopped by the addition of 20 mM EDTA. After the reaction was completed, the Bait-Fc proteins were 
washed as described before.  
To calculate the free Ca
2+
 concentrations in srtA reaction buffer titrating EDTA, EGTA, or BAPTA as 
chelator, the online tool WEBMAXC STANDARD (7/3/2009) was used available at 
(http://maxchelator.stanford.edu/webmaxc/webmaxcS.htm).  
 
Name Formulation REF number Supplier 
Diazirine-LPET*GG 
 
1702.79 Da, 97.5% purity by RP-HPLC, 2.5 mg, 
lyophilized as trifluoroacetic acid salt resolved in 10% 
(v/v) DMSO in water to 4000 µM, aliquots stored at –80°C 
protected from light 
n.a.  
(Lot 
13106/HS_ 
Fragment 
AB_F25-
28Pool) 
Intavis 
TAMRA-LPET*GG TAMRA-GGLPET*GG (* = depsi peptide) 67225 Peptide 2.0 Inc.  
Triglycine (Gly-Gly-
Gly) 
50 mM stock prepared in water, aliquots stored at -80°C G1377-1G Sigma 
srtA reaction buffer 20 mM HEPES, 150 mM NaCl, 10 mM CaCl2 in H2O, 
pH7.4 
n.a. n.a. 
Table 11. List of buffers and reagents used for sortase tagging. 
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Cross-Linker activation by UV light 
 
Cross-linker activation by BLX-365: 
For UV irradiation with the BLX-365 samples in 1.5 ml microcentrifuge tubes were placed into a 
rack with the lid open. The microcentrifuge tubes were placed centrally below a light tube. To 
illuminate the sample with a defined dose of U  light, the machine was set to ‘UV Energy 
exposure‘. For experiments with U  doses above 9 Joule the microcentrifuge tubes were placed 
into a rack where the lower part of the tube reached into an ice water bath.   
 
Cross-linker activation with the 500W arc lamp: 
The arc lamp was controlled and powered by the OPS-A500 from Oriel Instruments. The arc 
lamp used was a 500W Hg/Xe arc lamp set up together with the Lamp Socket Adapter in the Arc 
Lamp Housing. LIK-LMP Light Intensity Controller Kit was connected to the housing to control 
the light intensity. To limit infra red light a liquid filter was connected to the focusing mount of the 
Arc Lamp Housing and filled with deionized water. To limit the exposure of a sample, an 
electronic safety shutter was connected to the liquid filter followed by the Beam Turning Mirror 
Housing equipped with a 280-400nm dichroic mirror defining the wavelength applied to the 
sample. The light path was initially adjusted by the technical support of Newport. The light path 
was focused into 1.5 ml microcentrifuge tubes containing the samples. The electronic safety 
shutter automatically controlled the time of illumination.  
 
 
Figure 4. Schematic setup of the 
Hg/Xe Arc Lamp. 
The Hg/Xe 500W arc-lamp was combined 
with a focusing mount to enable a site 
specific application of UV irradiation, a water 
filter to remove the irradiated IR spectrum, a 
dichroic mirror to further reduce the 
irradiated spectrum, and a shutter to limit the 
irradiation time.  
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SDS-PAGE and protein detection 
 
For SDS-PAGE, samples were prepared with LDS Sample Buffer and if not stated elsewise, with 
Sample Reducing Agent. Both were used diluted to 1 times concentration in the samples that 
were then boiled at 85°C to 95°C for 10 minutes before being loaded on pre-cast 4-12% Bis-Tris 
gels. The gels were run in either MOPS or MES buffer using the X Cell system. The 
electrophoresis was performed under cooling conditions with 100 to 200 Volts as limiting factor, 
while Amperage and Watts were adjusted to the respective conditions based on the voltage set. 
Proteins were then detected either by western blotting, silver staining, Coomassie R250 staining, 
fluorescent detection, or by a combination of those. Proteins were either quantified in coomassie 
stained SDS-PAGE gels as described below, or with the BCA Protein Assay Kit according to the 
manufacturer’s manual.  
 
Protein detection via western blot:  
For the transfer of proteins from a SDS-PAGE gel to a PVDF membrane (Merck Millipore, 
Immobilon FL, REF #IPFL0010) the Thermo Fisher X Cell II Blot Module (REF #E19051) was 
used in combination with the X Cell system used for the SDS-PAGE according to the 
manufacturers protocol using 15% (v/v) methanol in Tris-Glycine buffer prepared from (Thermo 
Fisher, Pierce™ 10X Tris-Glycine Buffer, REF #28363). The PVDF membrane was activated 
with methanol before usage. After the transfer of proteins, the membrane was incubated for 1h 
at RT or over night at 4°C with blocking buffer in a 50 ml falcon. The proteins of interest were 
marked with specific primary Antibodies (see Table 13) and unspecific bound antibodies were 
removed with 3 washes of 10 ml of wash buffer. The primary antibodies or Fc tagged proteins 
were then marked with secondary antibodies fluorescently labeled with IRDye680 or IRDye800 
purchased from LI-COR. After removing unspecific bound antibodies with 2 washes of 10 ml 
wash buffer and one wash of 10 ml of TBS, the blots were scanned with the LiCor Odyssey and 
analyzed with the Image Studio Ver 4.0 software. The Channels were adjusted to a linear 
relation between signal input and output. The lower signal cut off was set to the minimal signal 
intensity measured on the blot. The higher signal cut off was set to the maximal signal intensity 
measured on the blot excluding the marker bands if not stated else wise. Images were exported 
as .png files.  
 
Protein detection via Coomassie: 
To stain proteins in SDS-PAGE gels with Coomassie R250, the gels were incubated for 15 
minutes in 50 ml of Coomassie staining buffer on a rotary shaker at RT. The staining buffer was 
removed and the gel was washed with water before 50 ml of Coomassie destaining buffer was 
 
  
 
33 
 
added. The destaining was performed over night on a rotary shaker at RT. The destaining buffer 
was once replaced in the evening and, in case the destaining was insufficient, in the morning. 
The gel was destained until most of the Coomassie was removed from the gel parts not 
containing any protein. Coomassie stained SDS-PAGE gels were imaged with the VersaDoc 
system and the setup suggested by the software. Gels were illuminated for 0.2-0.4 seconds 
depending on the remaining background staining. Illuminations were adjusted within the 
dynamic range of the system.  
 
Protein quantification in coomassie stained SDS-PAGE gels: 
To quantify a protein, a defined volume was loaded on a SDS-PAGE gel as well as known 
amounts of BSA (taken from the BCA kit). At least 0.5, 0.75, 1.0, and 1.5 µg of BSA were used. 
After the separation, proteins were detected via coomassie as described before. The gel was 
then imaged with the  ersaDoc and the image was imported into the software ‘Image Studio 
Lite’, or ‘Image Studio  er 4.0’. Shapes were placed around the protein to be quantified and 
around the BCA standards. The quantification values were imported into excel. A graph for the 
BSA standards was created with the known amounts on the y-axis and the quantification 
intensities on the x-axis. A trend line including x=y=0 was calculated. The amount of protein 
loaded in the sample wells was calculated by inserting the sample’s color intensity value into the 
trend line formula. The amount of protein calculated to be loaded onto the gel, divided by the 
volume of sample loaded, gives the concentration of protein within the sample.  
 
Protein detection via Silver Stain: 
To stain proteins in SDS-PAGE gels by silver staining the Pierce™ Silver Stain for Mass 
Spectrometry kit was used according to the manual. Silver stained SDS-PAGE gels were 
documented with the VersaDoc system with the setup suggested by the software. Illumination 
times were chosen within the dynamic range of the system.  
 
Protein detection via fluorescence: 
Proteins labeled with fluorescent molecules were visualized in the VersaDoc gel documentation 
chamber equipped with a Tamron 28-80mm f1/3.5-5.6 AF aspherical objective. The setup of the 
chamber was prepared according to the instructions provided by the software. Illumination times 
were chosen within the dynamic range of the system.  
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Name Formulation REF number Supplier 
BCA Protein Assay 
Kit 
Two-component, high-precision, detergent-compatible 
assay reagent set to measure total protein concentration 
compared to a protein standard. 
23225 Pierce
TM
 
Bis-Tris gel, 4-
12%,  
1.0 mm X 10 well 
1D well format, separation range: 15 to 260 kDa (MOPS 
buffer), 3.5 to 160 kDa (MES buffer) 
NP0321BOX Thermo Fisher 
Scientific 
Bis-Tris gel, 4-
12%,  
1.5 mm X 10 well 
1D well format, separation range: 15 to 260 kDa (MOPS 
buffer), 3.5 to 160 kDa (MES buffer) 
NP0335BOX Thermo Fisher 
Scientific 
Bis-Tris gel, 4-
12%,  
1.0 mm X 15 well 
1D well format, separation range: 15 to 260 kDa (MOPS 
buffer), 3.5 to 160 kDa (MES buffer) 
NP0323BOX Thermo Fisher 
Scientific 
Bis-Tris gel, 4-
12%,  
1.5 mm X 15 well 
1D well format, separation range: 15 to 260 kDa (MOPS 
buffer), 3.5 to 160 kDa (MES buffer) 
NP0336BOX Thermo Fisher 
Scientific 
Immobilon® FL Immobilon-FL PVDF, 0,45 µm, 26,5 cm x 3,75 m, needs to 
be treated with methanol before use.  
IPFL00010 Merck Millipore 
PageRuler™ Plus  Prestained Protein Ladder from 10 to 250 kDa 26619 Thermo Fisher 
Scientific 
Transfer buffer 15% (v/v) methanol in 1xTris Glycine buffer n.a. n.a. 
Tris Glycine buffer, 
10x 
Diluted to 1x: 25 mM Tris, 192 mM glycine, pH8.5  28363 Thermo Fisher 
Scientific 
α-hTYRO3 mouse 
IgG 
Detects human Tyro3 in ELISAs and Western blots. 
Monoclonal Mouse IgG1, Protein A or G purified from 
hybridoma culture supernatant 
The Immunogen is S. frugiperda insect ovarian cell line Sf 
21-derived recombinant human Tyro3/Dtk (Ala41-Ser428 
(predicted), Accession # Q06418) 
MAB859 R&D Systems 
α-hAXL rabbit Ig 
(Ectodomain) 
Detects human and monkey AXL in western blots, 
polyclonal antibodies of rabbits immunized with a synthetic 
peptide around Leu283 of the human Axl extracellular 
domain.  
#3269 Cell Signaling 
α-hAXL rabbit Ig 
(Kinase domain) 
 
Detects human AXL in western blots, polyclonal antibodies 
of rabbit synthetic peptide corresponding to sequences 
surrounding amino acid residue 740 of human Axl. 
#4977 Cell Signaling 
α-phospho Tyr702 
hAXL rabbit Ig 
Phospho-Axl (Tyr702) (D12B2) Rabbit monoclonal Antibody 
for western blot, may cross-react with related tyrosine-
phosphorylated tyrosine kinases, such as EGFR. 
#5724 Cell Signaling 
α-hAXL goat IgG 
 
Detects human Axl in direct ELISAs and Western blots. In 
direct ELISAs, less than 25% cross-reactivity with 
recombinant mouse Axl is observed. Polyclonal Goat IgG, 
Immunogen was Mouse myeloma cell line NS0-derived 
recombinant human Axl (Glu33-Pro440, Accession # 
AAA61243) 
AF154 R&D Systems 
α-hAXL mouse IgG 
 
Detects human Axl in direct ELISAs. In direct ELISAs, this 
antibody shows no cross-reactivity with recombinant mouse 
Axl, recombinant human (rh) TYRO3 or rhMER. Monoclonal 
Mouse IgG1, Immunogen was Mouse myeloma cell line 
NS0-derived recombinant human Axl (Met1-Pro440, 
Accession # AAA61243) 
MAB154 R&D Systems 
α-hMER mouse 
IgG 
(Ectodomain) 
Detects endogenous levels of human MER in western blots, 
does not show cross-reactivity, monoclonal mouse IgG1 of 
animals immunized with human MER ectodomain. 
# 9178S 
 
Cell Signaling 
α-hMER mouse 
IgG 
(Ectodomain) 
 
Detects human Mer in direct ELISAs and Western blots. In 
Western blots, does not cross-react with recombinant 
human (rh) Axl, rhTYRO3, or rmMER, Monoclonal Mouse 
IgG2B,  
Immunogen was cell line Sf 21-derived recombinant human 
MER (Ala21-Ala499, Accession # Q12866.2) 
MAB8911 R&D Systems 
α-hGAS6 goat IgG 
 
Detects human Gas6 in ELISAs and Western blots. Cross-
reaction is expected, Polyclonal Goat IgG, Immunogen was 
Mouse myeloma cell line NS0-derived recombinant human 
Gas6 (Asp118-Ala678, Accession # NP_000811) 
AB885 R&D Systems 
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α-hGAS6 goat IgG 
(biotinylated) 
Detects human Gas6 in Western blots. In Western blots, 
approximately 15% cross-reactivity with recombinant mouse 
Gas6 is observed. Polyclonal Goat IgG, Immunogen was 
Mouse myeloma cell line NS0-derived recombinant human 
Gas6 (Asp118-Ala678, Accession # NP_000811) 
BAF885 R&D Systems 
α-hGAS6 mouse 
IgG 
 
Detects human Gas6 in direct ELISAs and Western blots. In 
direct ELISAs and Western blots, this antibody shows 
approximately 5% cross‑reactivity with recombinant mouse 
Gas6. Monoclonal Mouse IgG2A, Immunogen was Mouse 
myeloma cell line NS0-derived recombinant human Gas6 
(Asp118-Ala678, Accession # NP_000811) 
MAB885 R&D Systems 
α-hGAS6 rat IgG 
 
Detects mouse Gas6 in direct ELISAs and Western blots. In 
direct ELISAs and Western blots, this antibody does not 
cross-react with recombinant human Gas6. Monoclonal Rat 
IgG2A, Immunogen was Mouse myeloma cell line NS0-
derived recombinant mouse Gas6 (Asp115-Pro674 (Del 
Pro530), Accession # Q61592.2) 
MAB986 R&D Systems 
α-hGAS6 mouse 
IgG 
Detects human GSA6 in western blots, polyclonal mouse Ig 
from animals immunized with GAS6 (NP_000811.1, 1 a.a. ~ 
678 a.a) 
SAB1410502 Sigma Aldrich 
α-hProtein S 
mouse IgG 
 
Detects human Protein S in direct ELISAs and Western 
blots. In direct ELISAs and Western blots, does not 
cross‑react with recombinant mouse Protein S. Monoclonal 
Mouse IgG1, Immunogen was Mouse myeloma cell line 
NS0-derived recombinant human Protein S (Ala42-Trp670, 
Accession # P07225) 
MAB4036 R&D Systems 
α-Mouse-
IRDye680 
IRDye® 680RD Donkey anti-Mouse IgG (H + L), 0.5 mg 926-68072 LI-COR  
α-Mouse-
IRDye800 
IRDye® 800CW Donkey anti-Mouse IgG (H + L), 0.5 mg 926-32212 LI-COR  
α-Rabbit-
IRDye680 
IRDye® 680RD Donkey anti-Rabbit IgG (H + L), 0.5 mg 926-68073 LI-COR  
α-Rabbit-
IRDye800 
IRDye® 800CW Donkey anti-Rabbit IgG (H + L), 0.5 mg 926-32213 LI-COR  
α-Goat-IRDye800 IRDye® 800CW Donkey anti-Goat IgG (H + L), 0.5 mg 926-32214 LI-COR  
Strept-IRDye680 IRDye® 680RD Streptavidin, 0.5 mg 926-68079 LI-COR  
Strept-IRDye800 IRDye® 800CW Streptavidin, 0.5 mg 926-32230 LI-COR  
LDS Sample 
Buffer, 4x 
NuPAGE® LDS Sample Buffer, lithiumdodecylsulfate, 
glycerol, pH8.4 
NP0008 Thermo Fisher 
Scientific 
Sample Reducing 
Agent, 10x 
NuPAGE® Sample Reducing Agent, 500 mM Dithiothreitol NP0009 Thermo Fisher 
Scientific 
MOPS buffer, 20x At 1x concentration: 50 mM MOPS, 50 mM Tris Base, 0.1% 
(w/v) SDS, 1 mM EDTA, pH 7.7 
NP0001-02 Thermo Fisher 
Scientific 
MES buffer, 20x At 1x concentration: 50 mM MES, 50 mM Tris Base, 0.1% 
(w/v) SDS, 1 mM EDTA, pH 7.3 
NP0002-02 Thermo Fisher 
Scientific 
Coomassie 
Brilliant Blue R-
250 
Binds primarily to basic amino acids in acidic conditions, the 
coomassie dye on a protein is approximately proportional to 
positive charges on the protein, absorption maximum 595 
nm 
20278 Thermo Fisher 
Scientific 
Coomassie 
staining buffer 
For 1L: 3 g Coomassie R-250, 450 ml methanol, 100 ml 
acetic acid, in water, dissolved for 1 day, filtered 
n.a. n.a. 
Coomassie 
destaining buffer 
15% (v/v) isopropanol, 10% (v/v) acetic acid, in water n.a. n.a. 
Silver Staining Kit Pierce™ Silver Stain for Mass Spectrometry containing 
Silver Stain Sensitizer, Silver Stain Enhancer, Silver Stain 
Developer, Silver Stain, Silver Destain Reagent A, Silver 
Destain Reagent B 
24600 Pierce 
Table 12. List of buffers, reagents, and kits for immunoblots. 
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Co-IP of cross-linker activated bait and control proteins from complex samples 
 
Preparation of bait proteins in complex samples: 
The proteins used as bait, TYRO3-Fc, AXL-Fc, and MER-Fc and the control protein CTRL-Fc 
were tagged with the photo-activatable cross-linker Diazirine. The complex samples used were 
human plasma, lysates from C57BL/6J wild type mice’s adipose tissue, brain, spleen, and testis, 
and human brain lysates from healthy patients, and patients either diagnosed with mild cognitive 
impairment (MCI) or Alzheimer’s disease (AD). Prof. Dr. Michael T. Heneka provided the human 
brain samples. Lysates and plasma from 3 individuals were used per bait protein. 
The samples were prepared on ice and in subdued light. Whenever possible the samples were 
protected from light until the activation of the photosensitive cross-linker. For each sample 13 
pmol of bait protein were added to 1 mg of lysate or 100 µl of human plasma in a 1.5 ml 
microcentrifuge tube. The volumes of bait proteins were adjusted to 29.74 µl with TRIS 
neutralized Pierce IgG elution buffer. The volumes of lysates and plasma were adjusted to 125.1 
µl with N-P40 tissue lysis buffer. The samples were incubated at 37°C for 30 minutes protected 
from light. 
 
Photo-activation of cross-linker: 
If not specified otherwise, the Diazirine cross-linker was activated with 9 Joules in the BLX-365 
U  box as described under ‘Cross-linker activation by BLX-365’. 
 
Co-immunoprecipitation of bait proteins: 
Following the UV activation of Diazirine, the bait proteins were immunoprecipitated with anti-
Mouse IgG Dynabeads. 61 µl beads per sample were washed two times in PBS, added to the 
samples and incubated 30 minutes at RT with constant rotation in a MACSmix Tube Rotator on 
maximal speed. The sample containing microcentrifuge tubes were placed in a DynaMagTM-2 
magnet for 2 minutes. The supernatant was discarded and 200 µl RIPA buffer was added before 
the beads were resuspended and washed by >2 minutes of rotation. The RIPA wash step was 
repeated 4 times. The supernatant was discarded and 200 µl PBS was added before the beads 
were resuspended and washed by >2 minutes of rotation. The PBS wash step was repeated 2 
times. The supernatant was discarded and the beads were stored and shipped at -80°C.  
 
Name Description REF number Supplier 
Neutralized Pierce 
IgG elution buffer 
For 280 µl: 250 µl Pierce IgG elution buffer (pH2.8), 30 µl 
1M TRIS (pH8.0) 
n.a. n.a. 
Table 13. List of Buffers and Solutions for Co-IP of cross-linked bait and control proteins.  
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Protein identification and quantification by LC-MS/MS 
 
The following procedures for ‘peptide identification and quantification by LC/MS’ were conducted 
and reported by Annika Frauenstein at the Max Planck Institute in Munich, supervised by Dr. 
Felix Meissner. Data of proteins identified and quantified comparing methods were provided log2 
transformed and filtered. Data of proteins identified and quantified screening for novel TAM 
interacting proteins were provided already transformed and filtered including meta-data.  
 
Preparation of samples on beads for LC/MS: 
The samples of baits and control proteins cross-linked to putative interacting proteins and 
molecules immunoprecipitated by anti-Mouse IgG Dynabeads were resolved in 50 µl 8M Urea in 
10 mM HEPES and sonicated for 10 minutes. 1 µl DTT was added before a 30-minute 
incubation at RT, followed by the addition of 10 µl IAA and 20 minute incubation at RT in the 
dark. Then 11 µl Thiourea and 2 µl LysC were added before a 1-hour incubation at RT, followed 
by the addition of 200 µl ABC and 2 µl Trypsin. The samples were then incubated over night 
before 27 µl of the stop solution was added.  
 
Preparation of lysates and plasma for LC-MS/MS: 
Aliquots of the lysates and of the plasma used for the co-immunoprecipitation of cross-linker 
activated bait and control proteins from complex samples were used as controls for the LC/MS 
analysis.  
 
LC-MS/MS: 
The peptides prepared were separated on an EASY-nLC 1000 HPLC coupled to the Q Exactive 
HF mass spectrometer via a nanoelectrospray source. For the separation, the peptides were run 
in buffer A through a column packed with 1.9 µm C18 particles and eluted with a nonlinear 180 
min gradient of 5-60% buffer B at a flow rate of 0.25 µl/min and a column temperature of 55°C. 
The column had an inner diameter of 75 µm and a length of 50 cm. The Q Exactive HF was data 
dependently operated with a survey scan range of 300-1,650 m/z and a resolution of 60,000 to 
120,000 at m/z 200. Up to 10 of the most abundant Isotype patterns having a charge above 1 
were isolated with a 1.8 Thomson window and administered to fragmentation by higher-energy 
collisional dissociation at normalized collision energy of 26. The fragmentation spectra acquired 
had a resolution of 15,000 at m/z 200. Sequenced peptides were dynamically excluded after 30 
seconds in order to reduce repeated sequencing. The thresholds used for ion injection time were 
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set to 20 ms and 3E6, and the thresholds for ion target values were set to 55 ms and 1E5 for the 
MS/MS scans. The Xcalibur software was used to acquire the data.  
 
LC-MS/MS protein identification and filtration: 
MS Raw files were analyzed with the MaxQuant software. Peptide sequences were compared to 
the UniProtKB FASTA files from human or mouse respectively (Version July 2015). Common 
contaminants were identified by a second database.  
In Perseus, the data of proteins identified and quantified were analyzed separately for mouse 
tissue samples, human brain samples and human plasma samples. The samples were grouped 
according to bait or control and tissue. The LFQ intensity values were log2 transformed and 
proteins marked ‘reverse’, ‘only identified by site’ or ‘potential contaminant’ were excluded from 
the matrix. The matrix was then reduced to proteins having 3 valid values in at least one group. 
Missing values were replaced by imputation with a width of 0.3 and a downshift of 1.8.  
 
Name Description REF number Supplier 
Octadecyl (C18) Solid 
Phase Extractions 
Disks 
Empore
TM
, provides up to 90% solvent reduction, 
contamination-free extractions 
n.a. n.a. 
Bioruptor Plus Sonication device n.a. Diagenode 
Concentrator plus Vacuum concentrator n.a. Eppendorf 
ReproSil-Pure C18-AQ 
column 
20-50 cm, 75 µm inner diameter, 1.9 µm resin n.a. Dr. Maisch 
GmbH 
UHPLC Ultra-high pressure liquid chromatography, e.g. EASY-
nLC 1000 ultra-high pressure system 
n.a. Thermo Fisher 
Scientific 
Mass spectrometer High resolution mass spectrometer, e.g. Q Exactive or 
Q Exactive HF  
n.a. Thermo Fisher 
Scientific 
Column oven n.a. n.a. Sonation 
MaxQuant Software available at http://www.coxdocs.org/ 
doku.php?id=maxquant: 
common:download 
_and_installation 
n.a. n.a. 
Perseus Software for MS data analysis (www.coxdocs.org/doku. 
php?id=perseus:common:download_and_installation 
n.a. n.a. 
SprayQC Software n.a. n.a. 
Table 14. List of equipment and software for LC & MS analysis. 
 
Name Description REF number Supplier 
1 M HEPES, 
pH8.0 
For 50 ml: 11.9 g HEPES in water, pH adjusted with NaOH, 0.22 
µm sterile filtered 
n.a. n.a. 
1 M ABC For 50 ml: 4 g NH4HCO3 in water, 0.22 µm sterile filtered  n.a. n.a. 
Digestion buffer, 
4x 
8M urea, 40 mM HEPES pH8.0, 0.22 µm sterile filtered n.a. n.a. 
1 M DTT 1M Dithiothreitol (DTT), 50 mM ABC, 0.22 µm sterile filtered n.a. n.a. 
0.55 M IAA 0.55 M Iodoacetamide (IAA), 50 mM ABC, 0.22 µm sterile filtered n.a. n.a. 
1M Thiourea 1M Thiourea, 50 mM ABC, 0.22 µm sterile filtered n.a. n.a. 
1 mM HCl For 50 ml of 1 mM hydrochloric acid (HCl): 4 µl (v/v) to 50 ml 
water 
n.a. n.a. 
Trypsin Used at 0.5 µg/µl trypsin in 1 mM HCl n.a. Sigma 
LysC Used at 0.5 µg/µl Lysyl endopeptidase (LysC) in 50 mM ABC n.a. Wako 
Stop solution 6% (v/v) Trifluoroacetic acid (TFA), 60% (v/v) acetonitrile n.a. n.a. 
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Buffer A 0.5% (v/v) acetic acid in water n.a. n.a. 
Buffer A* 0.5% (v/v) acetic acid, 0.1% (v/v) TFA, 2% (v/v) acetonitrile in 
water 
n.a. n.a. 
Buffer B 0.5% (v/v) acetic acid, 80% (v/v) acetonitrile in water n.a. n.a. 
Running buffer B 0.1% (v/v) formic acid, 80% (v/v) acetonitrile, in water n.a. n.a. 
Table 15. List of buffers and reagents for LC & MS analysis. 
 
 
Protein identification by MALDI-TOF and Ion trap-ESI-LC-MS  
 
Proteins contained in gel slices from silver stained SDS-PAGE gels were identified by the mass 
spectrometry core facility of the University of Bonn by MALDI-TOF and Ion trap-ESI-LC-MS 
instruments. The exact protocols of protein isolation and digestion as well as for the protein 
identification were not specified.  
 
 
Statistics 
Nomenclature for statistics: 
x = data point p = probability value 
xi = each of the data points q = corrected probability value 
  = mean of data points * = p or q < 0.05 
n = number of data point ** = p or q < 0.01 
  = standard deviation *** = p or q < 0.001 
Σ = sum of  = exponential curve fit 
√ = square root  = sigmoidal curve fit 
H0 = null hypothesis Q = threshold p-Value in % 
HA = alternative hypothesis S0 = artificial within groups variance 
 
Mean: 
The mean of data points was either calculated automatically by Prism6 or Prism7, by the 
function ‘=MITTELWERT(xi)’ in Excel, or manually by the following formula:  
    
           
 
 
 
Sample standard deviation (SD): 
The sample standard deviation of data points was either calculated automatically by Prism6 or 
Prism7, by the function ‘=STABW.S(xi)’ in Excel, or manually by the following formula:  
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Standard error of the mean (SEM): 
The sample standard deviation of data points was calculated automatically by Prism6 or Prism7, 
by the function ‘=STABW.S(xi)/WURZEL(ANZAHL2(xi))’ in Excel, or manually by the following 
formula:   
       
    
  
 
 
 
Analysis of protein enrichment by bait proteins in MS screen and method comparison: 
General differences or similarities of samples were analyzed by Perseus’ clustering according to 
the Spearman correlation (hierarchical cluster of row and tree by Spearman correlation of 
distances, and 300 clusters processing with k-means), by Spearman rank correlation of samples 
(Row correlation, Spearman rank correlation), and by principle component analyses (PCA 
without category enrichment). For each tissue two-sided and unpaired Student’s T.Tests with an 
alpha of 5% assuming same variance were performed comparing either TYRO3 or AXL to the 
control testing proteins with at least 3 valid values for the bait protein. Probabilities were 
corrected for multiple testing using Perseus’ permutation based FDR of 5% (two-sided Student’s 
t-test with S0=0, including rows with 3 valid values in the bait group, corrected by permutation-
based FDR, FDR=0.05 and 250 randomizations without preserving the grouping). Proteins were 
sorted for FDR discoveries or for significant enrichment in at least 3 conditions.  
 
Probability calculation of a certain number of significant events or more for a certain number of 
tests to be random: 
A two-sided t-test with a cut-off of 0.05 accepts 5% of events being considered as significant in a 
random and normally distributed system. As the test is two-sided 2.5% of all tests enriched 
towards the control and 2.5% of all hits enriched towards the bait result together in the total of 
5% accepted as significant. To calculate the probability of a certain number of ‘significant’ events 
enriched by bait protein in a random and normally distributed system, the probabilities of the 
events have to be multiplied with each other and with the number of possible combinations 
leading to the specific number of significant and non-significant events. The probability of a 
certain number of significant events or more is the sum of those probabilities.  
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Non-linear regression and multiple t-test for protein-protein binding in 96 well data: 
Using the program Prism7 it was tested whether the binding curves of different bait proteins to a 
recombinant protein share a common curve for all data sets as H0 or if they have different curves 
for each dataset as HA. First, using nonlinear regression testing ‘sigmoidal, 4PL, X is 
log(concentration)’ it was determined if one curve adequately fits all the other data sets using the 
extra sum-of-squares F-test, where the simpler model is selected unless the P value is less than 
0.05. In case a sigmoidal curve fit could not be calculated for the data, the data were tested for a 
‘second order polynomial (quadratic)’ curve fit using the same test parameter as for the 
sigmoidal curve fit. The null hypothesis was rejected when the p value was smaller than 0.05.   
In case the null hypothesis was rejected, multiple t-tests were performed comparing the bait 
proteins to the control. Discoveries were determined using the Two-stage linear step-up 
procedure of Benjamini, Krieger and Yekutieli with Q=5%. Each row was analyzed individually, 
without assuming a consistent SD. 
 
 
Network analysis 
 
The online database STRING10 (date: 10.04.2018) was used to search for published 
associations between proteins. Gene ontology enrichments were performed with the Cytoscape 
tools ClueGO & CluePedia. Protein localization was based on associated ‘Cellular Component’ 
GO terms. These GO terms were provided by the online databases ‘Gene ALaCart’ (date: 
16.04.2018; LifeMap Sciences and Weizmann Institute of Science) and QuickGO (16.04.2018; 
EMBL-EBI).  
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3. Results 
 
Since the discovery and characterization of the tyrosine receptor kinases TYRO3, TYRO7 
known as AXL and TYRO12 known as MER 1991 (87, 124) Protein S and GAS6 were 
discovered as the main functional ligands 1995 by evaluating conditioned media for their ability 
to activate TYRO3 (29). Examples of further interacting proteins are the proteins TUBBY and 
TULP1 identified as ‘eat me’ signals in a phage display assay and subsequently identified to 
bind MER in retinal pigment epithelial cells after testing various receptors in co-IP experiments 
(38). LGALS3 was identified in a functional phagocytosis and receptor binding enriched phage-
display screen (41) by the same group, which additionally reconfirmed the interaction of MER 
with TULP1 (125). An example of interacting receptors is IFNAR1, discovered by investigating 
how TAM receptor stimulation leads to the inhibition of inflammation (22).   
The goal of this study is the identification of novel TAM receptor interacting proteins focusing on 
interactions with the ectodomain of the receptors in a broader variety of tissues reported to 
express TAM receptors. To achieve this aim, first a method needed to be designed to enrich 
also weak and transient interacting proteins from a variety of tissues. The method of choice was 
based on co-immunoprecipitation of TAM receptor ectodomains by a c-terminally attached 
mouse IgG Fc domain. To allow the formation of dimers the hinge region of the Fc domain was 
included. An n-terminal srtA recognition motif (LPETG) enabled the site-specific attachment of 
molecules like cross-linkers or fluorescent dyes. For the cross-linker used, the addition of a 
biotin molecule and a disulfide bond connecting the biotin/Diazirine moiety to the LPETG motif 
enabled multiple ways of usage. Amongst others, it allows the cross-linker to be used either for 
the fixation of weak and transient interacting proteins to the bait and thereby for their enrichment 
via co-IP, or for labeling such proteins with biotin and enrichment of biotin labeled proteins. The 
cross-linker chosen was photo-activatable to control the time of activation. Avoiding the cross-
linker moiety being linked to a possible site of interaction on the bait protein, site-specific 
transpeptidation by the bacterial enzyme sortase A was chosen to link maximally one cross-
linker per bait protein specifically to its n-terminus. Following the conceptual design of the 
method all components were tested and optimized to ensure optimal functionality.  
 
 
TAM receptor ectodomain bait proteins bind GAS6 and Fibronectin but not Protein S 
 
TAM receptor ectodomains fused c-terminally to mouse IgG Fc domains were used succesfully 
in many studies for co-IP experiments and to prevent TAM receptor signalling by sequestering 
GAS6 and Protein S from the stimulating medium (29, 126, 127). GAS6 is reported to bind all 
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three TAM receptors with varrying affinities (1), while Protein S is reported to only show very 
weak affinity to TYRO3 and MER but not to AXL (126). Chen and colleagues determined the 
affinity of human TAM receptor ectodomain-Fc proteins to GAS6 by Surface Plasmon 
Resonance spectroscopy resulting in equilibrium dissociation constants (Kd) of 1.6±0.3 nM for 
hAXL-Fc, 3.6±1.3 nM for hTYRO3-Fc, and 9.7±1.8 nM for hMER-Fc (30). As the bait and control 
proteins used in the following experiments differ from previously published versions, especially in 
their n-terminally added hexa-His-linker peptide sequence, I reconfirmed the affinities of the 
used bait and control proteins to recombinant human GAS6 and Protein S (Figure 5). The 19L 
linker versions of the three TAM receptors bait proteins showed significantly higher affinities to 
GAS6 compared to the control-Fc protein. In compliance with literature (32), no TAM ectodomain 
Fc bait protein showed a distuingishable affinity to Protein S compared to Control-Fc protein 
(Figure 5 C). Bait and control protein binding detected for 81 nM immobilized Protein S were 
significantly higher as Control-Fc binding to a comparable concentration of GAS6. Together this 
indicates an affinity of the bait and control protein’s Fc domain to Protein S. In accordance with 
previous publications detection of TAM receptor-Fc protein binding to Protein S in ELISA or Co-
IP assays is not expected (32). However Protein S activation of TAM receptors could be 
detected by kinase receptor activation assays (126). Together, TAM receptor bait proteins show 
affinities to GAS6 significantly higher as the Control protein and affinities to Protein S as 
expected and are therefore valid to be used as bait for affinity enrichment experiments.  
 
 
Figure 5. Affinity of TAM receptor bait proteins to hGAS6 and hProtein S. 
The affinity of TAM receptor ectodomain bait proteins, schematically described under A, were tested for their affinity to 
hGAS6 (B) and hProtein S (C) in an ELISA assay and compared to control proteins including a spacer instead of a 
TAM ectodomain. Bait and control proteins with the 19L linker version lacking the n-terminal hexa-His tag were used 
to detect protein interaction. Wells without protein served as negative control (Neg). α-GAS6 IgG (MAB885) and α-
PROS1-IgG (MAB4036) as detection antibodies binding to the maximal concentrated GAS6 and Protein S 
respectively served as positive control (Pos).  
The MEAN values minus the negative control relative to the positive control are shown with the SEM of 3 technical 
repeats with technical duplicates each. The probability of a common sigmoidal curve fit (H0) is shown and significant 
differences of respective bait to control in FDR corrected T-Tests are indicated as follows: * q<0.05, ** q<0.01, *** 
q<0.001 
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Figure 6. Co-IP enriching FN1 as TAM receptor interacting protein in human plasma. 
Proteins, co-immunoprecipitated from human plasma with hexa-His-L2 bait or control proteins were separated via 
SDS-PAGE and silver stained. Differentially enriched proteins, marked with an arrow, were excised and identified via 
mass spectrometry. Protein bands with known contaminants as major protein identified are marked with a cross, 
otherwise the most abundant protein identified is named (A). Human Fibronectin was tested for TAM receptor 
interaction in an ELISA assay (B), utilizing L2 bait and control proteins as detection proteins. Wells without protein 
served as negative control (Neg) and AXL-Fc binding to 50 nM GAS6 served as positive control (Pos).  
The MEAN values minus the negative control relative to the positive control are shown with the SEM of 3 technical 
repeats with technical duplicates each. The probability of a common exponential curve fit (H0) is shown and significant 
differences of respective bait to control in FDR corrected T-Tests are indicated as follows: * q<0.05, ** q<0.01, *** 
q<0.001 
 
Although TAM receptor ectodomains fused to IgG Fc domains are commonly used for TAM 
receptor ligand studies and to neutralize ligands (29, 127), I tested whether the designed bait 
and control proteins can be used to isolate proteins binding specifically to TAM ectodomains via 
co-immunoprecipitation from a complex sample as an organ lysate or body fluid. Comparing 
proteins enriched by hexa-His L2 versions of CTRL-Fc, TYRO3-Fc, and AXL-Fc from human 
plasma, 4 protein bands were uniquely detected in the hexa-His L2 TYRO3-Fc 
immunoprecipitation (Figure 6 A). These unique protein bands were excised handed to the Mass 
Spectrometry Core Facility of the University of Bonn for identification of contained proteins. LC-
MS analysis identified Fibronectin as the major Protein from the first band, while no proteins 
were identified in the other excised bands exceeding Keratin, a known contaminant (data not 
shown). Recombinant human Fibronectin was then tested for direct interaction with TAM 
receptor ectodomains (Figure 6 B). Fibronectin showed a higher affinity to the ectodomains of 
TAM receptors compared to the control protein and the difference in binding of the MER bait 
protein compared to the control protein reached statistical significance, however bait proteins 
were detected with below 2% compared to the signal of AXL bait binding 50 nM hGAS6.  
With the functionality of the bait and control proteins confirmed, Fibronectin was successfully 
enriched from human plasma in a co-IP without cross-linking and detection by silver staining. 
However the assay was not sensitive enough to enrich TAM receptor ligands as GAS6 or 
Protein S.  
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Establishment of optimal SrtA transpeptidation conditions for n-terminal tagging 
 
In order to attach a single cross-linker molecule site specifically to the n-terminus of the bait and 
control proteins, transpeptidation mediated by the bacterial enzyme sortase A was the method of 
choice. As the products obtained by srtA transpeptidation of photo-activatable cross-linker to 
proteins were about to be used as bait and control in co-immunoprecipitation and label transfer 
experiments the products had to meet the following requirements: The bait and control proteins 
had to be in solution to ensure optimal distribution within the prey matrix. The proteins had to be 
separated from materials like beads, excess cross-linker molecules and enzyme used during 
transpeptidation. All steps including the photo-activatable cross-linker needed to be performed in 
conditions protecting from UV light to prevent premature cross-linker activation. Comparable 
amounts of cross-linker needed to be tagged to bait and control proteins.  
The protocol published for srtA transpeptidation used as reference needed to be optimized for 
the 5M srtA version used in this study, small molecules as peptides for n-terminal tagging, and to 
lower protein concentrations obtained by mammalian in contrast to bacterial protein expression. 
The following experiments determine optimal concentrations and conditions for srtA 
transpeptidation of small LPETGG peptide linked molecules to the n-terminus of mammalian 
expressed and purified bait and control proteins.   
To prepare a protein for n-terminal srtA transpeptidation with a payload, first a glycine needs to 
be exposed at the protein’s n-terminus. For this purpose the bait and control proteins were 
designed with an n-terminal hexa-His tag followed by an LPETG motif. SrtA was used to 
hydrolyze the bond between threonine and glycine in the LPETG motif leaving a glycine at the n-
terminus of the protein. To prevent re-ligation of the hexa-His-LPET peptide to the available free 
glycine of the protein, an excess amount of triglycine was added to the reaction. The 
concentration of enzyme needed to achieve maximal reaction efficiency at 30 minutes reaction 
time was determined for the control and the three bait proteins and for each linker version L2, 
L9, and L19 by titrating the srtA enzyme (Figure 7 A). For all control and bait protein versions, 
the minimal concentration of srtA necessary to achieve a complete exposal of a glycine at the n-
terminus characterized by the removal of hexa-His-LPET was 6 µM (Figure 7 B to E).  
For the transpeptidation of a payload to the exposed n-terminal glycine of control or bait proteins 
having completed the first tagging step, several conditions were compared in order to reach 
optimal efficiencies. TAMRA-LPET*GG was titrated with L19 AXL-Fc at a srtA concentration of 6 
µM, 30 minutes reaction time at 37°C. The titration resulted in a sigmoidal increase of TAMRA 
tagged to the protein. At 20 µM TAMRA-LPET*GG concentration, approximately 80% of the 
maximal efficiency was reached (Figure 8). 
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Figure 7. SrtA titration for the first tagging step. 
Titrations of srtA in reactions with 1000 µM tri-glycine and 0.75 µM bait or control proteins were tested for each linker 
version (A). The reaction efficiencies were accessed by detecting and quantifying hexa-His-LPET remaining on the 
respective protein after the srtA reaction via Western Blot. The efficiencies were compared to reactions performed 
with 4 µM srtA serving as a positive control (Pos) and reactions without srtA serving as the negative control (Neg). 
Signals of detected His tag were divided by the signal of detected Fc tag, subtracted by the positive control and 
divided by the negative control (B to E). 
The MEAN and SD of three technical replicates is shown. 
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Figure 8. Titration of TAMRA-LPET*GG in srtA reactions. 
TAMRA-LPET*GG was titrated in reactions with 0.75 µM L19 AXL-Fc and 6 µM srtA. The reaction was stopped with 
20 mM EDTA after 30 minutes incubation at 37°C. TAMRA linked to L19 AXL-Fc was quantified by detecting the 
fluorescence intensity of AXL-Fc proteins separated from free TAMRA-LPET*GG via SDS-PAGE. L19 AXL-Fc protein 
was quantified after Western Blot detection of its Fc tag. Reactions without TAMRA-LPET*GG served as negative 
control (Neg) and samples with 40 µM TAMRA-LPET*GG served as positive control (Pos). The relative TAMRA 
detection was calculated by subtracting the negative control from the TAMRA signal relative to the positive control. 
The MEAN and SD of three technical replicates is shown with a sigmoidal curve fit. 
 
To determine the effect of srtA concentration in reactions with 0.75 µM protein, 30 µM TAMRA-
LPET*GG and 30 minute reaction time at 37°C, titrations of srtA were tested for the bait and 
control proteins and each of their linker variants. The efficiencies determined shown in Figure 9 
do not vary depending on the linker separating the site of tagging from the protein, except for L2 
MER-Fc. For the MER-Fc linker version L2 the efficiency was lower compared to the L9 and L19 
linker versions at srtA concentrations below 3 µM. The efficiency curves from all protein variants 
rise from low srtA concentrations to reach a maximum between 3 and 9 µM sortase A. At 27 µM 
srtA, close to the concentration of TAMRA-LPET*GG, the tagging efficiency dropped.  
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Figure 9. SrtA titration for second tagging step. 
The efficiency of ligating TAMRA to the n-terminally free glycine of L2, L9, and L19 linker versions of control and bait 
proteins was tested for srtA titrations. Reactions without srtA served as negative control (Neg). TAMRA tagged to bait 
and control proteins was quantified via western blot (B to E). The relative TAMRA detection was calculated by dividing 
the TAMRA signal by the signal of Fc tag detected, followed by subtracting the negative control. The MEAN and SD of 
three technical replicates is shown. 
 
Optimal reaction times for srtA tagging TAMRA-LPET*GG to control and bait proteins were 
determined in a time course performed exemplarily for L19 control and bait proteins. One minute 
of reaction yielded at least 70% of maximal efficiency for each protein. Maximal reaction 
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efficiencies were reached between 4 to 16 minutes. Within 4 to 32 minutes the mean intensity of 
TAMRA detected on the respective proteins was stably above 95% of the mean maximal 
intensity. At reaction times longer than 32 minutes less TAMRA was detected being linked to the 
proteins tested.  
A reduction of peptide tagged to proteins after reaching the equilibrium is unreported. Without 
further data only speculative explanations such as chemical bleaching of TAMRA, or stable 
linkage of srtA to Threonine of TAMRA-LPET peptide can be offered. As TAMRA-LPET ligation 
to bait and control proteins was efficient up to reaction times of 32 minutes, incubations of the 
second step of srtA tagging were performed at 30 minutes. However this observation 
emphasized the necessity to tightly control the reaction time of the srtA enzyme. 
 
 
Figure 10. Time course for second srtA tagging reaction. 
Time courses were performed for srtA (6µM) mediated reactions of L19 linker variant control or bait proteins at 0.75 
µM with 30 µM TAMRA-LPET*GG. The fluorescence intensity of TAMRA linked to control or bait protein was detected 
via fluorescent imaging following SDS-PAGE separation. Control and bait proteins were detected via Western Blot 
(B). A reaction without srtA served as negative control (Neg). The quantified signals of TAMRA were divided by the 
signal of detected Fc tag, subtracted by the negative control. TAMRA intensities are represented relative to those at 
32 minutes reaction time. The MEAN and SD of three technical replicates is presented.  
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Figure 11. Comparison of control and bait proteins linker variants. 
Three independent SrtA (6µM) reactions were performed with 0.75 µM of control and bait proteins for each linker 
variant with 30 µM TAMRA-LPET*GG for 30 minutes at 37°C. The reaction efficiency was observed by the 
determination of fluorescence of TAMRA linked to control or bait protein. Fc tags of control and bait proteins were 
detected via Western Blot (B). One aliquoted sample of TAMRA L19 Control-Fc (7.6 µM) served as a common 
positive control (Pos) for all reactions. For reactions including TAMRA-LPET*GG, TAMRA signals were divided by the 
detected Fc intensities before being divided by the positive control (C). MEAN and SD of three independent reactions 
is shown. Reactions are labeled with one to three dots for the respective replicate. Reactions of Control-Fc and 
TYRO3-Fc, and reactions of AXL-Fc and MER-Fc were performed simultaneously. 
 
Three linker variants were used to separate the LPETG motif from the TAM receptor 
ectodomains of bait proteins, and from the Fc domain of control proteins respectively. To 
compare srtA reaction efficiency for the bait and control proteins for each linker version, these 12 
proteins were srtA tagged with TAMRA-LPET*GG. All samples were compared to a previously 
prepared batch of TAMRA L19 Control-Fc and equal amounts were added to each SDS-PAGE 
gel. While the AXL-Fc reactions yielded very reproducible efficiencies within the technical 
replicates for each linker variant, there was more variation within the technical replicates of the 
CTRL-Fc, TYRO3-Fc and MER-Fc reactions. In mean, the bait and control protein variants 
resulted in over all comparable efficiencies.  
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Figure 12. Inhibition of srtA by chelation of Calcium ions. 
In reactions with 6 µM srtA, 30 µM TAMRA-LPET*GG, and 0.75 µM L2 AXL-Fc in srtA reaction buffer containing 10 
mM CaCl2, EDTA was log2 titrated from 2.5 mM to 160 mM to determine the effect of calcium chelation on the 
transpeptidation efficiency of srtA. Reactions without addition of EDTA were used as positive control (Pos) and 
reactions without srtA were used as negative control (Neg). Proteins were separated via SDS-PAGE and TAMRA 
linked to L2 AXL-Fc was detected by fluorescent imaging. The Fc tag was detected via Western Blot (B). Images of a 
representative experiment are shown (A). The MEAN minus Neg relative to Pos for three technical replicates and the 
CI 95% is shown with an asymmetric sigmoidal curve fit (B).  
 
To predict the concentration of EDTA, EGTA or BAPTA to chelate free Ca2+ ions in the srtA 
reaction buffer the online tool by MAXCHELATOR by Chris Patton was used to predict the 
concentration of free Calcium ions in the presence of different chelating molecules (Figure App 
4). At concentrations of 10 mM and higher of EDTA, EGTA, or BAPTA the predicted 
concentration of free Ca2+ ions started to decrease rapidly to below 1 nM at 16 mM chelator 
concentration. Free Ca2+ concentrations at EDTA concentrations of 16 mM and above were 
predicted to be 2.8 or 8.3 fold lower compared to corresponding concentrations of EGTA or 
BAPTA respectively.  
The efficiency of srtA transpeptidation was determined for a log2 titration of EDTA added to the 
reaction buffer (Figure 12). The reactions were performed with 0.75 µM L2 AXL-Fc, 30 µM 
TAMRA-LPET*GG, and 6 µM srtA for 30 minutes at 37°C. Compared to the positive control 
where no EDTA was applied to the reaction, 10 mM EDTA efficiently inhibited srtA 
transpeptidation. Inhibition reached a minimum at 20 mM EDTA where approximately 5% of the 
TAMRA signal was detected compared to a reaction without EDTA. At EDTA concentrations of 
80 mM and 160 mM, the inhibition of srtA decreases and 11.6% and 23.4% of relative TAMRA 
signal was detected.  
 
As the first tagging step of a LPETG motif containing protein via srtA is not limited by the 
availability of peptide, the desired reaction time was defined as 30 minutes and 6 µM srtA was 
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found to remove the hexa-His-LPET from the n-terminus of bait and control proteins efficiently. 
Also for the second tagging step, 6 µM sortase A was found to be the concentration where 
linkage of payloads to the three bait proteins, or the control protein was either optimal or close to 
optimal. For this step as well optimal reaction times were observed to range between 5 to 32 
minutes. The reaction time was controlled with the addition of EDTA inhibiting srtA maximally at 
20 mM concentration. The establishment of optimal conditions for the enzymatic reaction 
achieved high efficiency of payload linking to the variants of bait and control proteins and 
product homogeneity.  
 
 
Characterization of Diazirine as cross-linker of bait and control proteins  
 
The influence of hexa-His (hexa-His) or Diazirine cross-linker molecule (Diazirine), or nothing (-/-
) attached to the n-terminus of L19 bait and control proteins on their affinity to recombinant 
human GAS6 was examined by an indirect ELISA with the bait and control proteins replacing the 
primary antibody and GAS6 serving as the antigen at a defined concentration (Figure 13 A). The 
ELISA was performed with 25 µl of 15 nM GAS6 immobilized by the high protein binding dish, 
blocking with 5% milk in PBS, and a 2h incubation at room temperature with the protein variants 
concentrated to 0.1 µM in blocking buffer, before detecting the bound proteins with an HRP 
linked anti-Mouse IgG and quantifying its conversion of TMB reagent to substrate (Figure 13 B). 
The experiment was performed under a yellow light source with a known spectrum avoiding UV 
light to prevent cross-linker activation.  
Hexa-His L19 Control-Fc shows hardly detectable binding to GAS6. Detection of hexa-His 
variants of MER-Fc and TYRO3 bound to GAS6 is at about 8 and 17 percent respectively 
compared to binding of hexa-His L19 AXL-Fc, which shows the highest affinity to GAS6 amongst 
the tested proteins in this experiment. The versions of Control-Fc, TYRO3-Fc, and AXL-Fc with a 
free n-terminus (-/-) show comparable affinities as the hexa-His versions, while the affinity of L19 
MER-Fc to GAS6 is increased 2.5 fold compared to hexa-His-L19 MER-Fc. Again TYRO3-Fc 
and AXL-Fc do not vary notably with the Diazirine cross-linker at their n-terminus compared to 
the other versions, while Diazirine-L19 Control-Fc and Diazirine-L19 MER-Fc show a 
significantly increased affinity to GAS6 compared to the other respective protein versions.  
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Figure 13. Effect of n-terminal modification of bait and control proteins on GAS6 binding. 
The effect of n-terminal tags on the affinity of bait and control proteins was tested for their affinity to GAS6 via ELISA 
assays. L19 bait and control proteins in versions with an either unmodified n-terminal hexa-His-LPET peptide (hexa-
His), without the peptide (-/-), or with the peptide replaced by the Diazirine cross-linker molecule (Diazirine) were used 
at 0.1 µM in 25 µl to bind to 25 µl of 15 nM GAS6 immobilized per well. Wells without GAS6 served as negative 
control. The MEAN subtracted by the negative control and SEM of four technical replicates with technical duplicates 
each is shown (B).  
 
The Diazirine cross-linker molecule was designed with the photo-activatable cross-linker 
Diazirine linked to a Biotin molecule, and both together linked via a disulfide bond to a LPET*GG 
peptide to be sortase tagged to the n-terminus of bait and control proteins. The star marking a 
depsi bond linking the threonine and the first glycine. In the following experiments the UV 
activation of Diazirine by two light sources is compared as well as the efficiencies of Diazirine 
L19 AXL-Fc to Diazirine L19 Control-Fc labeling GAS6 with the biotin moiety in an increasingly 
complex solution.  
To activate the photosensitive cross-linker Diazirine, two UV light sources were available (Figure 
14 B). The Bio-Link BLX-365 emits light from five 8W UV lamps installed above the UV chamber. 
The BLX-365 allows the application of light limited by time of exposure, or by Joules of energy 
exposed per square centimeter. The second available light source was a 500W Hg/Xe arc lamp 
emitting light down to a wavelength of 200 nm. The emitted light was focused with a 4 element 
Aspherab® condenser to produce large, collimated beams or small, bright, and focused spots. 
Finally, a dichroic mirror limited the emitted wavelength spectrum from 280nm to 400nm, and a 
digitally operated shutter limited the time of exposure.   
The activation of Diazirine dependent on UV doses of the two light sources was examined in 
solutions with low complexity. 10 µM SrtA and 20 µM Diazirine cross-linker molecule were 
combined in reaction buffer and incubated for 10 minutes at 37°C to allow the sortase to 
covalently link to the Threonine of the cross-linker molecule’s LPET*GG peptide. After the 
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incubation, Diazirine was activated by UV irradiation at different doses. To ensure optimal 
irradiation, the tubes were placed either centrally in the BLX-365 UV box or under the focused 
light beam of the arc lamp. The irradiation intensities compared for the BLX-365 UV box ranged 
between 1 J/cm2 to 15 J/cm2. Noteworthy, the time necessary to expose a sample with 12 J/cm2 
was approximately 45 minutes. Comparing the activation of Diazirine by the arc lamp, samples 
were exposed with maximal energy for 1 to 60 seconds. Following the activation, 20 mM DTT 
was added to reduce the disulfide bond and therefore releasing the Diazirine/Biotin group from 
the cross-linker molecule (Figure 14 A). The efficiency of Diazirine activation was characterized 
by quantifying Biotin cross-linked to srtA by Western Blot (Figure 14 C and D). Biotin detected 
relative the sortase A before UV irradiation or DTT release of the cross-linker molecule was used 
as positive control. Samples without UV irradiation but with DTT release of the cross-linker 
molecule served as negative control.  
The maximal cross-linking efficiency reached by UV irradiation with the UV box is estimated to 
be reached with 56% biotin detection relative to the positive control based on one-phase 
association non-linear curve fit. Approximately 79% of the maximal activation is reached with 12 
J/cm2 after 45 minutes. After approximately 3 minutes and 45 seconds or 1 J/cm2 only 
approximately 10% of the maximal activation is reached (Figure 14 C). With the higher energy of 
the arc lamp, after 5 seconds of exposure an efficiency of activation comparable to 12 J/cm2 
applied by the UV box was achieved. Arc lamp irradiations longer than 5 seconds lead to the 
degradation of srtA and the formation of complexes (Figure App 6). To avoid UV induced protein 
degradation and prolonged incubation times favor stronger interactions and lead to increased 
background (128), the 5-second Arc-lamp activation was favored as soon as it was available.  
The dose dependent hydrolysation of the disulfide bond connecting the Diazirine/Biotin group to 
the LPET*GG peptide of the cross-linker molecule was characterized for a batch of Diazirine L19 
AXL-Fc treated with a titration of DTT. Biotin bound to the AXL-Fc protein was quantified in 
relation to total AXL-Fc via Western Blot following a non-reducing SDS-PAGE (Figure App 5). 
L19 AXL-Fc without Diazirine cross-linker molecule tagged to its n-terminus served as positive 
control, while Diazirine L19 AXL-Fc without DTT treatment served as negative control. Diazirine 
L19 AXL-Fc diluted to 1.5 µM lost approximately 85% of its Biotin signal after treatment with 16 
mM DTT for 10 minutes at room temperature. Treatment with 64 µM DTT reduced the Biotin 
signal below 2% compared to the untreated sample.   
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Figure 14. Photo-activation of Diazirine via a UV box and an Arc lamp. 
Two UV light sources were tested for their Diazirine activation performance (B). SrtA was incubated with the Diazirine 
cross-linker molecule and incubated for 10 min at 37°C before the cross-linker was activated by either of the two 
lamps with increasing UV exposures. Following the activation, the disulfide bond linking the Diazirine/Biotin part to the 
LPET*GG peptide of the cross-linker molecule was reduced with DTT (A). Biotin linked to srtA and total srtA were 
detected and quantified via Western Blot for each light source (C&D). Samples without UV activation or DTT 
treatment were used as positive control (Pos). Samples without UV activation but with DTT treatment were used as 
negative control (Neg). Curves were fitted according to one-phase association. The MEAN minus Neg relative to Pos 
is shown with SD of three technical replicates.  
 
 
As the recovery of bait and control proteins in a co-immunoprecipitation is of crucial importance, 
various beads were compared for their recovery of Fc tagged proteins from complex solutions 
and for the purity of each preparation. Using Protein A microbeads and anti-Mouse IgG agarose 
slurry the highest recovery rates of 41% were achieved based on quantifications in Coomassie 
R250 stained SDS-PAGE gels. However the protein A Microbead purification showed a 
significant amount of unspecific purified proteins. The anti-Mouse IgG agarose even purified 
mostly unspecific proteins compared to Fc-tagged protein. Anti-Mouse IgG Dynabeads resulted 
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in the third highest recovery rate of 37.2% but, beside the heavy and light chain of the anti-
Mouse IgG, no undesired proteins could be detected via Coomassie staining. The experiment 
was performed once and the results are shown in the Appendix (Figure App3). 
As the previous described experiments have shown, the addition of a hexa-His tag to the n-
terminus of bait and control proteins only lead to a decrease in affinity to GAS6 by MER-Fc. 
More importantly, the addition of the cross-linker molecule lead to an increased affinity to GAS6 
by Control-Fc and MER-Fc while the affinities of TYRO3-Fc and AXL-Fc remained unchanged. 
The altered affinities of bait and control proteins compared to endogenous TAM receptors may 
lead to false positive or negative detection of interactions, which has to be taken into 
consideration analyzing the interactions of the following screen.  
 
 
Specificity confirmation of bait and control proteins for label transfer and comparison of 
enrichment methods  
 
With the components of the bait and control proteins individually tested for their functionality, the 
combinatorial functionality of all components remained to be confirmed. In tissue lysates Biotin is 
found due to its function as coenzyme, and the Fc domain of an IgG used as tag potentially gets 
recognized by Glycan and Fc-receptors (129, 130). Therefore the ability to label proteins known 
to interact with the ectodomain of TAM receptors separating bait proteins from the control protein 
needed to be confirmed in a complex matrix. Therefore Diazirine-AXL-Fc and Diazirine-Control-
Fc were compared for their specificity to transfer the Biotin label to recombinant GAS6 in 
increasingly complex matrices. Further 3 methods were compared for their performance in 
enriching AXL ectodomain interacting proteins from mouse spleen lysates.  
As shown in Figure 13, Diazirine tagged L19 Control-Fc shows an increased affinity to the TAM 
receptor ligand GAS6 even when 5% milk in PBS is used to block unspecific protein-protein 
interaction. To determine the difference in specificity of label transferred to GAS6 by Diazirine-
L19 Control-Fc compared to Diazirine-L19 AXL-Fc in matrices with increasing complexity, 0.3 
µM bait or control protein was added to 0.3 µM recombinant human GAS6 in 20 µl of either PBS, 
or 1, 3, or 9 µg mouse spleen lysate added to the PBS (Figure 15 A). Following 30 minutes of 
incubation at 37°C, the cross-linker was activated with 5 second exposures with the Hg/Xe arc 
lamp. The Diazirine/Biotin part of the cross-linker molecule was released during a 10 minute 
incubation with 50 mM DTT before the proteins were separated via SDS-PAGE. Via Western 
Blot GAS6 and Biotin were detected.  
Biotin was linked to GAS6 by the Diazirine-L19 AXL-Fc bait protein, as well as by the control 
protein when the label transfer was performed in a simple matrix as PBS (Figure 15 B). In more 
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complex matrices Biotin cross-linked to GAS6 by Diazirine-L19 Control-Fc was reduced to 20% 
compared to the label-transfer performed in the simple matrix. The decreasing effect of lysate 
applied to the label-transfer matrix is not dose dependent in the case of Diazirine-L19 Control-
Fc.  
By the addition of lysate to the Diazirine tagged AXL-Fc and Control-Fc proteins the efficiencies 
to biotinylate GAS6 were decreased for both proteins. With the addition of lysate, the sample 
turbidity increased having a negative effect in UV transmission. However for Diazirine-L19 AXL-
Fc, cross-linking of GAS6 was only reduced to 62% in the presence of 1 µg lysate in PBS 
compared to PBS alone, while for Diazirine Control-Fc GAS6 cross-linking was reduced to 20%. 
The effect of lysate proteins reducing the cross-linking efficiency to GAS6 by Diazirine-L19 AXL-
Fc was observed to be dose dependent. The efficiency in presence of 9 µg lysate was reduced 
to 40%, again possibly due to decreased UV transmission in the samples. With the labeling of 
GAS6 by control protein dropping to a level significantly lower than the labeling by AXL bait 
protein, and independent on the complexity of the matrix, the interaction of Control-Fc protein 
with GAS6 was shown to be unspecific. Therefore the control protein was confirmed for its use 
to separate proteins interacting specifically with the ectodomain of a bait protein from proteins 
interacting with any other part of the bait protein.  
The enrichment of proteins interacting with the bait proteins was compared for three methods 
(Figure 16 A). For all three methods Diazirine-L19 AXL-Fc and Diazirine-L19 Control-Fc were 
used. The bait and control proteins were incubated in mouse spleen lysate for 30 minutes 
preventing cross-linker activation. The first method was performed enriching the bait and control 
proteins with anti-mouse IgG coated magnetic beads. In the second and third method, Diazirine 
was activated for 5 seconds with the UV arc lamp and incubated for 10 minutes. The bait and 
control proteins were then enriched by either anti-mouse IgG coated or streptavidin coated 
magnetic beads. Enriched proteins were identified and quantified via mass spectrometry.  
According to Spearman rank correlation, the samples did not show a clear correlation by method 
(Figure 16 B). Rather samples clustered by bait and control in two groups (Figure 16 C). The 
groups are not separated by the enrichment method, neither by the batch. The grouping is also 
reflected in the first component of a PCA representing 48.7% of variation, where those samples 
that formed both groups when spearman clustered, associate either positively or negatively. 
AXL-Fc samples trend to associate slightly more positively with the first component compared to 
Control-Fc samples for the anti-mouse IgG coated magnetic beads enrichments with or without 
UV activation. Samples of streptavidin-coated enrichments do not separate by bait and control. 
The same trend can be observed more clearly in the second component representing 7.7% of 
variance, while in the third component representing 5.2% of variance only the AXL-Fc samples 
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of the anti-mouse IgG methods vary in their association for the component from positive to 
negative and the other samples show uniformly low association with the component.  
 
 
Figure 15. Specificity of label transferred by Diazirine-L19 AXL-Fc compared to Diazirine-
L19 Control-Fc. 
The specificity of Diazirine-L19 AXL-Fc and Diazirine-L19 Control-Fc cross-linking to human GAS6 was determined in 
media with increasing complexity (A). 0.3 µM Diazirine-L19 AXL-Fc or Diazirine-L19 Control-Fc  were incubated for 30 
minutes at 37°C together with 0.3 µM recombinant human GAS6 either in PBS, 1, 3, or 9 µg mouse spleen lysate in a 
total volume of 20 µl. Following the incubation, the cross-linker was UV activated with 5 seconds exposure by a 500W 
Hg/Xe arc lamp. The disulfide bond of the cross-linker molecule was reduced with 50 mM DTT before Biotin linked to 
GAS6 was detected and quantified via Western Blot (B & C). The MEAN, relative to 0 µg lysate, and SD of five 
technical replicates is shown. The test, whether both exponential curves share a common fit resulted in p<0.0001. 
Further the data sets of bait proteins were compared to the control within the individual conditions with a 2-step up 
method of Benjamini, Krieger and Yekutieli FDR corrected multiple T-Test. Discoveries with q<0.05 are labeled with 
the respective p value.  
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Figure 16. Comparison of enrichment methods. 
For the comparison of enrichment methods, aliquots of mouse spleen lysate were combined with either Diazirine-L19 
Control-Fc or Diazirine-L19 AXL-Fc (A). One set was protected from UV light, while for two sets Diazirine was 
activated via 5 second UV irradiation with the UV arc lamp. Control and bait proteins were isolated using anti-Mouse 
IgG Dynabeads from the UV protected, as well as from one set of UV treated samples. Biotinylated proteins were 
isolated from the second UV treated set of samples with Streptavidin Dynabeads. Enriched proteins were identified 
and quantified via mass spectrometry. Spearman Rank Correlation of samples (B), clustering of samples and proteins 
according to Spearman (C), and principle component analysis (D), were performed to describe the relations of 
samples. The enrichment of proteins within each condition visualized as volcano plots with the difference of means of 
log2 transformed LFQ intensities on the x-axis, and the negative log2 of p Values of unpaired two-sided T.Tests on 
the y-axis (E). Tests were controlled for multiple testing using the permutation based FDR by Perseus with 250 
randomizations. Proteins with multiplicity adjusted q values below 0.05 were marked with darker circles. The mean 
fold change and p Values of Control and AXL enriched proteins within the different conditions were compared (F).   
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When testing the difference of enrichment by AXL-Fc and Control-Fc with a two-sided t-test and 
an alpha of 5%, the highest number with 96 proteins ‘significantly’ enriched by AXL-Fc is 
observed for anti-mouse IgG coated magnetic beads enrichments without UV activation (Figure 
16 G). 1 protein is discovered significant after permutation based false discovery rate correction 
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of 5% for multiple tests in the anti-mouse IgG bead enriched samples. Anti-mouse IgG coated 
magnetic bead enrichment with UV activation of Diazirine lead to the significant enrichment of 63 
proteins, and enrichment after UV activation with streptavidin to 77 significantly AXL-Fc enriched 
proteins (Figure 16 F). Comparing the proteins significantly enriched by AXL-Fc of the two anti-
mouse IgG based enrichment methods, those enriched without UV show a higher confidence of 
the enrichments not being random by having the lower p values, while those enriched with UV 
activation are enriched stronger compared to those without UV activation. The enrichment 
methods based on anti-mouse IgG and streptavidin, both UV activated, have 8 out of 140 
significantly AXL-Fc enriched proteins in common. Again the UV activated anti-mouse IgG 
enrichment method resulted in a higher enrichment of significant AXL-Fc enriched proteins, 
although the enrichments with the UV activated streptavidin based method resulted in 
enrichments tested less likely to be random. Another positive observation of anti-mouse IgG 
enriched proteins with UV activation is, that only one of the 63 significantly AXL-Fc enriched 
proteins was found significantly enriched by Control-Fc in one of the other methods. In contrast 7 
and 9 proteins significantly AXL-Fc enriched respectively by the methods without UV activation 
using anti-mouse IgG beads, and with UV activation using streptavidin beads, were found 
significantly enriched by Control-Fc in an alternative method.  
The comparison of enrichment and labeling methods has shown that enrichment of bait and 
control proteins after UV activation of cross-linker lead to a stronger enrichment of AXL-Fc 
interacting proteins. Together with the lowest number of AXL-Fc interacting proteins identified as 
significantly Control enriched by the alternative methods, Fc enrichment after UV activation 
turned out to be the most promising method for the identification of weak and transient TAM 
receptor interacting proteins.  
 
 
Identification of novel TAM receptor interacting proteins in human and mouse tissues 
 
The central aim of this study is the identification of novel TAM receptor interacting proteins. To 
decide where to search for novel TAM receptor ligands and interacting proteins, the expression 
of TAM receptors and their ligands GAS6 and Protein S was compared for a variety of tissues 
(Figure 17 B). According to mRNA expression data published by the online database BioGPS, 
TYRO3 is highly expressed in brain and kidney tissues, AXL in adipose tissues, muscular 
tissues like arteries, kidney and certain glandular tissues, and MER mostly correlating with AXL 
expression. The TAM receptor ligand GAS6 is highly expressed in muscular tissues like arteries, 
the heart, and the diaphragm, glandular tissues like the seminal vesicle and the prostate gland 
as examples, and female sex organs like the uterus, vagina and the umbilical cord. Focusing on 
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the TAM receptor’s function as regulators of immune responses, human blood plasma and 
mouse spleen lysates were included amongst the tissues to be screened, while mouse testis 
lysate was included due to its constant and TAM receptor dependent phagocytosis of debris by 
Sertoli cells (26). Adipose tissue was included due to its high expression of AXL. Brain tissue 
was especially interesting as the TAM receptor TYRO3 is highly expressed while the ligands 
GAS6 and Protein S show a relatively low expression indicating a putative role of alternative 
ligands. Special thanks go to Prof. Dr. med. Michael Heneka for providing brain samples from 
healthy human patients, and patients either diagnosed with mild cognitive impairment or 
Alzheimer’s disease. Additionally mouse brain lysates were included amongst the screened 
tissues as by the example of GAS6, human TAM receptors have shown a higher affinity to the 
rodent version compared to endogenous version of the ligand.  
Homogenates were prepared from the described tissues and proteins that interacted with 
Diazirine tagged and L19 linked Control-Fc, TYRO3-Fc, and AXL-Fc were cross-linked by UV 
activation of Diazirine, and enriched by immunoprecipitation using anti-Mouse IgG Dynabeads. 
The enriched proteins were identified and quantified via mass spectrometry by Annika 
Frauenstein and Felix Meissner at the Max Planck Institute of Biochemistry who deserve thanks 
also for their advice concerning the data analysis.  
To obtain an overview on proteins enriched by the different baits and control proteins in the 
tissues used, samples were clustered according to Spearman (Figure 18, A, C, D). As the 
mouse tissue samples were processed again separate from the human tissue samples, where 
plasma samples were processed separately from the brain samples during the mass 
spectrometry measurements and data processing, the three sample groups were clustered 
individually. Within the mouse samples, clusters formed according to the respective tissue with 
the exception of the control, the TYRO3, and the AXL sample of Adipose tissue lysate 1, which 
clustered closer to the spleen samples. The control and bait samples clustering appears mostly 
random except for the spleen samples, where the control samples are clearly separated from the 
samples of both baits. For the human plasma samples clustering identified the control in plasma 
1 having a differential enrichment pattern compared to the other plasma samples where 
enrichments did not lead to clusters defined by baits or the individual plasma. For the human 
brain samples, AXL bait enrichment showed a clearly separated pattern compared to 
enrichments with TYRO3 bait or the control protein. Within the TYRO3 bait and the control 
samples two clusters were identified with one TYRO3 sample dominated cluster and one Control 
sample dominated cluster, leaving 3 samples out of both. No clustering based on healthy, MCI, 
or Alzheimer’s disease samples was observed. The clustering pattern of samples can be as well 
observed in component 1 of the principal component analysis performed separately for mouse 
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samples, human plasma, and human brain samples. Within the second and third component, 
differences between Control-, TYRO3-, and AXL-Fc enriched samples were less pronounced.  
 
 
Figure 17. Screening method and tissue selection. 
The method used to enrich TAM receptor binding proteins from various tissues begins with the addition of Diazirine 
tagged bait and control proteins to lysates of tissues. The photo-activatable cross-linker Diazirine is then irradiated 
with UV to cross-link any protein near to the bait and control proteins; preventing them to be removed by several wash 
steps during α-mouse IgG Dynabead based enrichment. The enriched proteins are then digested and separated by 
liquid chromatography and the mass to charge ratio (m/z) is measured my mass spectrometry. Finally peptides and 
thereby proteins are identified and label free quantified according to the m/z ratios detected (A). Tissue specific mRNA 
expression data provided by the online database BioGPS for TYRO3, AXL, MER, GAS6, and PROS1 are shown for 
the tissues screened for TAM receptor interacting proteins (B).  
 
 
 
 
Figure 18. Comparison of enrichments by bait and control in screened tissues. 
To describe and compare the enrichment characteristics of bait and control proteins to each other, and with regards to 
the method of enrichment used, samples were Spearman clustered (A, C, D) and principal component analysis was 
performed showing the data variance in terms of percentage at the y-axis (B, E, F).  
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The proteins enriched by TYRO3-Fc and AXL-Fc were each tested for differential enrichment 
compared to control-Fc enriched proteins. T.Tests were performed and multiple testing was 
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corrected by applying a permutation based FDR of 5%. The comparisons illustrated per bait and 
per tissue in Figure 19 A-H show generally more proteins being significantly enriched by AXL-Fc 
compared to TYRO3-Fc according to the p value of the respective T.Tests. The correlation of 
mouse spleen samples according to bait indicates that the number of specifically bait or control 
enriched proteins is exceptionally high compared to the other tissues. The proteins enriched 
from spleen lysates were therefore subjected to a more stringent threshold of q<0.01 for the 
FDR correction as the other samples, where q<0.05 was considered a discovery. FDR approved 
discoveries are presented in Figure 20 and labeled with a golden star. The respective bait and 
tissue is marked with a circle ranging in color from white to back according to the q value. 
Further information included are white circles illustrating tests that were performed but did not 
result in significance of bait enrichment and white circles with black dots as tests that did reach 
significance but did not reach a q<0.05 in the FDR. As enrichments of weak and transient 
interacting proteins are expected to have a higher variance than proteins with a high affinity, 
such enrichments are expected to be less significantly different. Therefore proteins were taken 
into consideration as discoveries that were significantly enriched with T.Test’s p values below 
0.05 in at least three tests and therefore in at least 2 different tissues (marked with a blue star). 
44 proteins fulfilled these requirements. Assuming random data normally distributed for these 44 
proteins, the probability of at least the individual number of significant events was calculated 
considering the total number of tests of the respective protein. With the example of PRDX5, 
which was enriched 5 times significantly and tested for a total of 7 times, the probability of 
having an event happening with a probability of 0.025 five, six, or seven times within a total 
number of seven events is 0.0255 * 0.9752 * 21 + 0.0256 * 0.975 * 7 + 0.0257 = 0.0000002. To 
maintain the chance of false accepting a protein as significant TAM interactor at 5% within 44 
tests, the individual significance level (alpha) needs to be at p<0.00117. From these 44 proteins, 
the proteins RPL28 (p=0.00164), RPS14 (p=0.00222), RPS23 (p=0.00222), GNB2L1 
(p=0.00222), PRDX1 (p=0.00462), SYNGAP1 (p=0.00462), and IGHG1 (p=0.00685) do not 
remain under the individual significance level. The probability of at least one false positive result 
within 44 tests is 26.098% when the individual significance level is p=00685 as obtained for 
IGHG1. 
 
For proteins identified as discovery by FDR corrected T-Tests, including proteins significantly 
enriched at least three times by uncorrected T-Tests, as well as MER, GAS6, and Protein S, the 
online database STRING10 (11.04.2018) was used to identify published connections between 
these proteins (Figure 21). Sources searched for interactions were Text mining, Experiments, 
Databases, Co-expression, Neighborhood, Gene Fusion, and co-occurrence. The confidence of 
network connections is displayed by the thickness of connections. The network was clustered to 
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a "MCL inflation parameter" of 3 separating clusters by color and conections in between clusters 
as dashed line.  
AHSG was the only protein that clustered together with the TAM receptors and the ligands 
GAS6 and Protein S being connected to Protein S, GAS6, and ACTN4. Protein S and AHSG 
were both identified to bind bions, mineralo-organic complexes formed from e.g. proteins, 
peptides, amino acids, lipids, or carbohydrates, that were identified in various body Fluids (131). 
Wu et al. identified AHSG as most, and Protein S as 8th most bion binding protein when 
preparing bions from DMEM with 5%FBS and a varriety of precipitating cations. Rawat et al. 
associated AHSG and GAS6 together with other proteins as inhibiting peptidase function or 
expression when characterizing differentially expressed proteins in a pregnancy biomarker 
screen in cows (132). Further AHSG and GAS6 were co-mentioned in articles investigating 
vascular mineralization and associated diseases (133-137). AHSG, ACTN4, GAS6, and Protein 
S were all listed as components in the currated patway: Exocytosis of platelet alpha granule 
contents. The indicated link between TYRO3 and RAN is based on a published screen for SYK 
interacting proteins, considering SYK a TYRO3 homologue. The screen based on co-IP 
enrichment and mass spectrometry identification of bound proteins identified RAN, as well as 
RanBP5 and XPO5 also called RAN binding protein 21 as SYK binding proteins (138). Further 
connections indicated are co-expression of homologs in Drosophila melanogaster and the yeast 
Schizosaccharomyces pombe, as well as co-mentioning in publications, which needs to be 
corrected as none of the indicated publications actually mentioned both indicated proteins 
together. ENO1 is linked experimentally as well as by co-mentioning in publications to the 
TYRO3 homologs SRC and FYN, as Enolase is used as an src-family kinase substrate (139-
142). Further publications indicated by String10 linking ENO1 to TYRO3 were text-mining 
artifacts. TYRO3 and AXL were linked to GAPDH due to co-expression of the TAM receptor 
homologs TSSK3 and TSSK6, which only posses a kinase domain without sharing the 
extracellular domains of TAM receptors. Further connections based on text mining between 
GAPDH and both TAM receptors, as well as between GAPDH and Protein S, were artifacts due 
to the frequent use of GAPDH as loading control and house keeping gene.  
 
 
Figure 19. Enrichment by TYRO3 and AXL for each tissue screened.  
For each tissue, the proteins enriched by either TYRO3-Fc or AXL-Fc were compared to Control-Fc 
enriched proteins. Differential enrichment is represented by the difference in log2 LFQ intensities and the 
respective T-Test’s log2 p-value graphed as volcano plots. Proteins identified as discoveries by 
permutation based FDR correction of the respective T-Test are indicated by darker coloration. Generally 
q<0.05 is considered a discovery, except for the spleen samples where the cut-off was q<0.01.  
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Figure 20. TAM receptor interacting proteins identified in multiple tissues. 
Summarizing the Vulcano Plots of Figure 19, protein enrichments compared between bait and control samples via T-
Test are shown for the respective baits compared to control for the respective tissues on the right. Proteins with 
p>0.05 comparing either TYRO3 or AXL to control via T-Test are labeled with an empty white circle for the respective 
tissue and bait. Proteins significantly enriched with p<0.05 are labeled with a black spot centered in a white circle for 
the respective tissue and bait. Proteins with a q<0.05, or in case of spleen samples with a q<0.01, correcting the T-
Test via permutation based FDR, are labeled with circles who’s intensity within a gray-scale from 50% gray (1) to 
black (3) represents the –LOG10 q value. Proteins that were identified as a discovery after FDR correction are labeled 
with a golden star. Proteins significantly bait enriched according to the T-Tests in at least three conditions are labeled 
with a blue star.  
Summarizing the test results, a bar graph shows the total number of tested conditions by a black frame for each 
protein. Significant enrichments with p<0.05 for the respective T-Tests are shown in light green for TYRO3 and light 
violet for AXL. FDR discoveries are shown in darker green or violet respectively. The number of conditions where 
proteins were significantly control enriched are shown in red.  
The log10 probability of the respective number of T-Test significant bait enrichments within the respective number of 
total tests is presented on the left. For those proteins significantly enriched in at least three conditions according to the 
T-Test (blue star) the bars are presented in black. For the number of these proteins the individual probability of 
p<0.00117 was calculated to maintain a probability of 5% of one or more false positives within the 44 proteins in case 
the data were random.  
 
 
 
 
Figure 21. Protein-Protein interaction network. 
To uncover connections in between proteins based on published data and information available online, the database 
STRING10 was used to cluster proteins identified as ‘TYRO3 and AXL interacting’ in Figure 20 by MCL clustering 
using an inflation parameter of 3. Interactions based on text mining, experiments, databases, co-expression, 
neighborhood, gene fusion, and co-occurrence between proteins of the same cluster are indicated as solid lines and 
in between proteins of different clusters as dotted line for those proteins recognized by the online tool. A higher 
confidence in the interaction is indicated by a darker coloration of the connection and vice versa. 
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Figure 22. TAM receptor 
enriched proteins characteristic 
for apoptotic bodies, 
microvesicles, and exosomes. 
Proteins enriched by the TAM receptors 
TYRO3 and AXL were compared to 
proteins characteristic to exosomes based 
on the top 100 proteins that are often 
identified in exosomes (B) based on 
Exocarta.org (143) (Appendix, Table 17), 
and proteins characteristic to either 
apoptotic bodies, microvesicles, or both 
based on a list of proteins published by 
Turi k et al. 2011 (144) (C).  
 
 
The screen for novel TAM interacting proteins has identified 83 proteins of which 3 proteins, 
AHSG, RAN, and ENO1, have been indirectly linked to TAM receptors or their ligands GAS6 and 
Protein S. A majority of these proteins share one or more cellular compartment associations with 
TYRO3, AXL, MER, GAS6, or Protein S. However, after the successful identification of proteins 
interacting with TAM receptors based on mass spectrometry, the functional relevance of these 
interactions remain to be investigated.   
 
 
Evaluation of putative TAM receptor interacting proteins 
 
After the successful identification of proteins interacting with TYRO3 and AXL, these interactions 
remained to be further characterized. With the experiments described in the following chapter, it 
was tested whether the TAM receptors directly interact with candidates of the screen. For this 
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purpose, titrations of recombinant proteins of interest were immobilized in reaction vessels and 
incubated with TAM receptor ectodomain containing Bait-Fc proteins and Control-Fc protein. To 
minimize the potential effect of n-terminal tags on the interactions tested, Bait-Fc and Control-Fc 
proteins were used in their 2 amino acid linker version without the n-terminal hexa-His-LPET tag. 
Each protein of interest titration was compared to AXL-Fc interaction with 50 nM recombinant 
human GAS6 to control for the correct opperation of the test and to enable the comparison 
inbetween tests.  
Recombinant human proteins tested in this assay were AHSG, ENO1, GNB2L1, IGHG1, PKM2, 
PRDX5, RAB14, RAN, RPS3, and SPR previously identified interacting with TAM receptors. 
These proteins were expressed in E. coli except for AHSG and the IGHG1 Fc domain (Figure 
23). From these proteins only the Fc domain of IGHG1 showed significantly higher binding by 
TAM receptor bait proteins compared to control protein. The signal of MER-Fc binding 625 nM 
IGHG1 reached 3% of the signal AXL-Fc reaches when binding 50 nM GAS6, however the 
signal at 625 nM IGHG1 was rising in log phase indicating higher signals may be reached with 
higher concentrations. Further AHSG and ENO1 showed weak binding to the Bait-Fc, but not 
differing significantly to Control-Fc. Further the signals of bait and control proteins bound to 625 
nM AHSG and ENO1 compared to approximately 2% of the signal measured with AXL-Fc 
binding 50 nM GAS6.  
 
Additional to those proteins identified to interact with TAM receptors in Figure 20, further proteins 
considered potentially interacting with TAM receptors were tested (Figure 24). From the proteins 
tested, bovine ALB and human C6, CNDP2, and S100A6 do not show any interaction with 
neither TAM receptor bait-Fc proteins, nor the control-Fc protein. Human and mouse MPO show 
binding of both, the bait-Fc and the control-Fc proteins without significant differences in the 
respective binding curves. The scavenger receptor B1 did show significant differences in it’s 
affinity to the three TAM receptor bait proteins, and most importantly, the affinity to Control-Fc 
was weakest. At 625 nM SR-B1 the binding curves of all proteins tested reach their maximum. 
MER-Fc reaches more than 13% of the signal detected by AXL-Fc bound to 50 nM GAS6. The 
second highest signal is reached by TYRO3-Fc with approximately 9.6% followed by AXL-Fc 
with 7% slightly higher than Control-Fc with 6%. When comparing the individual concentrations, 
AXL-Fc binding does not significantly differ from Control-Fc, unlike TYRO3-Fc and MER-Fc 
which significantly differ at 125 nM and 625 nM SR-B1-Fc. As the recombinant protein of SR-B1 
used was a chimeric protein fused c-terminally to the Fc domain of IGHG1, the TAM receptor 
ectodomains possibly interacted with the Fc domain instead of SR-B1. As the Fc domain fused 
to SR-B1 is from IGHG1 who’s TAM interaction curves are shown in Figure 24 H, a comparison 
of SR-B1-Fc to IGHG1 disects the binding to Fc from the binding to SR-B1. MER-Fc reaches a 
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relative signal of approximately 13% interacting with SR-B1-Fc while with IGHG1 Fc domain 
alone only 3% is reached. At 625 nM, the signal of MER-Fc and AXL-Fc is approximately 4.5 
times higher binding SR-B1-Fc compared to IGHG1 and even more than 11 times higher for 
TYRO3.  
 
 
Figure 23. Binding of screening identified proteins to TAM receptor bait proteins. 
The interaction of bait and control Fc proteins was measured by ELISA. Titrations of proteins identified as putative 
TAM interactors were bound to reaction vessels, blocked and incubated with 250 nM 2L versions of TYRO3-Fc, AXL-
Fc, MER-Fc and Control-Fc. Bound bait or control protein was quantified by anti-mIgG2a-HRP dependent substrate 
conversion. Signals are relative to 2L AXL-Fc binding 50 nM GAS6.  
MEAN and SEM of 3 technical repeats performed with technical duplicates are shown if not indicated otherwise. 
Probabilities of one curve fitting adequately all data sets were calculated by regression analysis for sigmoidal or 
exponential curves. In case of p<0.05, data sets of bait proteins were compared to the control within the individual 
conditions with two-stage step-up method of Benjamini, Krieger and Yekutieli FDR corrected multiple t-tests reporting 
bait enrichments significantly different to control as follows: * q<0.05 and ** q<0.01, *** q<0.001 
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Figure 24. Binding of proteins of interest to TAM receptor bait proteins. 
The interaction of bait and control Fc proteins was measured by ELISA. Titrations of proteins of interest were bound to 
reaction vessels, blocked and incubated with 250 nM 2L versions of TYRO3-Fc, AXL-Fc, MER-Fc and Control-Fc. 
Bound bait or control protein was quantified by anti-mIgG2a-HRP dependent substrate conversion. Signals are 
relative to 2L AXL-Fc binding 50 nM GAS6.  
MEAN and SEM of 3 technical repeats performed with technical duplicates are shown if not indicated otherwise. 
Probabilities of one curve fitting adequately all data sets were calculated by regression analysis for sigmoidal or 
exponential curves. In case of p<0.05, data sets of bait proteins were compared to the control within the individual 
conditions with two-stage step-up method of Benjamini, Krieger and Yekutieli FDR corrected multiple t-tests reporting 
bait enrichments significantly different to control as follows: * q<0.05 and ** q<0.01, *** q<0.001 
 
 
Testing several proteins of interest biochemically for direct interaction with TAM receptors 
sucessflly identified Scavenger receptor B1 and IGHG1 interaction with the TAM receptors 
TYRO3 and MER but not AXL, and MER but not TYRO3 and AXL respectively. As for the 
current test of protens identified as potential TAM receptor interacting mostly recombinant 
proteins expressed in bacteria were used lacking human post-translational modifications, little 
can be concluded from negative data. In order to draw a meaningful conclusion, also from 
negative data, the proteins of interest should be expressed in human cells and tested for their 
effect on TAM receptor function. With SR-B1 and IGHG1 confirmed to interact with TAM 
receptors and further promissing proteins to be investigated, future experiments will shed light 
on TAM receptor function and regulation.  
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4. Discussion 
 
 
Benefits and improvements of the specialized screening method 
 
Since the discovery of TYRO3, AXL, and MER and their classification as distinct receptor 
tyrosine kinase family in 1991 by Lemke and colleagues (124), few efforts were made to 
systematically screen for ligands and interacting proteins. Four years after the discovery of TAM 
receptors, Protein S and GAS6 were identified as ligands. First conditioned media were 
screened for their ability to cause TAM receptor phosphorylation, followed by receptor based 
affinity chromatography of TYRO3-Fc with fetal bovine serum and Axl-Fc with concentrated 
ABAE conditioned medium (29). Tubby and Tulp1 were characterized to be TAM receptor 
ligands inducing phagocytosis in retina and brain. Tubby binds Mer, while Tulp1 binds to Tyro3, 
Axl, and Mer (38, 39). The initial discovery of Tubby and Tulp1, which act as ‘eat me’ signals for 
phagocytosis in the year 2010 was based on a phage display assay. In this assays, phages 
presenting proteins of a murine eye cDNA library were enriched by 4 rounds of phagocytosis by 
retinal pigment epithelial cells (145). The same group amended its phage display phagocytosis 
protocol by two additional Mer affinity purification steps and identified Galectin-3 as a Mer 
specific phagocytosis ligand (41). Galectin-3 was shown to opsonize desialylated cells for 
microglia (40) and might potentially be involved in other phagocytic processes with desialylation 
as ‘eat me’ signal as for example in platelets (146). The hypothesis that semian virus 40 mimics 
host ligands lead to the discovery that the major capsid protein VP1 binds to AXL and to a lesser 
extent to TYRO3 and MER. The homology of VP1 to GAS6 was uncovered by bioinformatic 
screening for VP1 homologous and receptor associated proteins (104). 
Besides the binding of these ligands or ligand mimicking proteins, TAM receptors were shown to 
co-operate with other receptors to engage in various signaling pathways. Wu and colleagues 
characterized the co-operation of MER and αvβ5 integrin recognizing PtdSer by GAS6 or Protein 
S and by MFG-E3 respectively, after investigating both receptors signaling cascades. Only when 
MER recruits αvβ5 by FAK, a synergistic increase of phagocytic activity is reached (71). Like Wu 
and colleagues, Todt et al. found MER binding and co-operating with Scavenger Receptor A to 
synergize for phagocytosis as both receptors are involved in the same process (147). Carla 
Rothlin and colleagues discovered that simultaneous activation of AXL and IFNAR leads to the 
induction of SOCS1 and SOCS3 expression. They could demonstrate, that AXL usurps IFNAR 
signaling after direct binding. Together these findings explain the initial observation of dendritic 
cell’s hyper activation in TAM receptor triple knock out mice. After establishing that GAS6 
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stimulation of TAM receptors induces SOCS1/3 expression in dependency of IFNAR, direct 
interaction of AXL and IFNAR1 was discovered via co-IP (22). 
Focusing on the methods used for the identification of TAM receptor ligands, only bovine serum, 
conditioned ABAE media, and murine eye proteins were screened for ligands, representing a 
limited spectrum of TAM receptor expressing tissues (29, 145). The affinity purification leading to 
the discovery of GAS6 and Protein S was majorly limited by the low sensitivity of staining 
differentially purified proteins in SDS-PAGE gels (29). The phage display assay successfully 
enriched Tubby and TULP1 by 4 rounds of phagocytosis and phage selection. However the 
assay was biased towards phagocytosis representing only one of three major TAM receptor 
functions. Another bias was the limitation of the screened protein library towards proteins 
expressed in murine eye (145). Retinal pigment epithelial cells are specialized to phagocytize 
the outer segments of photoreceptors (148). Subsequent studies were able to show a relevance 
of Tubby and Galectin 3 for Mer dependent phagocytosis by microglia, with Galectin 3 
suggested to opsonize apoptotic cells presenting desialylated sugar chains (39, 40). Beside 
desialylated sugar chains being indicated as a second ‘eat me’ signal additional to PtdSer for 
Mer dependent phagocytosis, the identification of Tubby and Galectin 3 did not reveal novel 
TAM receptor functions.  
Using a method similar to the affinity purification used by Stitt et al., I was able to enrich 
Fibronectin bound to TYRO3-Fc from human plasma (Figure 6, A) and confirm its interaction to 
TAM receptors in a reverse ELISA assay (Figure 6, B). Fibronectin is a major component of the 
extracellular matrix and involved in wound healing (149), cell adhesion (150) and migration. It 
participates in biological processes like proliferation, survival, and differentiation (151). 
Interestingly, the effect of Fibronectin on proliferation, survival, and differentiation is dependent 
on FAK pp125 phosphorylation (151). FAK is phosphorylated by SRC upon MER activation and 
binds to the β5 subunit of integrin αvβ5, which then co-operates with MER to phagocytize the 
outer segments of photoreceptors (70, 152). Finally McCutcheon and colleagues described the 
beneficial effect of Fibronectin addition on the phagocytosis of apoptotic neutrophils by 
macrophages, which is independent of β1 integrin (153). Together these findings suggest that 
Fibronectin is recognized by multiple receptors, and that Fibronectin supports of phagocytic 
events, which may involve TAM receptor activation.  
Motivated by the TAM receptor specific enrichment of Fibronectin using simple affinity 
purification, I established a method to attach a photo-activatable cross-linker to TAM receptor 
baits to capture weak and transient interacting proteins and compared three methods of protein 
enrichments  (Figures 7 to 16). After the successful establishment of bait protein modification, 
and after deciding for an optimal enrichment method, murine adipose tissue, brain, spleen and 
testis, as well as human plasma and brain samples from patients diagnosed with mild cognitive 
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impairment (MCI), Alzheimer’s patients and control patients were chosen to be screened for 
novel TAM ligands. TAM receptor function is dependent on the ligand and co-receptor 
environment, which varies within tissues and within health and disease states. To decrease the 
bias introduced by selecting certain environments to be screened, the tissues were selected to 
represent the major TAM receptor functions including phagocytosis, immune inhibition, and 
proliferation and survival. In detail, human plasma was screened, as TAM functions were initially 
discovered in the hematopoietic system (22, 24, 87). Brain tissue was chosen, since microglia 
were described to express TYRO3, AXL, and MER and, additional to GAS6 and Protein S, bind 
ligands like Tubby, TULP1, and Galectin 3 (40, 82, 154, 155). The utilization of alternative 
ligands indicates brain samples as valuable sources of further TAM receptor ligands. Like in 
testis (25), TAM receptors are reported to be involved in phagocytic processes in the spleen 
(24). In addition to phagocytosis TAM receptors are reported to essential for NK cell 
differentiation in spleen (156). Besides plasma, brain, testis and spleen representing tissues with 
described TAM receptor functions, adipose tissue was selected for screening. Although none of 
the three major TAM receptor function has been described in adipose tissue yet, mRNA 
expression data show that AXL is relatively high expressed compared to the other tissues 
described (Figure 17, B). GAS6 and AXL are indicated to have an effect in obesity, as increased 
GAS6 and soluble AXL levels were detected in overweight individuals (157). Like the diversity of 
TAM receptor functions, the tissues selected for the novel TAM interactor screening were 
chosen to represent diverse TAM receptor and ligand expression patterns (Figure17, B).  
The screening method used for this study differs from the methods used before by the reduction 
of tissue bias, as multiple tissues of mouse and human origin, as well as in case of human brain 
healthy and diseased tissues were screened. Instead of enriching strong interacting proteins, the 
method used enables the capture of weak and transient interacting proteins. Finally, mass 
spectrometry was used to identify and quantify novel TAM interacting proteins with the highest 
sensitivity of all methods used for protein identification (Figure 17, A).  
 
 
The screening for TAM interacting proteins identifies 83 novel candidates 
 
Screening for TAM interacting proteins in lysates of the tissues defined above resulted in the 
enrichment of 83 proteins following no directly obvious pattern, except for an overrepresentation 
of ribosomal proteins (Figure 20). To reveal associations between the enriched proteins and 
TAM receptors as well as their ligands GAS6 and Protein S, the online database STRING10 was 
used. STRING10 is a protein interaction database based on published high throughput and co-
expression experiments, automated text mining, genomic context predictions, and data provided 
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by other databases. Therefore, STRIN10 is a powerful tool to identify connections between 
proteins of interest. Provided with the list of 83 TAM enriched proteins completed with MER, 
GAS6, and Protein S, this meta-analysis revealed AHSG and ACTN4 to be associated with 
GAS6 and Protein S. RAN and ENO1 were found to be associated with TYRO3 (Figure 21). 
Using the Cytoscape applications ClueGO and CluePedia, gene ontology enrichment analysis 
for ‘Biological Process’ of the 83 TAM ligand candidates highlighted IGHG1, IGHM, and IGLL5 
as proteins involved in phagocytosis. Further ribosomal proteins were enriched for several 
biological processes not directly associated with TAM receptors (Figure App 7). ‘Cellular 
Component’ GO terms associated with the TAM enriched proteins were grouped to commonly 
associated terms and beside the cellular localizations, a general pattern of vesicular association 
of 55 proteins was found (Figure App8). Differentiating the general vesicle patterns even further 
revealed 21 TAM enriched proteins described to be characteristic for exosomes, microvesicles 
and apoptotic bodies (Figure 22). In the following sections the identified patterns and associated 
proteins will be discussed regarding their potential role to engage in TAM receptor functions.  
 
 
AHSG or Fetuin A may bridge mineral complexes and mineralized vesicles to TAM 
receptors for phagocytosis 
 
To identify previously reported interactions, the online database STRING10 was used (Figure 
21). STRING10 linked the acute-phase protein AHSG, or Fetuin A, to the TAM receptor ligands 
GAS6 and Protein S due to their binding of mineralo-organic complexes and cardiovascular 
calcification (131, 133). Vascular calcification can be prevented by Vitamin K, but GAS6 was 
shown to not aggravate calcification (133). AHSG was found to have a cytoprotective effect on 
neurons after challenges of oxidative stress in vitro (158), as do GAS6 and Protein S. Loss of 
AHSG leads to increased inflammatory gene expression in spleen indicating an anti-
inflammatory role (159). On the contrary, AHSG was shown to function as an adaptor for free-
fatty acids (FFA) to induce TLR4 dependent inflammation in adipose tissues (160). AHSG 
clusters calcium and phosphate into larger aggregates preventing soft-tissue mineralization 
(161). These calciprotein particles are cleared by liver Kupffer cells and marginal zone 
macrophages in spleen involving scavenger receptor A (SR-A) (162). Elevated calcium and 
phosphate levels synergistically induce calcification of vascular smooth muscle cells (VSMC) in 
the absence of serum (163). AHSG found at high concentrations in human plasma with 0.3 
mg/ml (164) was shown to inhibit apoptosis (165) and thereby prevent vascular calcification 
(166). Another serum protein inhibiting apoptosis induced by elevated inorganic phosphate is 
GAS6 by engaging AXL and the PI3K/AKT survival pathway (167). Under conditions of high 
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calcium and phosphate concentrations, VSMC release apoptotic bodies and matrix vesicles 
containing high concentrations of calcium and phosphate together with AHSG (163). The 
accumulation of matrix vesicles and apoptotic bodies due to impaired phagocytosis increases 
vascular calcification (166). Acetylated LDL (acLDL) was shown to compete with apoptotic 
bodies for binding to phagocytes (168) and by competing with apoptotic bodies for SR-A 
dependent phagocytosis. Thereby, acLDL increases vascular calcification (169). Another 
nucleating factor, which contributes to the formation of calcium phosphate complexes, is 
Phosphatidylserine (PtdSer) presented on the inner plasma membrane of matrix vesicles and on 
the outer leaflet of apoptotic body membranes (170).  
The characterization of AHSG interaction with TAM receptors as implicated by multiple 
significant enrichments in various tissues including spleen (Figure 20) may shed light on TAM 
receptor and ligand function in atherosclerosis beyond promoting VSMC survival.  
 
 
A novel function of TAM receptors in the recognition of extracellular vesicles 
 
The two proteins ENO1 and RAN identified in my screen were related to TYRO3 by STRING10 
(Figure 21). ENO1’s indicated relationship is based on TYRO3’s homology to the non-receptor 
tyrosine kinase FYN, where ENO1 is used as a phosphorylation substrate (171). RAN’s 
indicated relationship is based on TYRO3’s homology to the non-receptor tyrosine kinase SYK, 
where RAN was enriched in a SYK co-immunoprecipitation (138). Comparing the kinase 
domains of the proteins, TYRO3 (ref: Q06418, aa518-790) was found to share 34.3% pairwise 
identity with FYN (ref: XP_016866139.1, aa271-524) and a 32.1% pairwise identity with SYK 
(ref: P43405, aa371-631). Indeed TYRO3 is described to bind and use FYN for signaling to 
induce Schwann cell myelination (172), while SYK binds to activated AXL in B-cells from chronic 
lymphatic leukemia patients (173). Therefore, TYRO3 adaptor proteins potentially may have 
indirectly enriched ENO1 and RAN. However, adaptors like SYK and Fyn are not able to interact 
with the kinase domains of TYRO3 and AXL in case of this screen, as they are not included in 
the bait proteins used.  
ENO1 and RAN, as well as 9 other proteins including PKM, EEF2, ACTB, HSPA8, ACTN4, 
GAPDH, HSPA5, RAC1, and PRDX1 are proteins characteristically identified in apoptotic 
bodies, microvesicles, and exosomes (144). Further EEF1A1, RAB14, RPS3, TUBA1B, 
GNB2L1, TUBB, TAGLN2, and CTSD are associated with one or two of the extracellular vesicle 
types, but not all three of them indicating an interaction with multiple types of vesicles (Figure 
22). Literature research revealed an association of TAM receptors with the clearance of 
apoptotic cells is abundantly available. In contrast, only few publications describe a direct 
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connection of extracellular vesicles to TAM receptors. However these few publications indicate 
potential delivery signals to activate TAM receptors by apoptotic bodies, microvesicles, 
ectosomes, and exosomes. For example, Eken and colleagues could show that ectosomes 
released by activated neutrophils have a regulatory effect on TLR activation of macrophage 
lasting for 24h, which is MER dependent (174, 175). Additionally, exosomes were shown to 
induce STAT1 phosphorylation in dependence of GAS6 or Protein S on TAM/IFNγR1 reporter 
cells (176), indicating that exosomes participate in the induction of anti-inflammatory cell 
programs by binding to TAM receptors. Another example for TAM activation by vesicles are 
plasma membrane-derived microparticles (PMPs) released by Platelets upon activation (177). 
Endothelial cells phagocytize these PMPs in dependence of AXL and GAS6. Further the 
clearance of PMPs was not reduced in GAS6 knock out mice, leading to the hypothesis, that the 
GAS6/AXL interaction is targeted and local but that this mechanism is not the main mechanism 
to clear the vast majority of PMPs from the circulation (177). Microvesicles from chronic 
lymphatic leukemia patients were found to activate PI3K/AKT signaling in bone marrow stromal 
cells. The authors concluded, that the microvesicles induced the intracellular signaling cascades 
either by the activation of AXL, or by the delivery of active AXL via microvesicles. The authors 
further postulate the hypothesis, that activated AXL is delivered by microvesicles to recipient 
cells even in the absence of GAS6 expression in those recipient cells (178).  
The herein described screening for novel TAM ligands (Figure 22) enriched multiple proteins 
associated to apoptotic bodies, but also microvesicles and exosomes. The high number of 
vesicle-associated proteins might indicate an enrichment of total vesicles complexes, rather than 
TAM receptor interactions with single vesicle components. Comparing bait and tissue 
combinations where GAS6 was significantly enriched to those where the vesicle-associated 
proteins were significantly enriched, no co-enrichment of GAS6 with vesicle markers was found. 
To verify proteins like PKM, ENO1, RAB14, RPS3, GNB2L1, and RAN, which were identified as 
novel potential TAM ligands, ELISA assays were performed to test their affinity to TAM 
receptors. Yet the screening identified these proteins as TAM interacting proteins, the ELISA 
assay did not reveal direct interaction (Figure 23, B, C, F, H, I, and J). However, the recombinant 
proteins used for these assays were mostly E. coli derived and after TAM receptor binding, 
several washing steps ensured stringency but impaired the detection of weak and transient 
interaction.  
In summary, deeper investigation of TAM receptor activation is needed to clarify how TAM 
receptors are able to elicit differential responses to at first glace similar signals like GAS6 and 
Protein S bound to PtdSer presented by apoptotic (24-26) or living cells (55) or to vesicles. The 
illumination of vesicular signal transmission via TAM receptor activation will deepen our 
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understanding of immune regulation by TAM receptors and offer ways to target cells and direct 
their responses via vesicles carrying therapeutics.  
 
 
Apoptotic cell associated molecular patters 
 
Additional to the proteins identified by screening multiple tissue lysates, further proteins were 
tested for TAM receptor interaction via ELISA assays (Figure 24). C6 and MPO, as 
representatives of proteins reported to label membranes for immune cells (179, 180), were 
tested. Neither protein demonstrated affinities to any TAM receptor bait protein exceeding the 
affinity to the control Fc protein (Figure 24, B, D, E). Another candidate based on literature 
research was the scavenger receptor B (SR-B), as it’s family member SR-A was described to 
synergize with MER for efficient phagocytosis in murine macrophages (147). SR-B was shown to 
directly bind PtdSer on apoptotic cells and induces phagocytosis (181) highlighting the receptor 
as a potential TAM cooperation partner. Titration of recombinant SR-B1 protein in an ELISA 
assay showed direct binding of MER and TYRO3 (Figure 24, G), an interaction yet unpublished. 
Further characterization is needed to investigate the interaction of TAM receptors and 
Scavenger receptor B with respect to phagocytosis, potentially in absence of TAM receptor 
ligands GAS6 and Protein S.  
Beside Phosphatidylserine presentation on the outer plasma membrane recognized by TAM 
receptors, Scavenger receptors, and integrins (71, 147), apoptotic bodies present a unique 
range of proteins (144) discriminating them from living cells. In 1994, the Rosens described 
blebs of RNA surrounded by ribonucleoprotein Ro, fragmented endoplasmic reticulum and 
ribosomes, and DNA blebs surrounded by ribonucleoproteins Ro, La, and small nuclear 
ribonucleoproteins and considered them to be targets of auto-antibodies in systemic lupus 
erythematosus (SLE) (182). Nishida and colleagues further characterized the degradation of 
ribosomal proteins, structural change of ribosomes and the surface presentation of ribosomal 
proteins during apoptosis (183). Mice expressing a kinase deficient MER variant develop 
systemic lupus including autoantibodies against chromatin, DNA, and IgG due to impaired 
clearance of apoptotic cells (63). Moreover mice lacking TAM receptors express autoantibodies 
against a range of ribonucleoproteins, but especially against heterogeneous nuclear 
ribonucleoprotein P2 (184). The presentation of ribosomes and ribosomal proteins on apoptotic 
cell surfaces, together with the TAM receptor specific enrichment of 40S ribosomal proteins 
RPS3, RPS4X, RPS11, RPS13, RPS14, RPS16, RPS20, RPS23, RPS27, and 60S ribosomal 
proteins RPL11, RPL23, and RPL28 (Figure 20) indicate an interaction of TAM receptors with 
ribosomes presented on the surface of apoptotic cells. Yet the arguments for a direct interaction 
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of ribosomes with TAM receptors are strong, recombinant RPS3 was negatively tested for direct 
interaction with TAM receptors using ELISA (Figure 23, J). The bait proteins used in the ELISA 
assay did not capture weak and transient interacting proteins via cross-linking and therefore the 
interaction may be too weak to be detected. In conclusion, the interactions of TAM receptors 
with ribosomal proteins need to be confirmed with more sensitive methods to characterize the 
interaction and potential discrimination of living and dead cells presenting PtdSer. 
 
 
TAM receptor enriched proteins and cancer 
 
Searching for TAM receptor enriched proteins associated with cancer by PubMed revealed 15 
proteins with more than 100 publications, which were therefore considered as cancer associated 
(Appendix, Table 18). Of these 15 cancer associated proteins, PKM, ENO1, ACTB, HSPA8 & 
HSPA5, RAN, and GAPDH were enriched in multiple tissues with at least one FDR discovery in 
the TAM receptor ligand screen (Figure 20). Most interestingly, ENO1 was described to regulate 
pancreatic cancer adhesion, invasion, and metastasis by αvβ3 integrin. Small hairpin RNA 
knockdown of ENO1 resulted in an impaired ability to adhere to Collagen I and IV and 
Fibronectin (185). ENO1 is expressed on the cell surface, where it binds and activates 
plasminogen (186) leading to extracellular matrix break down (187). HSPA8 is another surface 
protein associated with influencing the metastatic potential of cancer cells, promoting 
proliferation and cell survival (188). Extracellular GAPDH interacts with the cell adhesion 
molecule L1 (189), which shows parallels to TAM receptors due to the domain structure 
containing Ig-like domains and Fibronectin-type III-like domains (189) as do TAM receptors. 
Further parallels of L1 to TAM receptors are shedding by ADAM10 and ADAM17, cytosolic tail 
release by -secretase, and ERK signaling (190, 191). L1 is cancer associated, as L1’s 
expression correlated with tumor proliferation (192), and it’s identification as survival factor in 
colon cancer cells (193). A link to TAM receptor ligands is the expressional regulation of GAS6 
and L1 by TWIST1 (45). Another twist to the involvement of TAM receptors might be the 
communication between cancer cells and their environment via vesicles. B-cells from chronic 
lymphatic leukemia patients were demonstrated to release microvesicles activating TAM 
receptors bone marrow stromal cells (178). Although this particular interaction might just be due 
to the transfer of active AXL by vesicles, further indications for TAM receptor involvement in 
vesicle mediated cancer cross talk can be found.  Examples are the involvement of MER binding 
Fibronectin in target cell interaction (194), the MER interacting αvβ5 integrin on lung-tropic 4175-
LuT exosomes increasing liver metastasis (195), and gastric cancer exosomes activating 
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PI3K/AKT and MAPK/ERK pathways (196). PI3K/AKT, as well as MAPK/ERK are pathways 
engaged by TAM receptors to induce proliferation and survival.  
In summary, the recognition of extracellular vesicles by TAM receptors might not only contribute 
to the regulation of immune responses, but also support proliferation and survival in case of 
vesicles released by cancer cells. Characterizations of the indicated connections might improve 
our understanding of how extracellular vesicles of immunologic or malignant cells elicit 
differential TAM receptor function in recipient cells.  
 
 
Conclusion 
 
TAM receptor function in cell proliferation and survival, phagocytosis, and inhibition of 
inflammatory responses are well established with respect to the ligands GAS6 and Protein S. 
The only alternative ligands discovered and characterized are TUBBY, TULP1, and Galectin 3. 
Early studies reported TAM receptor activation by GAS6 or Protein S bound to 
Phosphatidylserine (PtdSer) to induce phagocytosis and immune inhibition when studying 
apoptotic cells. Recently, living cells were found to present PtdSer, which is bound by GAS6 and 
Protein S and thereby inducing TAM receptor dependent immune inhibition but not 
phagocytosis. As PtdSer is described to induce differential effector functions via TAM receptor 
activation when presented either by living or dead cells, additional yet unknown factors must 
enable the differentiation of messages.  
To discover novel TAM receptor interacting proteins, a novel method of screening was required. 
The method used for this study was tailored for the capture of weak and transient interacting 
proteins. A sortase A based transpeptidation method was successfully established for the site 
specific application of cross-linker molecules to the n-terminus of bait proteins. By employing 
these baits in multiple tissues, 83 proteins, not previously associated with the TAM receptor 
family, were enriched. AHSG (Fetuin A) was identified indicating TAM receptor dependent 
phagocytosis of mineralo-organic complexes and mineralized apoptotic cells, as present in 
atherosclerotic lesions. Ribosomal proteins were highly represented amongst the identified novel 
interacting proteins. Together with the reported development of anti-ribosomal protein 
autoantibodies in the absence of MER, this may indicate the recognition of apoptotic bodies by 
TAM receptors via ribosomal proteins in addition to PtdSer. Another pattern that emerged from 
the proteins enriched were vesicle markers. Several publications indicate the utilization of 
vesicles by immune cells to regulate responses of neighboring cells via TAM receptors, a 
concept further employed by malignant cells. Finally, it is shown in the here presented study, 
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that Scavenger receptor B binds directly to TYRO3 and MER. This highlights once more the 
variability of TAM receptor co-operation with other receptors.  
This study reveals 83 points of reference for a more extensive dissection of phagocytic and anti-
inflammatory TAM receptor stimuli beyond Phosphatidylserine to maintain tissue homeostasis, 
regulate inflammatory responses, and cell proliferation and survival. Such insights would 
especially improve the design of extracellular vesicle therapeutics towards an additional mode of 
anti-inflammatory action and targeted phagocytosis.  
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Appendix 
 
List of Abbreviations 
Abbreviation Complete form Abbreviation Complete form 
aa Amino acids L2 2 amino acid Linker 
ABC Ammonium bicarbonate L9 9 amino acid Linker 
AD Alzheimer’s Disease L19 19 amino acid Linker 
APC Antigen presenting cell LC Liquid chromatography 
ATP Adenosine triphosphate LysC Lysyl endopeptidase 
BCA Bicinchoninic acid assay MCI Mild Cognitive Impairment 
CDS Coding sequence min Minute / minutes 
CmR Chloramphenicol resistance protein MS Mass spectrometry 
DAMP Danger associated molecular pattern ms Milliseconds  
DMEM Dulbecco’s Modified Eagle’s Medium n.a. Not applicable 
DMSO Dimethylsulfoxide OD Optical density 
DNA Deoxyribonucleic acid OD600 Optical density at 600 nm 
dsDNA Double stranded DNA PAMP Pathogen associated molecular pattern 
DTT Dithiothreitol REF number Reference number 
E. coli Escherichia coli ref. seq. Reference sequence 
ELISA Enzyme Linked Immunosorbent Assay rpm Rounds per minute 
FBS Fetal Bovine Serum RT Room temperature 
FCS Fluorescence Correlation Spectroscopy s Second / seconds 
FLCS Fluorescence Lifetime Correlation 
Spectroscopy 
S. aureus Staphylococcus aureus 
S. pyogenes Streptococcus pyogenes 
FLIM Fluorescence Lifetime Imaging SLE Systemic lupus erythematosus 
ESI Electrospray ionization SMD Single Molecule Detection 
h Hour / hours TBS Tris buffered saline 
Hg Mercury  TCS True Confocal Scanner 
His / H Histidine TFA Trifluoroacetic acid 
IAA Iodoacetamide UHPLC Ultra-high pressure liquid chromatography 
Ig Immunoglobulin v/v Volume by volume 
IP Immunoprecipitation WB Western Blot 
p probability w/v Weight by volume 
PBS Phosphate buffered saline  Xe Xenon 
PCA Principle Component Analysis α Alpha or anti (context dependent) 
PEI Polyethylenimine °C Degree Celsius  
PMSF Phenylmethylsulfonyl fluoride ‘ Minutes 
PtdSer Phosphatidylserine “ Seconds  
q corrected probability   
Table 16. List of abbreviations. 
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Supplemental data 
 
Comparing purification strategies used for n-terminal sortase A transpeptidation.  
The two-step process of n-terminal sortase A tagging contains necessary purifications of the 
intermediate and end product. Purification after the first tagging step is necessary to separate the 
protein with the exposed n-terminal glycine from the removed LPET containing peptide to prevent a 
re-ligation of LPET containing peptides to the free n-terminal glycine, and from the triglycine, which 
would interfere with the second step. Following the second tagging step, where a LPETG motif-
containing payload is tagged to the free n-terminal glycine, another purification is performed to 
separate the tagged product from the srtA enzyme and from the unused payload.  
Three purification methods were tested for srtA transpeptidation efficiency, protein recovery, and 
reliability. Protein A elution buffers, based on low pH and high salt concentrations were tested for 
elution of proteins from Protein A Dynabeads. The best elution of approximately 75% compared to 
the LDS eluted control was achieved with the Pierce IgG Elution Buffer (Figure App 3). Protein A 
microbeads were tested as an alternative to Dynabeads as microbeads, due to their size of 50 nm, 
they are described to distribute equally in liquids, and not to sediment over time. Further each particle 
binds less protein leading to a homogenous distribution of particle bound bait and control protein in a 
sample. During the use of microbeads in srtA reaction buffer the beads aggregated. Variations of the 
reaction buffer could not fully prevent the aggregation, especially following magnetic attraction and 
washing in the HOKImag (data not shown). The efficiency and reliability of the three methods was 
further compared performing both tagging steps exemplary with hexa-His-L2 AXL-Fc (Figure App 1).  
The first srtA tagging step was performed equally for all three conditions without purification by beads 
or column. The L2 AXL-Fc proteins were then purified either by dyna-, or microbeads or by using a 
FPLC column. In case of the FPLC purification, proteins were eluted, the buffer was exchanged to 
srtA reaction buffer and the proteins were quantified before further steps. In case of the bead 
purifications, L2 AXL-Fc proteins were bound by the respective and washed with srtA reaction buffer 
before the second tagging step without elution and quantification. The second tagging step was 
performed with L2 AXL-Fc protein being either bound to Dynabeads, or microbeads, or in solution 
after FPLC purification and TAMRA-LPETGG. The reaction was stopped by denaturing proteins in 
DTT containing LDS buffer at 95°C and separation in SDS-PAGE (Figure App 5).  
As the first steps for each purification method was performed under equal conditions, removing the 
hexa-His-LPET peptide resulted in equally high efficiencies. Following the purification and second 
tagging step, only low amounts of L2 AXL-Fc protein was detected for dynabead and microbead 
based methods (Figure App 1, B, C). Losses during FPLC purification, buffer exchange and 
quantification were compensated for the second tagging step, which resulted in TAMRA being 
detected on the L2 AXL-Fc protein comparable to the positive control (Figure App 1, D). 
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Figure App 1. 
Purification methods 
used for n-terminal 
srtA transpeptidation. 
A schematic workflow shows 
the different purification 
methods that were compared 
to purify tagged Fc protein 
after srtA transpeptidation 
(A). The first srtA tagging 
step was performed with 1 
µM hexa-His-L2-AXL-Fc, 6 
µM 5M srtA, 1 mM triglycine 
in srtA reaction buffer at 37°C 
for 30 minutes. The reaction 
was stopped with 20 µM 
EDTA and samples for 
western blot were taken. The 
AXL-Fc proteins were then 
purified with either 
Dynabeads, Microbeads or 
via FPLC columns. The 
second srtA step was 
performed with either the 
AXL-Fc protein bound to the 
respective beads or 1 µM of 
FPLC purified AXL-Fc 
together with 6 µM 5M srtA 
and 40 µM TAMRA-
LPET*GG at 37°C for 30 
minutes. After completion of 
the second tagging step, the 
reaction was stopped with 20 
µM EDTA and samples for 
western blot were taken. As a 
positive control (Pos.),  1 µM 
of either hexa-His-L2 AXL-Fc, 
or L2 AXL-Fc, or TAMRA-L2 
AXL-Fc previously prepared 
by FPLC were added. (B, C, 
D) N-terminal srtA tagging 
was performed on hexa-His-
L2 AXL-Fc bait protein either 
using Protein A Dynabeads 
(B), Microbeads (C), or FPLC  
columns (D) for the purification steps. The presence of hexa-His tag and Fc-tag before and after the first srtA tagging 
step, as well as the presence of TAMRA and Fc-tag before and after the second srtA tagging step were detected via 
SDS-PAGE and western blotting. Relative hexa-His detection was determined by dividing the detected hexa-His 
signal by the Fc signal relative to the mean of hexa-His/Fc of the – srtA samples of the first srtA tagging step. The 
relative detection of Fc or TAMRA of the second srtA tagging step was determined by dividing the detected Fc or 
TAMRA signal of a sample by the detected Fc or TAMRA signal of the positive control. The MEAN and SD of three 
technical replicates is shown. 
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Figure App 2. Comparison of Ig elution 
buffers. 
Comparison of buffers to elute protein from Protein A 
Dynabeads. Hexa-His-L2 control protein was loaded on 
Protein A Dynabeads and eluted the described buffers. 
Proteins remaining on the beads and beads without 
previous elution were eluted with DTT containing LDS 
buffer at 95°C. Proteins were detected via Western Blot 
after SDS-PAGE gel electrophoresis and quantified. 
 
A 
 
B 
 
Figure App 3. Comparison of beads for separation of bait proteins from complex 
matrices. 
A defined amount of AXL-Fc was spiked into brain lysate samples. Recovery by various beads was compared 
according to efficiency and purity. Recovery was determined by quantifying bands in Coomassie stained SDS-PAGE 
gels. n=1 
 
 
 
Figure App 4. Prediction of free Ca2+ in 
titrations of EDTA, EGTA, and BAPTA. 
The concentration of free Calcium ions in dependence on the 
concentration of the chelators EDTA, EGTA, and BAPTA for 
a total concentration of 10 mM Calcium were predicted by 
the online tool MAXCHELATOR.  
Concentrations were predicted for the following conditions: 
pH7.4, 20°C, and an ionic strength of 0.16 
(http://maxchelator.stanford.edu/webmaxc/webmaxcS.htm, 
09.02.2018). 
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Figure App 5. Titration of DTT to release Diazirine/Biotin part of cross-linker molecule. 
Titration of Dithiothreitol (DTT) to determine efficient concentration for reduction of disulfide bond connecting the 
Diazirine cross-linker and the biotin label to the bait protein. Bait protein not tagged with the Diazirine cross-linker was 
used as the positive control (Pos), while Diazirine cross-linker tagged bait protein not treated with DTT was used as 
negative control (Neg). The bait protein and the biotin were detected via western blot. The * marked bands were 
quantified. The ratio of biotin to bait protein was calculated, subtracted by Pos and divided by the Neg. MEAN and SD 
of technical triplicates 
 
Figure App 6. Label transfer from 
Diazirine tagged AXL-Fc or CTRL-Fc 
to GAS6. 
Supplemental illustration of less cropped 
representative Western Blots for label transfer 
from either Diazirine-L19 AXL-Fc or Diazirine-
L19 Control-Fc to GAS6 in matrices of 
increasing complexities.  
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Figure App 7. Gene Ontology enrichment for Biological Processes and protein 
localization. 
Cytoscape and the application ClueGO+CluePedia were used to perform an enrichment analysis of the GO term 
‘Biological Process’ with the proteins listed in Figure 20 as significantly TAM receptor enriched. Proteins included are 
linked to the respective biological processes are sorted for their cellular localization.  
 
 
 
Figure App 8. Cellular Components and associated proteins identified in screen. 
The online database GeneALaCart (https://genealacart.genecards.org/) was used to identify ‘Cellular Component’ GO 
terms associated with the proteins identified as significantly TAM receptor enriched in Figure 20. Identified terms were 
regrouped into commonly associated terms thereafter named according to the common term and ‘associated’. 
Proteins including terms not associated with any common term were grouped to ‘Cellular Component associated’. 
TYRO3, AXL, MER, GAS6, and Protein S are specially marked.  
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1 CD9  98 26 VCP  62 51 HSPA1A  53 76 HIST2H4A  47 
2 PDCD6IP  96 27 TPI1  62 52 GNAI2  53 77 GNB1  47 
3 HSPA8  96 28 PPIA  62 53 ANXA1  53 78 THBS1  46 
4 GAPDH  95 29 MSN  62 54 RHOA  52 79 RAN  46 
5 ACTB  93 30 CFL1  62 55 MFGE8  52 80 RAB5A  46 
6 ANXA2  83 31 PRDX1  61 56 PRDX2  51 81 PTGFRN  46 
7 CD63  82 32 PFN1  61 57 GDI2  51 82 CCT5  46 
8 SDCBP  78 33 RAP1B  60 58 EHD4  51 83 CCT3  46 
9 ENO1  78 34 ITGB1  60 59 ACTN4  51 84 AHCY  46 
10 HSP90AA1  77 35 HSPA5  58 60 YWHAB  50 85 UBA1  45 
11 TSG101  75 36 SLC3A2  57 61 RAB7A  50 86 RAB5B  45 
12 PKM  72 37 HIST1H4A  57 62 LDHB  50 87 RAB1A  45 
13 LDHA  72 38 GNB2  57 63 GNAS  50 88 LAMP2  45 
14 EEF1A1  71 39 ATP1A1  57 64 RAB5C  49 89 ITGA6  45 
15 YWHAZ  69 40 YWHAQ  56 65 ARF1  49 90 HIST1H4B  45 
16 PGK1  69 41 FLOT1  56 66 ANXA6  49 91 BSG  45 
17 EEF2  69 42 FLNA  56 67 ANXA11  49 92 YWHAH  44 
18 ALDOA  69 43 CLIC1  56 68 ACTG1  49 93 TUBA1A  44 
19 HSP90AB1  67 44 CCT2  56 69 KPNB1  48 94 TKT  44 
20 ANXA5  67 45 CDC42  55 70 EZR  48 95 TCP1  44 
 
  
 
xi 
 
21 FASN  66 46 YWHAG  54 71 ANXA4  48 96 STOM  44 
22 YWHAE  65 47 A2M  54 72 ACLY  48 97 SLC16A1  44 
23 CLTC  64 48 TUBA1B  53 73 TUBA1C  47 98 RAB8A  44 
24 CD81  64 49 RAC1  53 74 TFRC  47 99 MYH9  44 
25 ALB  63 50 LGALS3BP  53 75 RAB14  47 100 MVP  44 
Table 17. Exocarta list of top 100 proteins that are often identified in exosomes. 
exocarta.org (2018.06.18) 
 
 
Search name + cancer 
PubMed 
hits Search name + cancer 
PubMed 
hits Search name + cancer 
PubMed 
hits 
APC (plus Adenomatous 
polyposis coli protein) 2274 Psme1 39 LPA (plus Apolipoprotein) 10 
Idh1 (plus Isocitrate ) 1470 HBB (plus Hemoglobin) 38 Taldo1 10 
GAPDH 1076 Api5 36 Gys1 9 
RAN (RAN excluded from 
autor) 1076 Cpq 32 RPL23 9 
AXL 670 Ppp1r12a 32 Phactr1 8 
Idh2 (plus Isocitrate) 546 RPS27 30 RPS11 8 
S100A9 364 Myl9 29 RPS4X 8 
ACTB 210 Tagln2 28 Slc39a10 8 
Ly6c1 (replaced with Ly6c) 184 Ak1 27 Myo1c 7 
Eno1 176 HSPA6 27 TUBA1B 7 
HSPA8 149 RPS3 26 RPL28 6 
PRDX1 147 Rab14 25 Snx5 6 
GCLC 139 Pdha1 24 IGLL5 5 
Ctsd 129 Myo10 23 Slc12a5 5 
TYRO3 128 Chd3 20 Tmod3 5 
PKM 113 Prps1 20 Pex16 4 
Hspa5 104 IGHG1 18 Spr 4 
Rac1 (plus Ras-related protein) 98 GNB2L1 16 Myl12a 3 
EEF1A1 91 Prdx5 16 SYNGAP1 3 
Actn4 90 RPS20 16 Eif2s3x 2 
EEF2 84 Dstn 15 Ccdc88b 1 
Ighv3-4 (replaced with IGHV3) 79 IGHM 13 Dmtn 1 
AHSG 70 Pdhb 13 Itpk1 1 
RPL11 69 RPS23 13 Myl12b 1 
Ighv1-64 (replaced with IGHV1) 68 Ube2i 13 Npepps 1 
TUBB 48 Ctnna2 12 Sacs (plus Sacsin) 1 
Ctsa 43 RPS13 12 Igkv16-104 (replaced with IGKV16) 0 
Hnrnpdl 42 RPS16 11 Kct2 0 
RPS14 41     
Table 18. Number of PubMed search results of TAM enriched proteins plus 'cancer'. 
PubMed searches were performed using the TAM enriched proteins name if not stated otherwise together with 
‘cancer’ to determine the number of cancer related publications (2018.06.19). 
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Image Name Source / License information 
 
Max Quant Software logo http://www.biochem.mpg.de/5111795/maxquant _ 14.02.20147 
 
Different laptop desiang 
template vector Free vector 
8.27MB 
freedesignfile.com; License: Creative Commons (Attribution 3.0); part of 
image implemented into figure 
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Free vector 
www.openclipart.org; License: Public domain license; image 
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